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Abstract 
 
(+)-Peloruside A is a novel cytotoxic marine natural product isolated from the New 
Zealand sponge Mycale hentscheli.
42
 Peloruside A is a potential anticancer agent that 
has a similar mode of action to that of the successful drug paclitaxel. Biological 
analysis indicated that (+)-peloruside A promotes tubulin hyperassembly and cellular 
microtubule stabilisation which lead to mitosis blockage in the G2/M phase of the cell 
cycle and consequent cell apoptosis.
43, 47
 (-)-Laulimalide is also a cytotoxic natural 
product with microtubule stabilising bioactivity, and is a potential anticancer agent.
47
 
Biological analysis showed that (+)-peloruside A and (-)-laulimalide are competitive, 
suggesting that they bind to the same active site.
47
 (+)-Peloruside A and (-)-
laulimalide also display synergy with taxoids.
47
 
 
 
Due to the structural complexity of peloruside A, our research has focused on 
developing an analogue 151 for ease of synthesis. Thus, the simplified C5–C9 
dihydropyran moiety of (-)-laulimalide, with fewer stereocentres than that of (+)-
peloruside A, has been incorporated into analogue 151 whilst retaining the 16-
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 3 
membered ring backbone of (+)-peloruside A. The proposed synthesis of 151 involves 
a Yamaguchi macrolactonization, a 1,5-anti-aldol coupling, and a ring closing 
metathesis as key reactions. This thesis reports on the synthesis of key fragments of 
analogue 151 and the crucial 1,5-anti-aldol coupling reaction for the assembly of the 
carbon backbone. 
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Chapter 1 - Introduction 
 
1.1 The impact of cancer in modern society 
 
Cancer is an ailment that has afflicted humans throughout history. Evidence of the 
existence of cancerous growth was found in fossils, mummies, and ancient 
manuscripts.
1
 In today‟s medically advanced society, cancer has become one of the 
leading causes of death. Cancer accounted for 12% of all deaths worldwide in 2000 
with fatality reported at 6.2 million.
2
 Furthermore, the total number of cancer cases 
worldwide and cancer related the mortality rate is expected to increase.
3
 
 
Cancer imposes a huge burden of individual suffering on the patients and their 
families. Furthermore, the “epidemic” of cancer is also an enormous financial drain 
on economic resources. The estimated overall cost of the cancer in the United States 
for 2002 only, was approximately $171.6 billion.
1
 The scale of this cancer “epidemic” 
causes a large strain on healthcare systems. Of the estimated 2002 cost, $60.9 billion 
was for direct medical costs.
1
 Governments and private agencies alike are putting 
large amounts of resources into helping cancer patients, as well as developing more 
effective treatments for the disease.  
 
Human knowledge regarding cancer has advanced tremendously in the past decades. 
However, despite the effort, dedication and resources poured into understanding the 
nature of cancer, the magic bullet remains elusive. The search for a single effective 
treatment of cancer might not be forthcoming in any foreseeable future because of the 
diversity of the disease. Cancer is caused by uncontrolled proliferation of abnormal 
cells, leading to fatal results.
4
 There are more than one hundred known types of 
cancer. Cancerous cells can affect any organ and bodily component at any location. 
However, the lung, intestine, pancreas, liver, breast, prostate, bladder, bone and blood 
cells are the most common areas inflicted by cancerous cells.
4
  
 
Most cancers arise from changes in cellular DNA (deoxyribonucleic acid). Such 
changes might be the results of exposure to ultraviolet radiation, production of 
abnormal diseased cells, or damage to the immune system. Reactive chemicals can 
 15 
cause inflammation and abnormal metabolism that lead to DNA damage. Changes in 
DNA as the result of errors in the reading, translation, or replication processes can 
also lead to the production of damaged DNA. 
 
Generally, the causes of cancer have been blamed on factors such as lifestyle, 
carcinogens, hormones, viral infection, and genetic predisposition. Lifestyle, 
including diet, is believed to have a great impact on a person‟s predisposition towards 
developing certain types of cancer. A diet that is high in fat content but low in fibre 
intake is known to induce liver, stomach, endometrium and bowel cancers.
4
 Similarly, 
a diet that contain mostly grilled and fried food can also promote the development of 
liver, stomach, endometrium and bowel cancers.
4
 Studies have found that the intake 
of processed meat and meat cooked at high temperature increases the risk of colon 
cancer.
5
  
 
Smoking and alcohol consumption have long been established as leading causes of 
cancer. It is widely known that heavy smokers tend to develop lung, mouth, 
oesophagus, and stomach cancers.
6
 Excessive alcohol intake has also been associated 
with the development of mouth, oesophagus, stomach, and liver cancers.
4, 7
 Prolonged 
exposure to ultraviolet radiation from the sun on unprotected skin is attributed to the 
development of skin melanoma.
8
 
 
Exposure to carcinogenic and toxic chemicals such as polycyclic aromatics, asbestos, 
azo dyes, and pesticides has been proven to increase the chance of cancer 
development.
4, 7
 Breast cancer and prostate cancer have been associated with exposure 
to high levels of hormones. Repeated exposure to high concentrations of oestrogen 
from hormone replacement therapy and fertility drugs may increase the likelihood of 
ovarian and breast cancer development in females.
4, 7
 In men, repeated exposure to 
high concentration of testosterone from hormone replacement therapy can cause 
prostate cancer.
4
  
 
Studies have also shown that certain types of cancer are caused by viral infection. 
Hepatitis B virus has the potential to induce hepatocellular carcinoma.
9
 Human 
papilloma virus is known to be the cause of cervical cancer.
7
 Burkitt‟s lymphoma is 
cancer caused by untreated infection of Epstein-Barr virus.
4
 Furthermore, some 
 16 
individuals might also have genetic predispositions towards developing certain types 
of cancers.
10
 
 
1.2 Treatments for cancer 
 
The main goal of a successful cancer treatment is the total eradication of cancer cells. 
The reason that total eradication is essential is because cancerous cells replicate in an 
uncontrolled fashion. If a gram of cancerous tissue contains ten thousand cells and 
only a hundred cells survive the treatment, these remaining cells will still be able to 
reform the cancerous tissue.
4
 Furthermore, there is also the possibility that the cells 
that developed from the surviving cancer cells will be resistant to, and therefore 
unaffected by, the previously applied cancer therapy. 
 
Most cancerous cells form benign tumours, which are relatively harmless if treatment 
is applied early. However, an untreated tumour can became unconstrained and 
progress into a malignant, invasive cancer. Aside from the difficulty of treating a 
large tumour effectively, unconstrained cancer cells can also spread throughout the 
body, producing a secondary metastatic cancer in organs other than the original 
cancer site. Metastasis is estimated to be the cause of more than 90% of all cancer 
related deaths.
11
 Invasive cancer cells can spread by invading the tissues surrounding 
the original cancerous site or by travelling through blood vessels and lymphatic 
systems to a remote metastasis site.
 4, 11
 
 
The cancer therapies that are currently used to manage tumours usually involve 
combination of two or more different treatments. Most patients will have surgery to 
remove the majority of the cancerous tissue, with chemotherapy and radiation therapy 
used to kill the remaining cancer cells.
8
 Chemotherapeutic drugs that are currently 
used for clinical treatment can be categorised based on their mode of action. These 
anticancer agents target a wide number of cell survival mechanisms. 
Chemotherapeutic drugs include tubulin interactive agents, actin active agents, 
inhibitors of topoisomerases, inhibitors of histone deacetylases, inhibitors of Hsp90 
(heat shock protein 90), proteasome inhibitors, protein kinase inhibitors, inhibitors of 
hypoxia inducible factor, caspase activating and apoptosis inducing agents, inhibitors 
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of DNA polymerase, actin interactive agents, and telomerase inhibitors.
11, 12
 Most of 
the clinical drugs used for cancer chemotherapy target the cell cycle, resulting in the 
prevention of cell proliferation and therefore the death of the cancerous cells. 
 
Tubulin interactive agents promote polymerisation or depolymerisation of tubulin 
heterodimers. The consequent disruption of microtubule dynamics leads to mitotic 
arrest and eventual cell death. Tubulin interactive agents such as the taxanes and 
epothilones are clinically used as promoter of tubulin polymerisation, while 
discodermolide, peloruside, and laulimalide are currently under development as 
potential anticancer drugs. Tubulin interactive agents that inhibit tubulin 
polymerisation include the vinca alkaloids, dolastatins, and halichondrins.  
 
Actin is another cytoskeletal component with important roles in the maintainance of 
the cellular cytoskeleton and interacts with the microtubule network during cell 
division. Therefore, disruption of actin filaments by actin active agents such as 
latrunculins can lead to cell death.
11
 
 
Inhibitors of topoisomerases can be divided into inhibitors of topoisomerase I, 
inhibitors of topoisomerase II, and dual topoisomerase inhibitors. Topoisomerases are 
enzymes that release torsional constraints on the DNA double helix during 
transcription, replication, or repair processes. Topoisomerases create a restorable local 
strand break through formation of a complex with the DNA strand.
13
 Topoisomerase I 
inhibitors such as camptothecin (Figure 1.1) and its derivatives stabilise the DNA-
topoisomerase I complexes and prevent re-ligation of strand breaks leading to cell 
death.
12, 13
 Anthracyclines (Figure 1.1) and their derivatives are inhibitors of 
topoisomerise II.
12
 Derivatives of the protein kinase inhibitor staurosporine (Figure 
1.1) are examples of dual topoisomerise inhibitors.
12
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Figure 1.1 Topoisomerase inhibitors. 
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Histone deacetylases are a group of proteins that remove acetyl groups from the N-
terminus of acetylated histones during gene expression.
14
 Inhibitors of histone 
deacetylases are designed to interfere with the catalytic domain of histone 
deacetylase.
14
 Inhibitors of histone deacetylases block substrate recognition that leads 
to induction of gene expression resulting in apoptosis. Vorinostat (Figure 1.2) is a 
histone deacetylase inhibitor that has been approved by the FDA (Food and Drug 
Administration) for treatment of cutaneous T-cell lymphoma.
14
 
 
Figure 1.2 Vorinostat, an inhibitor of histone deacetylases. 
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Hsp90 is a chaperone protein that maintains the proper functioning of many cell 
signalling proteins.
12
 Therefore, Hsp90 is very important for the survival of 
cancerous, as well as normal, cells. Inhibiton of Hsp90 will eventually leads to 
cellular destruction. Ansamysin (Figure 1.3) and its derivative, tanespimycin, are 
examples of anticancer agents that act as inhibitors of Hsp90.
12
  
 
Figure 1.3 Ansamysin and tanespimycin, inhibitors of Hsp90. 
 
 
 
Ansamycin R = OCH3 
Tanespimycin R = NHCH=CH2 
 
 
The proteasome is a multi-enzyme complex that controls the progression of the cell 
cycle and signal transduction cascade termination.
12
 The proteasome is also 
responsible for the removal of damaged, mutated, and misfolded proteins. 
Salinosporamide A, epoxomicin, and eponemycin (Figure 1.4) are examples of 
natural microbacterial metabolites that exhibit cytotoxic activities through inhibition 
of the proteasome.
12
 
 
Figure 1.4 Proteasome inhibitors. 
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Recently, immunotherapy has been developed as an alternative option for cancer 
management and treatment. This utilises antigen specific T-cell responses to combat 
the cancer cells (Figure 1.5). Cancer vaccines containing antigens specific to the 
cancerous cells enhance the number of immune T-cells in the body.
15
 The antigens 
present in cancer vaccines trigger a recognition response by T-cells. The T-cells will 
then proliferate, infiltrate and kill the tumour tissues that carry the specific antigens.
15
 
The advantage of immunotherapy for cancer management is that it can be tailored to 
give the most effective results for an individual.
15
 
 
Figure 1.5 The basis of cancer immunotherapy. 
 
 
 
 
 
 
 
 
 
1.3 The cell cycle 
 
The cell cycle (Figure 1.6) is a process by which cells ensure self-renewal.
1
 
Production of undifferentiated cells is essential to provide a pool of precursor cells for 
differentiation into cells with specific functions. The undifferentiated precursor cells 
can mature into a range of cell types, such as germ cells to enable genetic transfer to 
the next generation, blood cells that need constant replenishing, and specific cell types 
to replace damaged cells.
1
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Figure 1.6 The cell cycle. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
The cell cycle consists of five stages.
16
 Prior to entering the cell cycle, a cell exists in 
a quiescent state called G0. When the correct external stimuli are received, the cell 
will move out of the G0 and into the G1 state.
17
 G1 or the primary growth state is the 
first stage in the cell cycle. G1 is the state in which the cell spends most of its life 
span, gaining nutrients, growing, and preparing to undergo cell division.
16,17
 Upon 
fulfilling the requirements for cell division, the cell will enter the S phase. During the 
S phase, the cell will synthesise a replica of its genome in the form of sister 
chromatids. The cell then moves into the G2 phase and prepares for genomic 
separation. During G2 phase, the cellular organelles replicate, the chromosomes 
condense, and microtubule spindles assemble. Collectively, the G1, S, and G2 phases 
of the cell cycle form the interphase.
16
  
 
The next stage in the cell cycle is mitosis, also called the M state. The prophase, 
metaphase, anaphase, and telophase sub-stages constitute mitosis.
16
 During prophase, 
the nuclear membrane of the dividing cell disintegrates and the nucleolus, a site 
within the cell‟s nucleus for synthesis of rRNA (ribosomal ribonucleic acid), 
dissolves. Mitotic spindles will start to form and attach themselves to the maturing 
kinetochores. The kinetochore is a disc-shaped protein assembly that anchors a 
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chromosome pair to microtubules within part of the mitotic spindles.
17
 In the 
metaphase, chromosomes will self-align at the equator of the cells. Upon entering 
anaphase, kinetochore-associated microtubules pull the sister chromatids apart 
towards opposite poles of the cells as they shorten. Simultaneously, the polar 
microtubules elongate in preparation for cellular division. Upon entering telophase, 
the separated chromosomes recondense, the kinetochores dissolve, the nuclear 
membrane reforms and the nucleolus reappears.
16, 17
 
 
The final stage of the cell cycle is the cytokinesis or the C phase.
16
 During this stage, 
actin filaments form a constricting belt. The constricting belt causes formation of a 
cleavage furrow around the circumference of the cell. The constricting belt will 
gradually tighten until the mother cell eventually splits into two separate daughter 
cells.
16, 17
 Upon finishing the cell cycle, the daughter cells can either re-enter into 
another cell cycle for further proliferation, or withdraw into G0 state. Interference at 
one or more stages of the cell cycle through disruption of DNA replication, 
microtubule assembly or formation of the other cellular components essential for the 
cell cycle will either suspend the cell cycle or drive the cell into activating a self-
regulated suicide mechanism called apoptosis.
1
 
 
1.4 Microtubules as targets in cancer treatment 
 
Microtubules (Figure 1.7) play essential roles in cell division. Microtubules are 
hollow cylindrical tubes made of the protein tubulin. A microtubule‟s morphology is 
adjusted to the role it is performing, either as a kinetochore microtubule or a polar 
microtubule. Correct microtubule morphology is crucial to the completion of a 
successful cell cycle. Tubulin subunits polymerise and depolymerise to adjust the 
length of microtubules.  
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Figure 1.7 Structure of a microtubule. 
 
Microtubules are built of heterodimeric subunits made up of α- and β-monomers of 
tubulin. The heterodimers assemble in head-to-tail fashion
18
 (Figure 1.8) into threads 
of protofilaments with the β-monomers oriented to the plus end of the microtubule 
and the α-monomers towards the minus end.19 During microtubule lengthening, the 
heterodimers polymerise at the plus end of the microtubule.
20
 When microtubules 
shorten, the heterodimers start to depolymerise from the minus end.
20
 The regulated 
changes in length through polymerisation and depolymerisation are called 
microtubule dynamics. 
 
Whilst tubulin dynamics can lead to lengthening or shortening of microtubules, they 
can also lead to treadmilling (Figure 1.8). Treadmilling is a constant tubulin 
polymerisation at one end and depolymerisation at another end. The net result of 
treadmilling is a fixed tubular length but can lead to changes in its relative position in 
the cell.
20
 Treadmilling enables a microtubule to move around in the cellular matrix. 
This dynamic mechanism provides one means by which microtubules achieve cellular 
transportation and signalling.
21
 Thus, microtubule dynamics are very important for 
proper cellular functioning, and their disturbance can have fatal consequences for the 
affected cell. Therefore, disruption of microtubule dynamics during cellular division 
as well as G0 can be effective for inhibition of tumour and cancer progression.  
 


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Figure 1.8 Microtubule treadmilling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5 Anticancer agents targeting microtubules 
 
A review of anticancer agents that entered into clinical trials in 2005 to 2007 showed 
that over 25% of the candidates operated by a mode of action that affected 
microtubule dynamics.
22
 Anticancer agents disturb microtubule dynamics by two 
main interaction mechanisms: stabilising and destabilising microtubules.  
  
1.5.1 Microtubule stabilising agents 
 
Microtubule stabilisers promote stabilisation of microtubule structure and prevent 
microtubule depolymerisation. Taxanes (Figure 1.9) are well known examples of 
microtubule stabilising agents whose mode of action involves binding to tubulin along 
the length of the microtubule.
23
  
 
Taxanes bind to a site called the „taxane binding site‟ on monomers β-tubulin. The 
taxane site is located on the inner surface of the microtubule with one taxane site per 
β-tubulin monomer. Taxanes gain entry into the taxane site by diffusion through small 
+ end- end
+ end- end
+ end- end
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openings in the microtubule wall or during fluctuation of microtubule lattices.
24
 
Binding of taxane molecules to their site promotes conformational changes that 
increase the affinity between neighbouring tubulin molecules and stabilise the 
microtubule structure. 
 
The taxane family of anticancer agents include the natural compound paclitaxel 
(Figure 1.9), also known as Taxol
®
, and several of its synthetic analogues, such as 
docetaxel, abraxane, larotaxel, cabazitaxel, taxoprexin, and milataxel just to mention a 
few. Most of these taxanes are still in clinical trials. Only paclitaxel, docetaxel and 
abraxane have been approved for use in cancer treatments.
22
 
 
Figure 1.9 Taxanes. 
 
Taxanes R1 R2 R3 R4 
Paclitaxel OH OAc Ph Ph 
Docetaxel OH OH O
t
Bu Ph 
Cabazitaxel OMe OMe O
t
Bu Ph 
Milataxel OCOEt OH O
t
Bu Furyl 
 
Paclitaxel was initially isolated by Wall and Wani in 1967 from the bark of the Pacific 
yew tree (Taxus brevifolia).
25
 The efficacy of paclitaxel as a microtubule stabilising 
anticancer agent was demonstrated by Schiff and Horwitz in their 1979 study.
26
 
Paclitaxel was approved by the FDA in 1992 for use in cancer treatment.
22
 The 
increasing demand for paclitaxel led Holton and co-workers to devise a semisynthetic 
route for procuring paclitaxel from 10-deacetylbaccatin III (Scheme 1.1), a 
structurally related compound isolated from the needles and leaves the of the 
European yew (Taxus baccata).
22, 27, 28
 Docetaxel is a semisynthetic analogue of 
paclitaxel developed by the Potier group from France and was approved for use in 
cancer treatment by the FDA in 1995.
22, 29
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Scheme 1.1 The semisynthetic route to paclitaxel from 10-deacetylbaccatin III and 
protected β-lactam. 
 
Epothilones A and B (Figure 1.10) were discovered in soil myxobacteria called 
Sorangium cellulosum by Reinchenbach and co-workers in 1986.
22, 30, 31
 Epothilones 
also promote microtubule stabilisation by binding to the taxane site on the β-subunit 
of tubulin.
32
 Several epothilones and epothilone-derived analogues have been in 
clinical trials. Ixabepilone (Figure 1.10) is a semisynthetic analogue of epothilone B 
that was approved by the FDA in 2007 for the treatment of breast cancer.
22
 
Ixabepilone was prepared in a one-pot reaction from epothilone B by replacement of 
the ester moiety with an amide.
22
 Sagopilone and dehydelone (Figure 1.10) are 
synthetic analogues of epothilone that have gone into clinical trials for the treatment 
of advanced and recurrent metastatic cancers.
22, 31
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Figure 1.10 Epothilones and synthetic analogues. 
 
 
 
 
 
Epothilone R1 R2 Xxxxxxxx          xxxx Epothilone R1 R2 
A Me H  C Me H 
B Me Me  D Me Me 
E CH2OH H  F CH2OH H 
 
Ixabepilone    Sagopilone   Dehydelone 
 
1.5.2 Microtubule destabilising agents 
 
Vinca alkaloids (Figure 1.11) were isolated from extracts of the Madagascan 
periwinkle (Catharanthus roseus).
22
 Two of the most widely used natural vinca 
alkaloids are vinblastine and vincristine.
24
 Vinca alkaloids are anticancer agents that 
disturb microtubule dynamics and their mode of action depends on the administered 
dosage. At relatively high concentrations of 10 to 100 nM in HeLa cells, vinca 
alkaloids promote depolymerisation and dissolving of microtubule spindles.
24
 
However, when administered at lower dosage, vinca alkaloids bind to the tips of 
microtubule filaments and suppress microtubule dynamics, thus preventing 
depolymerisation of the microtubule spindles.
33
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Figure 1.11 Vinca alkaloids 
 
Vinca alkaloids R 
vincristine CHO 
vinblatine Me 
 
 
 
Vinca alkaloids have a distinct binding site at the β-subunit of tubulin called the 
„vinca domain‟.24 Binding of a vinca alkaloid molecule to a β-subunit causes 
conformational changes in the tubulin subunit. Subunits with associated vinca 
alkaloid molecules have increased affinity for self-association
 
into discrete tubulin 
subunit pairs which lowers the concentration of polymerised tubulin.
24
 
 
Colchicine (Figure 1.12) was extracted from Autumn crocus (Colchicum 
autumnale).
34
 Colchicine is an anticancer agent that has a similar mode of action to 
vinca alkaloids. Colchicine promotes microtubule depolymerisation at high 
concentration while arresting microtubule dynamics at low dosage resulting in the 
disruption of the correct orientation of microtubule protofilaments.
24, 33
 Colchicine 
binds to a site called the „colchicine domain‟ on the intradimer interface between the 
α- and the β-tubulin dimer.33 However, colchicine was deemed unsuitable for use in 
cancer treatment, due to its potent toxicity towards normal tissue.
24
 
 
Figure 1.12 Colchicine. 
 
 
 
 
 
 
Although colchicine is not administered as an anticancer agent, the colchicine domain 
has proven valuable for other anticancer agents including the combretastatins (Figure 
1.13), which are a family of natural anticancer agents isolated from Cape bushwillow 
(Combretum caffrum) by Pettit et al.
22, 34, 35
 The natural combretastatins and several 
O
O
O
N
H
O
O
O
N
OH
N
H
MeOCO
MeO
N
N
R
OCOMe
HO COOMe
 29 
synthetic analogues have gone into clinical trials as anti-mitotic agents for cancer 
therapy targeting microtubules. Combretastatins have been shown to inhibit the 
polymerisation of tubulin and the formation of microtubule spindles.  
 
Figure 1.13 Combretastatins and derivatives. 
 
 
 
 
Combretastatins R1 R2 
Combretastatin A-4 H OH 
Combretastatin A4 phosphate H OPO3Na2 
Combretastatin A-1 OH OH 
OXi4503 OPO3Na2 OPO3Na2 
AVE8062A H NHCOCH(NH2)CH2OH 
AVE8063A H NH2 
 
1.6 Anticancer agents from marine sources 
 
The marine environment has been contributing an increasing list of natural anticancer 
agents in the recent decades. Antitumour marine natural products have been isolated 
from a variety of marine vertebrates and invertebrates. The anticancer agents have 
been derived mainly from marine sponges and molluscs. Several anticancer agents 
targeting microtubule dynamics as the mode of action are discussed below.  
 
(+)-Discodermolide (Figure 1.14) was isolated from the deep-water sponge 
Discodermia dissoluta in 1990 by Gunasekera et al.
36
 (+)-Discodermolide was 
originally studied as an immunosuppressant. However, further studies proved that (+)-
discodermolide is also an anti-mitotic suppressor of the cell cycle at 3 to 8 nM 
concentration.
37
 A study on the mode of action of (+)-discodermolide has shown that 
the compound is a potent microtubule stabiliser that inhibits tumour cell growth by 
accelerating senescence.
38
 (+)-Discodermolide binds to β-tubulin at the taxane site 
and is a competitive inhibitor to paclitaxel.
37, 38
 A clinical trial using (+)-
O
O
O
O
R2
R1
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discodermolide was discontinued after phase I due to toxicity problems and lack of 
efficacy.
31, 37
 
 
Figure 1.14 Discodermolide. 
 
 
 
 
 
 
Dolastatin 10 (Figure 1.15) is a member of the dolastatin family. The dolastatins are a 
series of cytotoxic peptides first isolated from the sea hare Dolabella auricularis in 
1972.
37
 Dolastatin 10 exhibits anti-mitotic activity with an IC50 of 1.2 µM.
37
 Studies 
showed that prolonged intracellular retention facilitates binding to tubulin, which 
leads to the inhibition of tubulin polymerisation, and thus prohibits microtubule 
assembly and promotes the subsequent depletion of the cellular microtubule network, 
resulting in cellular arrest at the mitotic stage.
37
 Dolastatin 10 binds to a distinct 
peptide site near the vinca domain on the β-subunit.11, 22 However, dolastatin 10 did 
not pass phase II clinical trials and has been withdrawn due to a lack of significant 
activity.
11, 22, 37 
Several synthetic derivatives of dolastatins such as soblidotin, 
cematodin, and synthadotin (Figure 1.15) have entered clinical trials.
11, 38
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Figure 1.15  Dolastatin 10 and its derivatives. 
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Halichondrin B (Figure 1.16) is a member of the halichondrin class of marine 
macrolide. Halichondrin B, homohalichondrin B, and norhalichondrin B were 
originally isolated from the sponge Halichondria okadai by Uemura and co-workers 
in 1985.
11, 39
 Since its original discovery, Halichondrin B has also been found in 
several other sponges including Axinella sp., Lissodendory sp., and Phakellia 
carteri.
11
 An initial study determined that halichondrin B is a tubulin interactive agent 
that affects microtubule depolymerisation through binding to a distinct site near the 
vinca domain.
11
 Further studies have shown that halichondrin B is a non-competitive 
inhibitor of vinblastine.
22
 Halichondrin B is highly cytotoxic and a potent inhibitor of 
cell growth at subnanomolar concentrations towards the NCI-60-cell lines.
22, 37
 
Eribulin mesylate (Figure 1.16), a less neurotoxic but more potent truncated analogue 
of halichondrin B, has gone into crinical trials.
11, 22, 37, 38
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Figure 1.16 Halichondrin B and analogues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zampanolide (Figure 1.17) is a macrolide initially isolated from the Japanese marine 
sponge Fasciospongia rimosa by Tanaka and Higa in 1996.
40
 Zampanolide has 
recently also been extracted from the Tongan sponge Cacospongia mycofijiensis by 
Northcote‟s group.41 Zampanolide is a potent microtubule stabilising agent with an 
IC50 of 2 to 10 nM for growth inhibition of a number of cancer cell lines.
41
 
Zampanolide causes G2/M arrest of the cell cycle and promotes microtubule bundle 
formation at interphase.
41
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Figure 1.17 Zampanolide. 
 
 
 
 
 
 
 
 
1.7 Peloruside A 
  
Peloruside A (1, Figure 1.18) is a novel cytotoxic marine natural product isolated 
from the New Zealand sponge Mycale hentscheli in 2000 by Northcote‟s group.42 
Northcote also reported the isolation of peloruside B to D, mycalamides (a family of 
heterocyclic amides), and the macrolide pateamine in the same sponge.
42
 Peloruside A 
has a highly oxygenated 16-membered macrolide ring containing a dihydropyran ring, 
a gem-dimethyl group, and a hemiketal. Its side chain bears a branched Z-olefin. 
Preliminary biological analysis indicated that peloruside A is cytotoxic with an IC50 of 
6 to 66 nM in a number of cancer cell lines.
43, 46, 47
  
 
Peloruside B (2, Figure 1.18) is a 3-des-O-methyl variant of peloruside A which 
showed a slightly reduced bioactivity compared to peloruside A.
44
 Peloruside C (3, 
Figure 1.18) is a dideoxy variant of peloruside A and has a significantly reduced 
bioactivity.
45
 Peloruside D (4, Figure 1.18) was found to be biologically inactive.
45
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Figure 1.18 The naturally occurring members of the peloruside family. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7.1 Biological activity of peloruside A 
 
A biological study by the Miller group established that peloruside A is a microtubule 
interactive agent with microtubule-stabilising activity (Figure 1.19).
43
 Peloruside A 
promotes tubulin hyperassembly and cellular microtubule stabilisation leading to 
G2/M phase cell cycle blockage and cell apoptosis.
46, 47, 48
 Peloruside A is therefore a 
potential agent for anticancer therapy. Peloruside A binds to a non-taxane site, 
believed to be located in the β-tubulin subunit. Furthermore, peloruside A displays 
synergy with taxoids and has potential as a synergistic drug with other microtubule 
stabilising agents such as the taxanes, epothilones, and (+)-discodermalide.
46, 47, 48
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Figure 1.19 α-Tubulin antibody staining of microtubules in 1A9 ovarian cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microtubules are shown in green. 
Used with the permission of Prof. John Miller and confocal images supplied by Arun 
Kanakkanthara. 
 
The physical properties of peloruside A excel over those of most taxoid drugs as it is 
less lipophilic, thus less susceptible to over-expressed Pgp (P-glycoprotein) efflux 
pumps in multidrug resistant cells.
43, 46
 Susceptibility to over-expression of Pgp efflux 
pumps has been an issue that has undermined the efficacy and safety of other 
anticancer drugs. Cancerous cells have the tendency to over-express the Pgp efflux 
pumps, which non-specifically remove the more lipophilic molecules from cells and 
thus lower the efficacy of many drugs.  
 
1.7.2 Synthesis of peloruside A 
 
The scarcity of the available natural source of peloruside A has led to aquaculture-
based attempts to produce the cytotoxic agent, however production of the natural 
 36 
product in large quantities by this approach has not yet been fruitful.
49, 50
 The absolute 
stereochemistry of peloruside A was revealed in the course of its first reported total 
synthesis by De Brabander‟s group.51 The product turned out to be the unnatural 
enantiomer, (-)-peloruside A (5, Figure 1.20).
51
 Unfortunately, this unnatural 
enantiomer of peloruside A does not express cellular cytotoxicity.
51
  
 
Figure 1.20 Synthetic and semisynthetic variants of (+)-peloruside A. 
 
  
 
 
 
5      6 
(-)-Peloruside A     (-)-2-epi-Peloruside A 
 
 
 
 
 
  
  7      8 
NaBH4 reduction analogue of   Monocyclic peloruside A analogue 
Peloruside A 
 
The first total synthesis of natural (+)-peloruside A was achieved in 2005 by Jin and 
Tayor.
52
 Following in their footsteps, Ghosh and Evans have also achieved the total 
synthesis of peloruside A.
53, 54
 Smith and co-workers reported the total synthesis of (-
)-2-epi-peloruside A (6, Figure 1.20), an unexpected synthetic result due to torsional 
strain-driven epimerisation at C2 during the macrolactonisation step.
57
 However, the 
cytotoxic potential of (-)-2-epi-peloruside A has yet to be determined. Almost all of 
the total synthesis strategies developed for peloruside A to date used convergent 
synthetic approaches with aldol coupling as the key reaction.
55, 56
 The major synthetic 
approaches are discussed below. 
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Aside from (-)-2-epi-peloruside A, two other analogues (7 and 8, Figure 1.20) have 
already been made and tested with a disappointing lack of cytotoxic potential 
compared to peloruside A.
43, 58
 Analogue 7 is a product of sodium borohydride 
reduction of peloruside A, resulting in the loss of the C5–C9 pyran moiety and 
formation of hydroxyls at C5 and C9.
43
 Analogue 8 was designed without the C5–C9 
pyran backbone.
45
 Analogues 8 and 7 lack the pyran moiety and similarly showed loss 
of bioactivity, which highlighted the importance of the C5–C9 pyran backbone in the 
structure of peloruside A. 
 
1.7.2.1 Synthesis of (-)-peloruside A by De Brabander (Scheme 1.2)
51
 
 
De Brabander‟s approach to the synthesis of peloruside A begins from the PMB (p-
methoxybenzyl) protected hexenediol 14. TES (triethyl silyl) protection of the C5 
alcohol followed by oxidative cleavage of the C3 alkene provided aldehyde 15.  
Addition of a (Z)-alkoxyallylborane 16 to the aldehyde 15 followed by methylation of 
the resulting alcohol provided alkene 17. Deprotection and oxidation of the C7 
hydroxyl gave the aldehyde 18. Subsequent aldol reaction with 19 followed by Dess-
Martin oxidation provided β-diketone 20.  
 
The β-diketone 20 was cyclised to give the dihydropyranone 21. Luche reduction, 
epoxidation, methanolysis, and methylation furnished the functionalised 
dihydropyran. Protection of C8 hydroxyl as a TES ether provided 22. Methyl ester 
functionality at C1 was formed through oxidative transformation of the alkene double 
bond to an acid followed by diazomethane treatment to give 23. Deprotection and 
oxidation of the C11 hydroxyl gave the aldehyde 24. Allylation with allyldiethylborane 
gave the allyl alcohol 25. Subsequent oxidative cleavage of the C13 alkene finished the 
synthesis of the major portion of the target structure as the aldehyde 26. 
 
The methyl ketone 13 was synthesised from 2,5-dihydrofuran through zirconium 
catalysed asymmetric carbomagnesation.
16
 The resulting enantiopure homoallylic 
alcohol 10 was acylated with methacryloyl chloride. The resultant olefin 11 was ring-
closed using Grubb‟s 2nd generation catalyst to facilitate the metathesis. The resulting 
lactone 12 was treated with methyllithium to provide the methyl ketone and followed 
with silylation to protect the primary alcohol. 
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Scheme 1.2 Synthetic route to (-)-peloruside A by De Brabander.
51
 
 
Conditions: (i) EtMgBr, (S)-(EBTHI)-Zr-BINOL, THF,
59
 (ii) methacryloyl chloride, 
DIPEA, DMAP, DCM; (iii) 10 mol% Grubbs‟ 2nd generation catalyst, DCM, reflux, 
17 h; (iv) MeLi, THF, -78 °C; or Me3SiCH2Li, pentane, -78 °C; (v) TBSCl, 
y 
(over 4 steps)
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imidazole, DMAP, DMF; (a) TESOTf, 2,6-lutidine, DCM; (b) catalytic OsO4, NMO, 
acetone/H2O; (c) Pb(OAc)4, pyridine, DCM; (d) sBuLi, THF, -78 °C, 15 min, then 
(+)-Ipc2BOMe, -78 °C, 1 h, 0 , °C, 1.5 h, then 15; -95 °C, 3 h, slowly warmed to RT, 
30% H2O2, NaOH, 16 h; (e) NaH, MeI, DMF, -5 °C; (f) DDQ, DCM/ H2O, 0 °C; (g) 
SO3.pyridine, TEA, DMSO, DCM, 0 °C; (h) 19, LDA, THF, -78 °C, then 18, -78 °C; 
(i) Dess-Martin periodinane, DCM, -10 °C; (j) PTSA, PhMe, RT; (k) NaBH4, 
CeCl3.7H2O, MeOH, -30 °C; (l) mCPBA, NaHCO3, DCM/MeOH, 0°C; (m) tBuOK, 
MeI, THF, 0 °C; (n) TESOTf, 2,6-lutidine, DCM; (o) catalytic OsO4, NMO, 
acetone/H2O; (p) Pb(OAc)4, pyridine, DCM; (q) NaClO2, NaH2PO4, 2-methyl-2-
butene, tBuOH/H2O; (r) CH2N2, Et2O, 0 °C; (s) H2, 10 % Pd/C, MeOH; (t) 
SO3.pyridine, TEA, DMSO, DCM, 0 °C; (u) allylBEt2, Et2O, -10 °C; (v) catalytic 
OsO4, NMO, acetone/H2O; (w) Pb(OAc)4, pyridine, DCM; (x) 13, DIPEA, Et2BuOTf, 
DCM, -78 °C, 15 min, -30 °C, 45 min, add 26, -78 °C, 2 h; (y1) 20 eqv Me3OBF4, 2-
6-di-tert-butyl-4-methylpyridine, DCM, RT; (y2) 20 eqv (R)- or (S)-B-Me-CBS, 7 egv 
BH3.SMe2, DCM, -30 °C, 1 h, to RT 4 h, add MeOH; (y3) 0.3 N aq. LiOH, THF, RT; 
(y4) PPh3, DIAD, THF, RT, 15 min, add seco-acid over 2 h, then 1 h at 0 °C; (z) 4 N 
HCl, THF, RT, 3 h. 
 
A late stage 1,3-anti aldol coupling between the side chain C14–C24 methyl ketone 13 
and fully functionalised C1–C13 aldehyde 26 was the key step in the synthesis. The 
aldol reaction was rather unselective and gave a 2:1 separable mixture of product with 
87% yield. Proceeding with both epimers of the aldol product 27, the C13 hydroxyl 
was methylated and the C15 ketone was asymmetrically reduced to give another set of 
epimers.  
 
Using all of the four resulting epimers, Mitsunobu macrolactonisation gave only 
lactone 28. This leads to the conclusion that geometrial/conformational constrains of 
the epimers drove a configuration-dependent mechanistic switch during the 
macrolactonisation. The configuration-dependent mechanistic switch occurred via an 
acyloxyphosphonium intermediate (retention) for the (R)-C15 epimer and via an 
alkoxyphosphonium intermediate (inversion) for the (S)-C15 epimer. Simultaneous 
cleavage of MOM (methoxymethyl) and TES protecting groups concluded the 
synthesis of (-)-peloruside A. The synthesis sequence took 29 steps with an overall 
yield of 3% from the hexenediol 14. 
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1.7.2.2 Synthesis of (+)-peloruside A by Jin and Taylor (Scheme 1.3)
52, 60
 
 
Jin and Taylor approached the synthesis of (+)-peloruside A from a readily available 
oxazolidinone 34.
60
 Stereoselective alkylation of the oxazolidinone with 
benzyloxymethyl chloride promoted by titanium tetrachloride, followed by exchange 
of protecting groups and reductive removal of the chiral auxiliary gave the 
monoprotected diol 35. Dess-Martin oxidation and Still-Gennari olefination provided 
the (Z)-trisubsituted alkene 36.
60
 Subsequent conversion of the C15 methyl ester to the 
corresponding aldehyde followed by Brown asymmetric allylation provided the allyl 
alcohol 37 with a 97:3 diastereomeric ratio.
60
  
 
The desired 1,3-syn relationship between C13 and C15 hydroxyls was generated by a 
sterically directed electrophilic iodination sequence to give the six-membered 
carbonate 38.
60
 Successive epoxidation and reaction with a dithiane synthon, after 
methylation and dithiane hydrolysis, gave the β-methoxy aldehyde 39. Mukaiyama 
aldol reaction of the β-methoxy aldehyde 39 with the enol silane 40 gave an 8:1 
diasteromeric mixture in favour of the 1,3-anti relationship between C11 and C13 
hydroxyls.
60
 Subsequent protection of the C11 hydroxyl as a MOM ether completed 
the synthesis of the ketone 41.
52
 
 
The aldehyde 33 was synthesised from the commercially available (S)-glycidyl 
tosylate 29.
52
 (S)-Glycidyl tosylate was treated with lithiated dithiane, followed by 
copper-catalysed Grignard addition.
52
 The resulting secondary alcohol was silylated 
and the dithiane was hydrolysed.
52
 Coupling of the resulting aldehyde 30 with the 
oxazolidinone 31 provided the aldol adduct 32 as a single diastereomer.
52
 
Methylation, reprotection of C2 with methoxymethyl chloride, and finally oxidative 
cleavage of the terminal alkene by ozone gave the aldehyde 33.
52
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Scheme 1.3 Synthetic route to (+)-peloruside A by Jin and Taylor.
52, 60
 
 
Conditions: (i) nBuLi, dithiane; (ii) vinylMgBr, CuI; (iii) TESCl; MeI; (iv) CaCO3; 
(v) Bu2BOTf, TEA; (vi) Me3OBF4; (vii) DDQ; (viii) MOMCl; (ix) ozone, PPh3; (a) 
TiCl4, BOMCl; (b) H2, Pd/C; (c) TIPSCl; (d) LiBH4; (e) Dess-Martin periodinane; (f) 
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18-crown-6, bis(2,2,2-trifluoroethyl)-1-(methoxycarbonyl)ethylphosphonate, THF, 
KHMDS; (g) DIBAL-H; (h) Dess-Martin periodinane; (i) (+)-Ipc2Ballyl; (j) Boc-ON; 
(k) NIS, MeCN; (l) K2CO3, MeOH; (m) TBSCl, imidazole; (n) 1,3-dithiane, nBuLi; 
(o) tBuOK, MeI; (p) MeI, MeCN/H2O; (q) BF3.OEt2, DCM, -78 °C; (r) MOMCl, 
DIPEA; (s) LDA; (t) Dess-Martin periodinane; (u) PTSA, PhMe; (v1) HF.pyridine; 
(v2) TIPSCl; (v3) LiOH, H2O; (v4) 2,4,6-Cl3C6H2COCl, TEA, DMAP; (w) NaBH4, 
CeCl3; (x) mCPBA; (y) Me3OBF4, 2,6-di-tBu-pyridine; (z) 4 N HCl. 
 
An aldol coupling of the C1–C7 aldehyde 33 segment with the C8–C24 ketone 41 
provided the aldol adduct as a mixture of diastereomers, which was oxidised to give 
the β-diketone 42. The pyranone 43 was obtained following an approach adapted from 
De Brabander‟s synthesis of peloruside A.51 Desilylation followed by resilylation with 
triisopropylsilyl chloride and removal of the auxiliary with lithium hydroxide 
provided a seco-acid which was activated to undergo Yamaguchi macrolactonisation, 
yielding 44.
52
  
 
A stereoselective Luche reduction followed by epoxidation of the resulting allylic 
alcohol yielded the triol 45, and provided for a selective deprotection of the C11 MOM 
in the process.
52
 Jin and Taylor proposed intramolecular glycal epoxide ring 
fragmentation involving the MOM group, passing through a six-membered transition 
state, followed by hydrolysis of the intermediate oxo-carbenium ion and the loss of 
the resulting unstable methyl glycoside upon workup as a rationalisation for the 
deprotection of the C11 MOM.
52
 Subsequent methylation and global deprotection gave 
the desired (+)-peloruside A.
52
 The synthesis was achieved in 29 steps with an overall 
yield of 0.4% from the oxazolidinone 34. 
 
1.7.2.3 Synthesis of (+)-peloruside A by Ghosh (Scheme 1.4)
53, 61
 
 
Ghosh opted to synthesise peloruside A from the commercially available (-)-2,3-O-
isopropylidene-D-threitol 52.
53
 The threitol 52 was monoprotected, iodinated, and 
vinylated to give the alkene 53. The isopropylidene was removed and 
iodoetherification followed by methylation of the C3 hydroxyl led to the 5-membered 
cyclic iodoether 54.
53
 The iodoether 54 was then cleaved and the C2 hydroxyl was 
protected as MOM ether, overall achieving differential protection at the C2 and C3 
 43 
ethers. The resulting olefin 55 was converted to an aldehyde, then Brown allylation 
performed to give the allylic alcohol 56.
53
 
 
The allyl alcohol 56 was silylated and the terminal olefin was again converted to an 
aldehyde then subjected to Z-selective Ando method of HWE (Horner-Wadsworth-
Emmons olefination to provide the Z-olefin 57.
53
 Sharpless asymmetric 
dihydroxylation of the olefin 57 gave a diol which was protected as an isopropylidene 
acetal 58 under acidic conditions. Subsequent DIBAL-H (diisobutylaluminium 
hydride) reduction, Grignard addition to the aldehyde, and Dess-Martin oxidation of 
the alcohol gave the desired enone 59.
53
  
 
The aldehyde 51 was synthesised from the oxazolidinone 46. Asymmetric alkylation 
of the imide 46 with benzyloxymethylene chloride followed by reductive removal of 
the chiral oxazolidinone gave the alcohol 47.
61
 Swern oxidation and the subsequent Z-
selective HWE reaction of the aldehyde with the sodium enolate of (o-
creosol)2P=O(CH3)CHCO2Et provided tri-substituted Z-olefin 48.
61
 Subsequent 
DIBAL-H reduction, Dess-Martin oxidation and Brown asymmetric allylboration 
gave the homoallylic alcohol 49 as the major diastereomer (dr = 97:3).
61
 Protection of 
the C15 hydroxyl as TES ether followed by oxidative cleavage to an aldehyde and the 
subsequent asymmetric allylation gave alcohol 50 with 5:1 diastereomeric ratio.
53
 
Subsequent methylation and oxidative cleavage of the C11 olefin provided the 
aldehyde 51. 
 
 
 
 
 
 
 44 
Scheme 1.4 Synthetic route to (+)-peloruside A by Ghosh.
53, 61 
 
Conditions: (i)TiCl4, TEA, DCM, PhCH2OCH2Cl, 0 °C, 1.5 h; (ii) LiBH4, MeOH, 
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creosol)2P(O)(Me)CHCO2Et, NaH, THF, -78 to -40 °C, 2h; (v) DIBAL-H, DCM, -78 
to -40 °C, 1 h; (vi) Dess-Martin periodinane, NaHCO3, DCM, 23 °C, 1.5 h; (vii) (+)-
Ipc2Ballyl, Et2O, -80 °C, 3 h; (viii) TESOTf, 2,6-lutidine; (ix) OsO4, NMO; (x) 
Pb(OAc)4, DCM; (xi) (-)-Ipc2BOMe, allylMgBr; (xii) Me3OBF4, Proton-sponge
®
; 
(xiii) OsO4, NMO; (xiv) Pb(OAc)4, DCM; (a) NaH, PMBCl; (b) PPh3, I2, imidazole; 
(c) CuI, vinylMgBr; (d) 10% HCl, MeOH; (e) I2, NaHCO3; (f) Me3OBF4, Proton-
sponge
®
; (g) Zn, aqueous EtOH; (h) MOMCl, DIPEA; (i) OsO4, NMO; (j) NaIO4, 
aqueous THF; (k) Ipc2Ballyl, Et2O; (l) TBSCl, imidazole; (m) OsO4, NMO; (n) 
NaIO4, aqueous THF; (o) (o-cresol)2P(O)CH2CO2Et, NaH; (p) AD-mix-α, tBuOH-
H2O; (q) CH2=C(OMe)Me, PPTS; (r) DIBAL-H, THF; (s) iPrMgBr; (t) Dess-Martin 
periodinane; (u) L-selectride, Et2O, -78 °C, then 51, 1 h; (v1) DDQ (cat.), aq. THF; 
(v2) DDQ, DCM; (v3) TPAP, NMO, DCM; (v4) NaClO2, NaH2PO4; (v5) 2,4,6-
Cl3C6H2COCl, DIPEA, then DMAP, toluene; (w) 1M HCl, THF; (x) Me3OBF4, 2,6-
di-tBu-pyridine; (y) Pd/C, MeOH, formic acid; (z) 4 M HCl, THF.
 
 
A conjugate reduction-aldol coupling between the enone 59 and the aldehyde 51 
completed the C1–C24 backbone, which proceed by selective enolisation. The aldol 
product 60 was obtained as a 4:1 mixture of diastereomers.
53
 The C15 TES and C1 
PMB protecting groups were then selectively removed with DDQ. The primary 
alcohol at C1 was oxidised to an aldehyde which was then further oxidised to a 
carboxylic acid. The carboxylic acid was subjected to Yamaguchi lactonisation to 
provide the corresponding macrolactone 61.
53
 The subsequent deprotection of the C5 
TBS (tert-butyldimethylsilyl) and the isopropylidene protecting groups gave a 
mixture of ketone and hemi-ketal. Selective methylation of the resulting diol 
converted the C7 hydroxyl to the desired methyl ether, giving 62.
53
 The benzyl ether at 
C24 was removed by transfer hydrogenation. The subsequent treatment with aqueous 
acid removed the MOM ether at C2, completing the synthesis of (+)-peloruside A.
53
 
The synthesis was completed in 30 steps with 1% total yield from (-)-2,3-O-
isopropylidene-D-threitol. 
 
1.7.2.4 Synthesis of (+)-peloruside A by Evans (Scheme 1.5)
54
 
 
The Evans group based their synthesis of peloruside A on aldol coupling reactions to 
build the skeleton of peloruside A. The peloruside A backbone was assembled from 
 46 
three major synthons: the C1–C6 methyl ketone 66, the C7–C11 aldehyde 70, and the 
C12–C24 methyl ketone 78. The synthesis of the methyl ketone 78 commenced from 
the oxazolidinone alcohol 73.
62
 Silylation of the C24 hydroxyl followed by removal of 
the oxazolidinone moiety provided the alcohol 74. Subsequent Swern oxidation and 
phosphonate coupling provided the enoate 75. DIBAL-H reduction of the ester 75 
gave the allylic alcohol 76. Subsequent oxidation and Brown allylation of the 
resulting aldehyde gave the alcohol 77. Protection of the C15 hydroxyl as a PMB ether 
and redox reaction provided the methyl ketone 78.  
 
The synthesis of the aldehyde 70 was started from (S)-pantolactone (67). The 
pantolactone 67 was benzylated and the lactone was ring opened to the corresponding 
Weinreb amide. Subsequent silylation of the C11 hydroxyl gave 68. Olefination of the 
amide 68 provided the ketone 69. Chelation-controlled reduction of the ketone 69 
provided the corresponding alcohol with 95:5 diastereomeric ratio. Protection of the 
resulting C8 hydroxyl with tert-butyldimethylsilyl chloride followed by oxidative 
cleavage at C7 furnished the aldehyde 70. Methyl ketone 66 was synthesised from 
commercially available (S)-4-benzyl-2-oxazolidinone, which was converted to the 
corresponding glycolate oxazolidinone 63 and coupled to the aldehyde 64. The 
subsequent 1,2-syn aldol product 65 was methylated and the C5 acetal was removed to 
provide the methyl ketone 66.  
 
1,5-Anti aldol coupling, mediated by 9-BBNOTf (9-Borabicyclo[3.3.1]nonyl 
trifluoromethanesulfonate), between the methyl ketone 66 and aldehyde 70 provided 
the alcohol 71 with an excellent diastereoselectivity (dr = 98:2). However, the 
selectivity for the desired (R)-diastereomer depends on the dialkylboryl enolate 
employed in the reaction and the size of the C11 protecting group. The use of 
dicyclohexylboron chloride as coupling reagent saw a shift to favour the (S)-
diastereomer as the major product. Similarly, using a larger BOM (benzyloxymethyl) 
as C11 protecting group reduced the diastereoselectivity of the 1,5-anti aldol coupling 
reaction. The C5 ketone was selectively reduced to give the corresponding 1,3-anti 
diol (dr = 10:1). The less hindered C5 hydroxyl was selectively silylated followed by 
methylation of the C7 hydroxyl. The subsequent hydrogenation and Dess-Martin 
oxidation provided the C7–C11 synthon 70. 
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Scheme 1.5 Synthetic route to (+)-peloruside A by Evans.
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TESCl, TEA, DMAP, RT ; (4) Me2C=CHBr, tBuLi, Et2O; (5) Zn(BH4)2, -30 °C; (6) 
TBSCl; (7) O3, PPh3; (8) 9-BBNOTf, TEA, toluene; (9) Me4N(OAc)3BH, AcOH, 
MeCN, -30 °C; (10) TBSCl, imidazole, RT; (11) Me3OBF4, Proton-sponge
®
, DCM, 
RT; (12) Pd(OH)2/C, H2, EtOAc, RT; (13) Dess-Martin periodinane, pyridine, DCM, 
0 °C; (a) TBSCl, imidazole, DMF; (b) LiBH4, H2O, Et2O, 20 °C; (c) (COCl)2, DMSO, 
TEA, -78 °C to RT; (d) (PhO)2P(=O)CH(Me)CO2Et, NaH, THF, -78 to 0 °C; (e) 
DIBAL-H, DCM, -78 °C; (f) MnO2, DCM, RT; (g) (+)-IpcBallyl, Et2O, -78 °C; (h) 
NaH, THF, 0 °C; then PMBBr, 3:1 THF/DMF, RT; (i) PdCl2, Cu(OAc)2.H2O, O2, 7:1 
DMF/H2O, RT; (j) 9-BBNOTf, DIPEA, 72; (k) (iPr)2SiHCl, DMAP, DMF; (l) SnCl4, 
-78 °C; (m) TBAF, HOAc, THF, -20 °C; (n) Me3OBF4, Proton-sponge
®
, DCM, RT; 
(o) DDQ; (p) H2O2, LiOH; (q) 2,4,6-Cl3C6H2COCl, DIPEA, THF, RT, then DMAP, 
toluene, 60 °C; (r) 4 N HCl, MeOH, 1 h, 0 °C, 2 h, RT. 
 
A second 1,5-anti aldol coupling by 9-BBNOTf between the methyl ketone 78 and 
aldehyde 72 completed the backbone of peloruside A. The stereoselectivity was 
dependent on the reduced steric hindrance and enhanced electronic effects provided 
by the neighbouring C9 carbonyl. The resulting aldol product 79 was obtained in 20:1 
diastereomeric ratio. Subsequent conversion of the C11 hydroxyl, stereoselective 
reduction of the C15 ketone, removal of the resulting C11–C13 disilyloxane protecting 
group, selective methylation of C13 and deprotection of C15 gave the diol 80. Removal 
of the chiral auxiliary followed by Yamaguchi macrolactonisation afforded the 
desired macrolactone 81. Subsequent global deprotection of the macrolactone 81 
concluded the synthesis of (+)-peloruside A. The synthesis was achieved within 18 
steps with a total yield of 12% from the oxazolidinone alcohol 73. 
 
1.7.3 Synthesis of peloruside A analogues 
 
The following section will discuss the synthesis approaches towards the (-)-2-epi-
peloruside A analogue by Smith, monocyclic peloruside A analogue by Wullschleger, 
and peloruside B by Ghosh.  
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1.7.3.1 (-)-2-epi-peloruside A 
 
The original synthetic route of the Smith group was designed to provide (+)-
peloruside A. The synthetic strategy (Scheme 1.6)
57
 made use of ARC (anion relay 
chemistry) reaction as a key step for the assembly of the C1–C8 synthon 95. The 
synthesis began with ARC reaction between the lithium anion of the dithiane 91 and 
the two known epoxides 90 and 92 to give the alcohol 93. 
 
 
Subsequently, the C7 hydroxyl was methylated and the C3 TBS protecting group was 
removed. The C5 dithiane was converted to ketone and then selectively reduced. The 
resulting 1,3-syn diol was protected with acetonide. Subsequent hydrogenolysis to 
remove the C1 benzyl protecting group afforded the alcohol 94. Conversion of the 
alcohol 94 to the corresponding methyl ester followed by oxidative cleavage of the 
PMB functionality and Parikh-Doering oxidation of the terminal hydroxyl provided 
the aldehyde 95.  
 
The C9–C24 synthon 89 was synthesised from (+)-3-ethylbut-3-en-1-ol (82). The C24 
hydroxyl was protected as BPS (tert-butyldiphenylsilyl) ether followed by ozonolysis 
of the alkene double bond to afford the aldehyde 83. A Z-selective Still-Gennari 
olefination yielded the ester 84 as a single diastereomer. Subsequent reduction 
followed by oxidation provided an aldehyde which underwent Brown allylation to 
give the allylic alcohol 85. The alcohol 85 was obtained in 77% yield with a 20:1 
diastereomeric ratio. 
 
Conversion of the C15 hydroxyl to PMB ether followed by dihydroxylation and 
oxidative cleavage provided the aldehyde 86. Subsequent coupling of the aldehyde 86 
with the dithianated ketone 87 provided the desired β-hydroxy ketone 88 in 86% yield 
with a 20:1 diasteromeric ratio. A selective Evans-Tischenko reduction by SmI2 
installed the C11 sterochemistry as a propionate ester, which was hydrolysed and 
protected as MOM ether. Subsequent DIBAL-H reduction and methylation provided 
the dithiane 89. 
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Scheme 1.6 Synthetic route to (-)-2-epi-peloruside A by Smith.
57
 
 
Conditions: (i) BPSCl, TEA; (ii) O3, PPh3; (iii) (CF3CH2O)2P(O)C(Me)CO2Et, 
KHMDS, 18-crown-6, THF; (iv) DIBAL-H; (v) SO3.pyridine, DMSO; (vi) (+)-
OH OBPS
OH
OBPS
O OH O S S
PMB
OBPS
O OMe O S S
PMB MOM
82
9 911 1113 13
22 21 22 2123 23
23
24 24
24
24
20 20
20
18 18
1818
20
15 15
15
OBPS
O
24
20
18
OBPS
OEt
O
23
24
18
20
15
OBPS
O O
PMB
23
24
20
18
15
O S S
9
22 21
83 84 85
86
87
8889
i, ii iii iv - vi vii - ix
xxi - xiv
O
OSEM
OBn
SS
TBS OPMB
O OH O OBn
OSEMOPMB
SS
TBS
OMe O O O
OMe
OSEMO
1
1
3
3
5
5
7
7
+ +
OMe O O OH
OSEMOPMB
1357
89
OBPS
O OMe O
PMB MOM
OMe O O O
OMe
OSEMOH
SS
SEMO
O
MOMO
OH
OMe
O
MeO
BPSO
O
O
SS
SEMO
O
MOMO
OH
OMe
O
MeO
BPSO O
OH
OH
(-)-2-epi-Peloruside A
5
11
24
7913
22 21
23
18
20
15
1 3
1
13
3
5
5
7
79
911
11
13
13
22 21
22 21
23
23
24
24
20
20
18
18
15
15
OBPS
OH OMe O
MOM
OMe O O O
OH
OSEMOH
SS
135791113
22 2123
24
20
18
15
99
90 91 92 93 94
9596
97 98
a
65%
b - g
37%
h - l
64%
m
45%
(dr = 9:1)
n - q   84%
r
71%
s
70%
t, u
56%
 51 
Ipc2Ballyl; (vii) PMBCl, NaH, TBAI; (viii) AD-mix-β, tBuOH; (ix) NaIO4, THF, 
H2O; (x) LiHMDS, TMSCl, C(SC3H6S)C(Me)2C(O)Me, BF3.OEt2; (xi) SmI2, 
EtCHO; (xii) MOMCl, DIPEA; (xiii) DIBAL-H; (xiv) MeI, NaH, 15-crown-5; (a) 91, 
tBuLi, Et2O, then 90 in Et2O, then 92, THF, HMPA; (b) MeI, NaH; (c) TBAF; (d) 
Hg(CIO4)2; (e) NaBH4, Et2BOMe; (f) DMP, PPTS; (g) Pd(OH)2, (C6H7)CH3, CaCO3, 
EtOH; (h) SO3.pyridine, DMSO; (i) NaCIO2, NaHPO4, 2-methyl-2-butene; (j) 
TMSCHN2, MeOH; (k) DDQ, pH 7.0 buffer; (l) SO3.pyridine, DMSO; (m) 89, tBuLi, 
HMPA, THF, -78 °C, 30 min, then 95, THF, -78 °C, 4 h; (n) DDQ, pH 7.0; (o) 
SO3.pyridine, DMSO; (p) (R)-Me-CBS, BH3.THF; (q) LiOH, H2O, THF; (r) 2,4,6-
Cl3C6H2COCl, DIPEA, THF, DMAP, PhCH3, 90 °C; (s) PhI(O2CCF3)2, MeCN, H2O, 
0 °C to RT; (t) Me3OBF4, 2,6-di-tert-butyl-4-methylpyridine; (u) 4 N HCl, MeOH. 
 
Felkin-Anh controlled coupling between the lithium anion derived from C9–C24 
dithiane 89 and C1–C8 aldehyde 95 produced the full C1–C24 backbone. The coupled 
product 96 was obtained with a 9:1 diastereomeric ratio. The initial attempt to utilise 
Mitsunobu protocol for macrolactonisation, after liberation of the C15 hydroxyl and 
the carboxylic acid, failed to provide the desired result. Therefore, the attempt was 
deflected to inverting the C15 hydroxyl for the purpose of achieving Yamaguchi 
macrolactonisation.  
 
The PMB protecting group of the C15 was removed to reveal the secondary hydroxyl 
group, which was then oxidised. Subsequent asymmetric CBS (Corey-Bakshi-
Shibata) reduction selectively provided the required stereogenicity. Saponification 
provided the seco-acid 97. The Yamaguchi macrolactonisation protocol generated the 
macrolide 98. However, the formation of the macrolide 98 involved an unexpected 
epimerisation at C2. A computer generated conformational study showed that, as a 
result of torsional strain in the macrocyclic ring, the major torsional differences 
between the lower energy conformers resided in the C1–C2 bond. The epimerisation 
was a result of the macrolide adopting the more stable conformation. 
 
Subsequent treatment of the macrolide 98 with Stork reagent resulted in the removal 
of the C3–C5 isopropylidene protecting group and hydrolysis of the 1,3-dithiane at C9, 
with concomitant hemiketal formation to give 99. Selective methylation of the C3 
hydroxyl followed by global deprotection afforded the (-)-2-epi-variant of peloruside 
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A. The synthesis was achieved in 21 linear steps with 2% total yield from the known 
epoxide 90. 
 
1.7.3.2 Monocyclic peloruside A analogue 
 
Recently, Wullschleger reported the synthesis (Scheme 1.7)
58
 of the first synthetic 
analogue of peloruside A with significant structural changes. The analogue was a 
monocyclic version of peloruside A which lacks the C6–C8 part of the pyran ring. The 
analogue was synthesised in 19 steps with an overall yield of 4% from epoxide 108. 
Antipoliferative activity assessment against three human cell line revealed that the 
monocyclic analogue has less bioactivity compared to peloruside A. The IC50 towards 
MCF-7 and HCT116 cell lines is >20 µM and the IC50 towards A549 cell line is 16.4 
µM. 
 
The synthetic route adopted by Wullschleger utilised conversion of (S)-aspartic acid 
to the epoxide 108. Ring opening and coupling of the epoxide 108 with lithiated 
dithiane 109, obtained from 2,2-dimethylpropane-1,3-diol, followed by conversion of 
the resulting hydroxyl at C13 to methyl ether provided 110. Subsequent removal of the 
C11 dithiane and C9 TBS protecting groups, followed by Swern oxidation of the 
resulting alcohol afforded the aldehyde 111.  
 
Asymmetric allyltitanation installed the olefin of homoallylic alcohol 112 with up to 
70:1 diastereomeric ratio. The C11 ketone was selectively reduced to give 1,3-anti 
diol. Double silylation of the resulting C11 and C9 hydroxyls as TBS ether ensued. 
Subsequent oxidative cleavage to remove the C15 PMB protecting group followed by 
oxidation of the resulting alcohol gave the aldehyde 113. 
 
The C16–C24 synthon 103 was synthesised from the oxazolidinone 100. 
Diastereoselective Evans alkylation of the oxazolidinone 100 with benzyloxymethyl 
chloride using TiCl4 provided the starting building block 101.
62
 Reductive removal of 
the oxazolidinone moiety of 101 afforded the alcohol 102. Subsequent Swern 
oxidation followed by Z-selective Wittig olefination furnished the vinyl iodide 103 (dr 
= 10:1). 
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Scheme 1.7 Synthetic route to monocyclic peloruside A analogue by Wullschleger.
58
 
 
Conditions: (i) BOMCl, TiCl4;
62
 (ii) LiBH4, EtOH, Et2O, 0 °C; (iii) (COCl)2, DMSO, 
TEA, -78 °C; (iv) Ph3P=C(Me)I, -78 °C; (1) TiCl4, DIPEA, NMP, acrolein, DCM, -78 
°C; (2) Me3OBF4, Proton-sponge
®
; (3) LiBH4, MeOH, THF, 0 °C; (4) DMP, DCM; 
(5) NaClO2, NaH2PO4, 2-methyl-2-butene; (a) 109, nBuLi, RT, then 110; (b) NaH, 
MeI, 15-crown-5; (c) NaHCO3, I2; (d) PTSA; (e) (COCl)2, DMSO, TEA, -78 °C; (f) 
asymmetric allyltitanation; (g) Me4NBH(OAc)3, -20 °C, 4 days; (h) TBSCl, 
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imidazole; (i) TBSOTf, lutidine; (j) DDQ; k) DMP; (l) 103, tBuLi, -78 °C, Et2O, then 
113; (m) Dess-Martin periodinane; (n) (R)-B-Me-CBS, catecholborane; (o) 107, TEA, 
DMAP, 2,4,6-Cl3C6H2COCl, toluene; (p) Grubbs‟ 2
nd
 generation catalyst, 
ClCH2CH2Cl, 80 °C; (q) HF.pyridine, THF; (r) PADA, AcOH, 40 °C, DCM; (s) 
Pd/C, H2, EtOAc. 
 
Lithiation of the vinyl iodide 103 and addition to the aldehyde 113 and the vinyl 
iodide 103 provided the allyl alcohol 114 with (S)-C15 hydroxyl functionality in 2:1 
diastereomeric ratio. In an attempt to enhance the yield, the diastereomeric mixture 
was oxidised to a ketone and the subsequent stereoselective reduction gave a 
stereochemically pure 114. 
 
The C1–C4 synthon 107 was obtained from the oxazolidinone 104. An aldol coupling 
between acrolein and the oxazolidinone 104 provided an allyl alcohol (105) in 69% 
yield. Methylation of the resulting C3 hydroxyl followed with reductive removal of 
the auxiliary gave the alcohol 106. Subsequent two-step oxidation at C1 provided the 
carboxylic acid 107. 
 
Yamaguchi esterification between the allyl alcohol 114 and the carboxylic acid 107 
assembled the required backbone for the analogue. Subsequent RCM (ring closing 
metathesis) by Grubbs‟ 2nd generation catalyst completed the macrolide formation, 
giving the E-isomer 115. The TBS protecting groups were duly removed and the 
alkene double bond selectively reduced. The hydrogenation reaction to remove the 
benzyl protecting groups completed the synthesis of the monocyclic analogue of 
peloruside A. 
 
1.7.3.3 Peloruside B 
 
Ghosh and collaborators have recently reported the discovery and total synthesis of 
peloruside B, the 3-des-O-methyl variant of peloruside A.
44
 Peloruside B was isolated 
from Mycale hentscheli from Kapiti Island in New Zealand. Biological studies on 
peloruside B showed a comparable, albeit lower, bioactivity to peloruside A. 
Peloruside B also promotes apoptosis by acting as microtubule stabiliser and 
interrupts the cell cycle at the G2/M phase.
44
 However, peloruside B is less cytotoxic 
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when compared to peloruside A. Peloruside A has an IC50 of only 10 ± 4 nM for HL-
60 cells while peloruside B has IC50 of 33 ± 10 nM for the same cell type.
44
  
 
The total synthesis of peloruside B was achieved utilising a similar synthetic strategy 
to that employed for peloruside A.
53, 61
 The key reaction steps involved Sharpless 
dihydroxylation, Brown‟s symmetric allylboration, reductive aldol coupling and 
Yamaguchi macrolactonisation (Scheme 1.8). The convergent synthesis of peloruside 
B was completed in 29 steps with the total yield of 0.3%.
44
 
 
The synthesis commenced by protection of the hydroxyls of diethyl D-tartrate as 
MOM acetals followed by LAH (lithium aluminium hydride) reduction of the esters 
to a diol and monoprotection of the C1 hydroxyl as the PMB ether. The resulting 
alcohol 117 was iodinated and vinylated to give the alkene 118.
44
 A sequence of 
similar transformation as in the synthesis of peloruside A provided the desired enone 
122.
44, 53, 61
 
 
The aldehyde 51 was synthesised by the methodology used in Ghosh‟s synthesis of 
peloruside A.
53, 61
 Conjugate reductive aldol coupling between the enone 122 and the 
aldehyde 51 gave the completed C1–C24 aldol product 123.
44
 The formation of the 
aldol product 123 was lower yielding compared to the corresponding aldol product 60 
in the synthesis of peloruside A but the diastereoselectivity was slightly improved.
44, 
53, 61
 
 
Subsequent protection of the C11 hydroxyl as a TES ether followed by the removal of 
C1 PMB protecting group afforded the alcohol 124.
44
 Two step consecutive oxidation 
of the alcohol 124 gave the corresponding carboxylic acid moiety at C1. Removal of 
the TES protecting group at C11 and C15 provided 125. Yamaguchi macrolactonisation 
followed by the desilylation of the C5 hydroxyl gave 126 as a 6:1 mixture of 
hemiketal and hydroxyketone.
44
 
 
Removal of the isopropylidene protecting group from the hemiketal and 
hydroxyketone mixture 126 gave the corresponding diol at C7 and C8.
44
 Subsequent 
selective methylation of the C7 hydroxyl and the removal of the MOM protecting 
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group from C2 and C3, followed by catalytic transfer hydrogenation to remove the 
benzyl moiety at C24, completed the synthesis of peloruside B.
44
 
 
Scheme 1.8 Synthetic route to peloruside B by Ghosh.
44, 53, 61 
 
Conditions: (a) P2O5, CH2(OMe)3; (b) LAH; (c) NaH, PMBCl; (d) PPh3, I2 , 
imidazole; (e) CuI, vinylMgBr; (f) OsO4, NMO; (g) NaIO4, aq. THF; (h) Ipc2Ballyl, 
Et2O; (i) TBSCl, imidazole; (j) OsO4, NMO; (k) NaIO4, aq. THF; (l) (o-
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cresol)2P(O)CH2CO2Et, NaH; (m) AD-mix-α, tBuOH-H2O; (n) CH2=C(OMe)Me, 
PPTS; (o) DIBAL-H, THF; (p) isopropylMgBr; (q) Dess-Martin periodinane; (r) L-
selectride, Et2O, -78 °C, then 51, 1 h; (s) TESOTf; (t) DDQ, pH 7 buffer; (u) DMP; 
(v) NaCIO2, NaH2PO4; (w) 2% HF.pyridine, THF; (x) 2,4,6-Cl3C6H2COCl, DIPEA, 
then DMAP; (y) HF.pyridine; (w1) 80% aqueous acetic acid, 50 °C, 3 h; (w2) 
Me3OBF4, 2,6-di-tBu-pyridine; (w3) 4 M HCl, THF; (w4) Pd/C, MeOH, formic acid. 
 
1.8 Laulimalide 
 
Laulimalide (127, Figure 1.21) is a cytotoxic natural product that was isolated in 1988 
from a Vanuatu chocolate sponge Cacospongia mycofijiensis by Quinoa.
63
 
Independently, Corley also isolated laulimalide from an Indonesian sponge Hyattella 
sp. in 1988.
64
 Both groups also found laulimalide in the predator nudibranch 
Chromodoriz lochi that feeds on the sponges.
63, 64
 Laulimalide has since been found in 
other species of sponges such as Dactylospongia sp. and Fasciospongia rimosa.
65, 66
  
 
 Figure 1.21 Laulimalide family. 
 
Laulimalide is a polyoxygenated 20-membered ring system containing two 
dihydropyran rings, several olefins, and a highly unstable epoxide. The laulimalide 
family also include two isomers of laulimalide: isolaulimalide (128, Figure 1.21) is an 
acid-catalysed epoxide ring-opened isomer, and neolaulimalide (129, Figure 1.21) is a 
ring-expanded regioisomer.
67, 68
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1.8.1 Biological activity of laulimalide 
 
Biological studies have shown that the laulimalides are biologically active cytotoxic 
agents.
47, 69, 70
 Laulimalide has an IC50 ranging from 6 to 15 nM depending on the cell 
line.
68
 Neolaulimalide is less potent than laulimalide, with an IC50 of 10 to 50 nM.
68
 
Isolaulimalide is the least active of the laulimalide family, with an IC50 of only 20 μM 
in almost all the cell lines tested.
68
 Bioactivity studies have shown that laulimalide is a 
microtubule stabilising agent that initiates mitotic arrest in proliferating cells, leading 
to apoptosis.  
 
Like peloruside A, laulimalide also has reduced susceptibility towards Pgp efflux 
pumps and is more potent in multidrug resistant cells than the taxoid drugs.
47
 A 
bioactivity study has established that laulimalide binds at the β-tubulin subunit.47 
Laulimalide does not bind to the taxane site, and therefore has a potential use as a 
synergistic drug with taxanes.
47
 Further studies to establish the binding site found that 
laulimalide and peloruside A do not synergise and compete with each other for 
binding to tubulin. The results indicate that peloruside and laulimalide bind to the 
same site on the β-tubulin.47  
 
1.8.2 Synthesis of laulimalide 
 
The complex structure and pharmaceutical potential of laulimalide have driven 
several attempts at the total synthesis of this natural product. The first total synthesis 
of (-)-laulimalide was reported by Ghosh and co-workers in a lengthy 35-step 
sequence with 0.1% overall yield.
71, 72, 73
 The synthesis strategy features RCM 
reactions for the construction of the dihydropyran rings, a Julia-Kocienski coupling 
between the C3–C16 and C17–C28 synthons (147 and 140, Scheme 1.9), and 
intramolecular Still-Gennari variation of HWE olefination that provide a 1:2 mixture 
of cis- and tran-isomers followed by photoisomerisation of the tran-isomer to a 
mixture of  cis- and trans-isomers for the construction of the macrolactone.
71, 73
 
 
The synthesis of synthon 147 commenced from the alcohol 141 which was obtained 
from methyl (S)-3-hydroxy-2-methylpropionate.
73
 Conversion of the alcohol 141 to 
the allyl alcohol 142 was achieved through mesylate formation, sodium cyanide 
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displacement, DIBAL-H reduction and Brown allylation of the resulting aldehyde. 
Subsequent alkylation, RCM, DIBAL-H reduction and ethyl glycoside formation 
furnished the desired dihydropyran 143 as a single anomer.
73
 
 
The ethyl acetal 143 was stereoselectively alkylated to an aldehyde, which was 
reduced with sodium borohydride. The resulting hydroxyl was protected as a TBS 
ether. Subsequent removal of the benzyl protecting group was followed by conversion 
of the alcohol to the iodide 144.
71, 73
 Alkylation with sulfonyl lactone 131 gave the 
C3–C16 fragment 145 as a 4.2:1 diastereomeric mixture. Subsequent conversion of the 
sulfonated lactone to the alcohol 146 was followed by MOM protection of the C15 
hydroxyl, PMB removal and Swern oxidation to provide the aldehyde 147.
71, 73
 
 
The C17–C28 segment 140 was synthesised from the tetrahydropyranyl glycidol 132. 
Epoxide ring opening of 132 and PMB protection of the resulting alcohol 133 
followed by removal of the THP (tetrahydropyranyl) protecting group and Swern 
oxidation gave the aldehyde 134.
73
 Additionally, epoxide ring opening and alkylation 
of 132 by isopropylmagnesium bromide gave the homoallylic alcohol 135. 
Subsequent treatment with allylbromide provided the diene 136 which underwent 
RCM followed by removal of the THP protecting group to give the dihydropyran 
137.
73
 Subsequent Swern oxidation followed by Corey-Fuch homologation provided 
the dibromo-olefin 138.  
 
The ensuing coupling between the alkynyl anion derived from 138 and the aldehyde 
134 afforded the alcohol 139 (syn:anti = 1.8:1).
71, 73 
Due to poor selectivity and 
separability, the C20 hydroxyl was oxidised to a ketone and then selectively reduced 
with L-selectride to give only the syn-isomer 139. Subsequent reduction of the alkyne 
to an alkene and PMB deprotection followed by protection of the resulting diol with 
p-methoxybenzylidene acetal and DIBAL-H reduction gave the alcohol 140.
71, 73
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Scheme 1.9 Synthetic route to (-)-laulimalide by Ghosh.
71, 73 
 
Conditions: (1) PhSO2CH3, nBuLi, THF, 0°C, 1 h, then HMPA, -78 to 23 °C, 2 h; (2) 
NaH, PMBCl, DMF, 0 to 23 °C; (3) CSA, MeOH; (4) DMSO, (COCl)2, DIPEA, 
DCM, -78 °C; (i) isopropylMgBr, catalytic CuCN, THF, -78 to 23 °C, 2 h; (ii) KH, 
catalytic 18-crown-6, allylbromide, THF, 0 to 23 °C; (iii) 10 mol% Grubbs‟ 2nd 
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generation catalyst, DCM,  23 °C, 2 h; (iv) CSA, MeOH; (v) DMSO, (COCl)2, 
DIPEA, DCM, -78 °C; (vi) CBr4, PPh3, DCM, 0 to 23 °C, 30 min (vii) 138, nBuLi, -
78 °C, 1 h and 23 °C, 1 h, then 134, -78°C; (viii) Dess-Martin periodinane, DCM, 23 
°C; (ix) L-selectride, THF, -78 °C; (x) Red-Al
®
, THF, - 20 °C; xi) TFA, DCM, 23 °C; 
(xii) p-methoxybenzylidene acetal, CSA, DCM, 23 °C; (xiii) DIBAL-H, DCM, -78 
°C; (a1) MsCl, TEA, DCM, 0 °C, 30 min; (a2) NaCN, DMSO, 60 °C, 2 h; (a3) 
DIBAL-H, DCM, 0 °C, 30 min; (a4) (-)-IpcBallyl, THF, -100 °C; (b1) acryloyl 
chloride, TEA, DCM, 0 to 23 °C; (b2) 10 mol% Grubbs‟ 2nd generation catalyst, 
catalytic Ti(OiPr)4, 40 °C, 5 h; (b3) DIBAL-H, DCM, -78 °C; (b4) CSA, EtOH; (c1) 
H2C=CHOTBS, Montmorillonite K-10, DCM, 23 °C; (c2) NaBH4, MeOH, 0 °C; (c3) 
TBSCl, imidazole, DMF, 23 °C; (c4) Li, liquid ammonia; (c5) I2, PPh3, imidazole, 
Et2O/MeCN (2:1); (d) 131, NaH, DMF, 0 °C for 15 min, then 144, 60 °C for 12 h; 
(e1) Red-Al
®
, THF, 0 °C; (e2) PhCOCl, TEA, DMAP, DCM; (e3) Na(Hg), NaHPO4, 
MeOH, -20 to 23 °C; (f1) MOMCl, DIPEA, DCM; (f2) DDQ, pH 7 buffer; (f3) 
DMSO, (COCl)2, DIPEA, DCM, -78 °C; (g1) 140, nBuLi, -78 °C, THF, 15 min, then 
147, -78 to -40 °C, 2 h; (g2) Ac2O, TEA, DMAP, DCM; (g3) Na(Hg), NaHPO4, 
MeOH, -20 to 23 °C; (h1) bis-(2,2,2-trifluoroethyl)-phosphonoacetic acid, 2,4,6-
Cl3C6H2COCl, DIPEA, DMAP; (h2) AcOH/THF/H2O (3:1:1), 23 °C; (i1) Dess-
Martin periodinane, DCM, 23 °C; (i2) K2CO3, 18-crown-6, -20 to 0 °C; (i3) hv, Et2O, 
50 min; (j1) PPTS, tBuOH, 84 °C; (j2) tBuOOH, (+)-DET, Ti(OiPr)4, -20 °C; (j3) 
DDQ, pH 7 buffer, 23 °C. 
 
Julia-Kocienski olefination was employed in the coupling of the alcohol 140 and the 
aldehyde 147. Subsequent acylation and treatment with Na(Hg) provided the coupling 
product 148 as a 3.4:1 mixture of trans- and cis- isomers.
71, 73
 Still-Gennari reagent 
formation followed by removal of the TBS ether provided 149. Dess-Martin oxidation 
followed by Z-selective HWE cyclisation gave a mixture of 2:1 trans- and cis-
macrolactones that were separable by chromatography. Subsequent 
photoisomerisation of the trans-isomer provide 150 as a 1:1 mixture.
71
 Subsequent 
removal of the MOM ether followed by Sharpless epoxidation with (+)-diethyl 
tartrate and removal of the PMB ether completed the synthesis of (-)-laulimlide.
71
 
 
Initially, the synthetic approach intended to utilise RCM to install the cis-olefin 
geometry and simultaneously form the macrolactone. However, various attempts 
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resulted in decomposition of the starting material. The approach was shifted to 
employing intramolecular HWE reaction. Although the desired cis-macrolide was 
obtained, the yield was low because formation of the trans-isomer was favoured and 
various attempts to influence the regioselectivity proved unsatisfactory.
71, 72, 73
 
Following a review of the synthetic strategy, Yamaguchi macrolactonisation reaction 
was investigated.
73
 The Yamaguchi protocol proceeded with a satisfactory 68% yield, 
giving the corresponding cis-macrolide as a single isomer.
72, 73
  
 
Following the synthesis by Ghosh, several other successful total syntheses of (-)-
laulimalide have been reported. Mulzer reported several approaches to the synthesis 
of (-)-laulimalide.
74-80
 Mulzer‟s first synthesis of (-)-laulimalide, reported in 2001, 
relied on a novel bi-directional RCM for the formation of the side chain dihydropyran, 
Julia-Kocienski olefination to install the C16=C17 trans-olefin bond (trans:cis = 
11.4:1), Still-Gennari cyclisation to simultaneously perform the macrolactonisation 
and form the C2=C3 cis-olefin bond (trans:cis = 1.8:1), and Sharpless asymmetric 
epoxidation of the C16=C17 trans-olefin to an epoxide.
74
  
 
In the same year, Mulzer reported another synthesis of (-)-laulimalide.
75
 The synthetic 
approach featured a competing silicon-mediated allyl transfer macrocyclisation that 
was governed by the orthogonality of two hydroxyl protecting groups.
75
 The mild 
absolutely anhydrous conditions employed in the reaction successfully prevented 
isomerisation of the established C2=C3 cis-olefin bond.
75
 Other key synthetic steps 
included a modified Kuwajioma‟s protocol using lithium chloride to provide the allyl 
silane precursor for the allyl transfer reaction, RCM to form the side chain 
dihydropyran ring and Sharpless asymmetric epoxidation to installed the C16=C17 
epoxide.
75
 
 
In the following year, Mulzer reported four other syntheses of (-)-laulimalide.
76-79
 The 
first synthesis featured two alternative routes for macrolactonisation: a Still-Gennari 
olefination and an Alexakis-type allylsilane/acetal addition.
76
 RCM for the formation 
of the dihydropyran rings and a Sharpless asymmetric epoxidation to install the 
epoxide moiety were the other key reaction steps.
76
 The second synthetic strategy 
highlighted the use of allylsilane addition to a chiral acetal as the major coupling step, 
Ando modified HWE olefination for the formation of the cis-olefin (cis:trans = 1:2.7), 
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Yamaguchi macrolactonisation for the ring closure of the carbon skeleton and 
selective Sharpless epoxidation to furnish the epoxide moiety.
77
 
 
The third synthesis utilised a novel asymmetric acyl halide-aldehyde 
cyclocondensation reaction to define the requisite stereochemical relationships.
78
 The 
synthesis strategy also featured RCM with Schrock‟s reagent for the dihydropyran 
formations, Yamaguchi macrolactonisation for the macrolide formation, alkyne 
hydrogenation with Lindlar‟s catalyst  for the installation of the C2=C3 cis-olefin, and 
diastereoselective Sharpless epoxidation.
78
 The fourth was a formal synthesis with 
improved efficiency, with an Evans‟ alkylation, a Brown allylation and a 
stereocontrolled ene-reaction as the key reactions.
79
 
 
Paterson reported a 27-step total synthesis of (-)-laulimalide with an overall yield of 
2.9%.
81 
The synthesis utilised diastereoselective chiral boron enolate coupling 
reaction, Mitsunobu macrolactonisation, enantioselective Jacobsen hetero-Diels-Alder 
formation of the side chain dihydropyran, and Sharpless asymmetric epoxidation.
81
 
Wender adopted a convergent synthetic strategy that relied on a complex asymmetric 
Sakurai coupling of an allyl silane with an aldehyde in the formation of the C14–C15 
bond and regioselective macrolactonisation of an unprotected C19–C20 diol to provide 
the target 20-membered macrolactone in 25 steps with an overall yield of 3.5%.
82
 
 
Williams‟ strategies for the synthesis of (-)-laulimalide featured asymmetric allylation 
that incorporated the C16–C17 trans-epoxide at an early stage in the synthesis pathway, 
chelation-controlled alkenylzincate addition, asymmetric conjugate addition with 
Yamamoto organocopper reagents and allenylstannane Ferrier reaction for the direct 
attachment of a C1 propargyl substituent to the dihydropyran moiety.
83
 Crimmins‟ 
synthesis of (-)-laulimalide highlighted the use of Evans asymmetric alkylation 
reactions to install the C–O bonds, a diastereoselective allylstannane addition for the 
assembly of the carbon skeleton, and Mitsunobu macrolactonisation for the 
macrocycle formation.
84
 
 
Uenishi and Ohmi approached the synthesis of (-)-laulimalide with a focus on the 
preparation of the dihydropyran moieties using a Pd
II
 and Pd
0
-catalysed stereospecific 
ring formation by 6-exo-trig and 6-endo-trig cyclisations.
85
 Other key reactions 
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included a Sakurai-Hosomi coupling to assemble of the carbon skeleton and 
Yamaguchi protocol for macrolactonization.
85
 Trost‟s synthetic strategy for (-)-
laulimalide utilised atom-economic transformations to achieved an efficient and 
convergent pathway that employed Rh-catalysed cycloisomerisation to form the 
endocyclic dihydropyran, a dinuclear Zn-catalysed asymmetric glycolate aldol to 
obtain the syn-1,2-diol, and an intramolecular Rh-catalysed alkene-alkyne coupling 
via isomerisation to form the macrocycle.
86 
 
 
Research has also been focused on developing analogues of laulimalide.
67,68,70,87-91
 
The analogue studies have attempted various modifications of the side-chain groups, 
the epoxy moiety and the side-chain dihydropyran.
67, 68, 70, 87-91
 Although an 
impressive range of analogues have been produced, none is more potent than the 
original laulimalide. Most of the synthesised analogues of laulimalide have moderate 
to total loss of cytotoxic activity. Recently, Mulzer successfully synthesised a des-
dihydropyran analogue of laulimalide (Figure 1.22).
91
 Bioactivity studies on the 
analogue showed a total loss of bioactivity that highlighted the importance of the C5–
C9 endocyclic dihydropyran moiety of laulimalides.
91
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Figure 1.22 Several analogues of laulimalide.
67, 68, 7 0, 87-91
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Chapter 2 - Objectives and strategies 
 
2.1 The research aim 
 
An analogue of a natural product is a compound with structural variation(s) compared 
to the naturally occurring lead compound, in which one or more parts of its carbon 
skeleton and/or functional groups have been replaced, rearranged or deleted. An 
analogue can be designed and modified to fit certain pharmacological specifications 
as required by its intended role. For the proposed research, the intention is to design 
an analogue to peloruside A that has comparable or better bioactivity to the parent 
compound. Restricted availability of the natural supply and the anticancer qualities of 
peloruside A are some of the reasons for its increasing attraction as a synthetic target. 
However, synthesis of peloruside A is difficult due to the complexity of its structure 
and its numerous stereogenic centres. The pursuit of a simplified analogue has 
obvious benefits. 
 
Peloruside A has ten stereocentres in its structure, four of which are located in the 
tetrahydropyran ring. Therefore, analogues simplified at the pyran moiety seemed to 
be a practical approach. Taking into consideration the fact that peloruside A and 
laulimalide share similar macrocyclic rings with embedded pyran rings, we proposed 
the synthesis of an analogue of peloruside A that incorporates the simpler backbone 
dihydropyran ring of laulimalide (151, Figure 2.1). The dihydropyran ring of 
laulimalide has only two stereocentres: two fewer than peloruside A. Therefore, the 
demand for stereospecific synthetic steps is also reduced.  
 
Figure 2.1 The proposed hybrid peloruside-laulimalide analogue. 
 
 
 
 
 
 
  151 
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The importance of the pyran ring for the bioactivity of peloruside A has been 
confirmed by Wullschleger and co-workers in the course of their synthesis of a 
monocyclic peloruside A analogue.
58
 A study by Mulzer of a des-dihydropyran 
analogue of laulimalide showed that the dihydropyran structure is also important 
here.
91
  Although, several computational studies based on spectroscopic data have 
made predictions on the interaction sites of both peloruside A and laulimalide with the 
tubulin dimer,
33, 92, 93, 94
 information regarding the exact binding interaction is still 
unavailable. Therefore, the strategy of incorporating the pyran structure of laulimalide 
into the backbone of peloruside A has the potential of providing an insight into the 
interaction of the pyran functionality of both peloruside A and laulimalide within the 
binding pocket of the β-tubulin. 
 
The proposed hybrid peloruside-laulimalide analogue 151 will feature mainly the 
backbone structure of peloruside A, with the exception of the C5–C9 pyranose ring. 
The dihydropyran ring motif of laulimalide, with an alkene between C6 and C7, is the 
primary target. The pyranose ring of peloruside A has a methyl ether group at the C7 
position, a hydroxyl moiety at the C8 position, as well as the C9 hemiacetal group. The 
elimination of two stereogenic centres and three oxygen moieties from the original 
pyran structure of peloruside A is expected to simplify the synthesis of the proposed 
analogue compared to peloruside A. 
 
The choice of peloruside A as the backbone donor took into consideration the greater 
stability of peloruside A than laulimalide. Laulimalide readily isomerises to 
isolaulimalide, due to the instability of its C16–C17 epoxide moiety. Therefore, the 
proposed analogue 151 will have the general (stable) structure of peloruside A while 
minimising the problem of isomerisation and still retaining the important 
dihydropyran feature of laulimalide. Furthermore, we anticipated that an analogue that 
incorporates the active features of both peloruside A and laulimalide would retain the 
potent biological cytotoxicity of its parent macrolides.  
 
Aside from the primary analogue 151, several other analogues can be obtained 
through variation of the synthetic route. Simple modification of the pyran ring, 
achieved utilising similar synthetic routes or addition of further synthetic steps, will 
also be explored. Our intention is to delve further into the study of the importance of 
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the pyran structure for the bioactivity of peloruside A and laulimalide. Therefore, 
producing several analogues that feature different functionalities might give further 
insight into the interaction between the pyran moiety and the binding pocket it 
occupies in the β-tubulin. 
 
Variation in the functionality might alter the hydrophobic/hydrophilic interactions 
within the binding pocket. Similarly, altered bulk might govern the orientation of the 
structure within the pocket. Simple modifications such as hydrogenation and 
dihydroxylation of the alkene can provide an idea of the importance of the functional 
groups and the hydrophobic/hydrophilic nature of the binding pocket. A methyl-
substituted alkene is expected to be introduced into the pyran structure by slight 
modification of the reagents used.  
 
2.2 Retrosynthetic strategy 
 
The synthesis of the analogue 151 (Scheme 2.1) will utilise, as the final step, a global 
deprotection after formation of the macrocycle by a Yamaguchi protocol. The 
assembly of the carbon skeleton will be achieved through a 1,5-anti aldol coupling of 
the C1–C11 aldehyde 172 and the C12–C24 ketone 180. A subsequent stereoselective 
reduction of the C13 ketone and methylation of the resulting hydroxyl will provide the 
requisite methyl ether functionality of the natural product.  
 
The synthesis of the C1–C11 synthon 172 will employ an oxazolidinone-directed 1,2-
syn aldol reaction between the C1–C2 oxazolidinone 159 and the C3–C11 aldehyde 
168. Subsequent methylation of the C3 hydroxyl will provide the necessary methyl 
ether functionality. The C1–C2 synthon is obtainable from bromoacetic acid (191) and 
(S)-4-benzyloxazolidin-2-one (157). The C3–C11 synthon is available from 2,2-
dimethyl-1,3-propanediol (192), allylmagnesium bromide (193), acryloyl chloride 
(194) and vinyloxy-trimethylsilane (195) through a series of reactions. The first step 
of the sequence will be the monoprotection of the diol 192. The next step will be the 
oxidation of the remaining hydroxyl group to an aldehyde. This will be followed by 
Brown allylation with allylmagnesium bromide and esterification with acryloyl 
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chloride. The subsequent step will be a RCM reaction to form the dihydropyran ring. 
The final step in the series will be an alkylation with vinyloxy-trimethylsilane.  
 
Scheme 2.1 Proposed retrosynthesis for the hybrid peloruside-laulimalide analogue 
151. 
 
The synthesis of the C12–C24 synthon will involve a RCM reaction to install the Z-
olefin of the side chain through the formation of an eight-membered silocene. Co-
silylation of the C12–C16 β-hydroxy ketone 177 and the C17–C24 alcohol 178 will give 
the necessary diene. The C12–C16 synthon is accessible from an aldol coupling 
O
OH
O
OH
OMeO
MeO
HO
1
5
9
1320
2221
23
15
24
Global deprotection
Yamaguchi macrolactonisation
Reduction and methylation
1,5-anti Aldol reaction
O
OH
N
OMeO
1
5
911
2221
12
20
23
18 15
24 O
SiO
O
O
OPMB
N
O
1 2 5
3
9
111320
23
16
17
24
OHOH O
O
O
Ph
O
Ring closing metathesis
Silyl tethering
Methylation
1,2-syn Aldol reaction
TBSO
Ph
Ph
OH
Br
HO
O
MgCl
MgBr
Cl
OHO
Ethylation Aldol condensation Coupling
Alkylation
Ring closing metathesis
Esterification
Allylation
Swern oxidation
Monoprotection
OTMS
H
H
O
O
H
151
172180
(R)-178 177 159 168
O
O
Ph
NH
O
O
196 195194193192191157197199198
O
Ph
O
 70 
reaction between acetone (196) and methacrolein (197). The C12–C16 synthon is 
obtainable from an ethylation reaction of 2,5-dihydrofuran (199) with  
ethylmagnesium chloride (198). 
 
Several analogues featuring further modifications on the pyran moiety, namely 152 to 
155 as shown below (Figure 2.2) will be attempted. Hydrogenation
95
 of the C6=C7 
alkene of the C5–C11 lactone will provide a precursor to the analogue 152. Sharpless 
asymmetric dihydroxylation
96
 or potassium permanganate oxidation
97
 of the C6=C7 
alkene will give the hydroxyl functionalities for the analogue 153. Acetonide 
formation
98
 will protect the resulting diol throughout the rest of the reaction 
sequences. 
 
Figure 2.2 Proposed variations of the primary analogue 151.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Substituting acryloyl chloride with methacryloyl chloride during esterification of the 
C7–C11 alcohol is expected to give the analogue 154. RCM of the resulting diene will 
give a methylated alkene at C6. Similarly, substituting allylmagnesium bromide with 
methallylmagnesium bromide or methallyllithium
99
 during the synthesis of the boron 
reagent for Brown allylation, will provide the precursor to analogue 155. 
Esterification with acryloyl chloride and RCM will provide a methylated alkene at C7. 
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2.3 Research precedence 
 
An attempt to synthesise the analogue 151 has been previously undertaken by Dr. 
Emma Casey (née Turner) during her PhD research.
100
 Therefore, the preparation of 
the ketone 180 has been established.
101
 Similarly, Casey has also paved the way 
towards the synthesis of the aldehyde 172.
100
 The main focus of this research is to 
complete the synthesis of the full analogue, particularly the 1,5-anti aldol coupling of 
the aldehyde 172 and ketone 180. Previous studies have shown that the 1,5-anti aldol 
reaction is highly dependent on the size and electronic nature of the substrates, as well 
as the type of the boron reagent used.
102
 Although the use of phenylsilane compared 
to non-aromatic silane substituents dramatically increased the enantioselectivity of the 
1,5-anti induction, the yield has been moderate.
102
  
 
2.4 The research objectives 
 
The objective for the current study was to synthesise the aldehyde 172 and the ketone 
180 in reasonable quantity. The RCM reaction and 1,5-anti aldol reaction, will be 
critically evaluated and, whenever possible, optimised. New reaction conditions that 
might benefit and improve current established synthetic protocols will be explored. 
Possible reaction conditions for derivatisations of the pyran ring will be examined. 
Any unpredicted outcomes to established reactions will be critically evaluated and, 
whenever possible, resolved. 
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Chapter 3 - Results and discussion 
 
3.1 Synthesis of C1–C11 
 
The peloruside A analogue 151 will be synthesised in a convergent manner from two 
smaller fragments, the C1–C11 segment 172 and the C12–C24 segment 180 (Scheme 
3.1). The C1–C11 segment of the peloruside A analogue 151 will be synthesised from 
two smaller fragments, a C1–C2 enolate 159 and a C3–C11 aldehyde 168. The 
construction of the C1–C11 synthon was to be completed by a 1,2-syn aldol coupling 
reaction that would connect the C1–C2 enolate and the C3–C11 aldehyde. Methylation 
of the C3 hydroxyl will provide the necessary methyl ether functionality.  
 
Scheme 3.1 Retrosynthesis of C1–C11 segment 172. 
 
3.1.1 Synthesis of the C1–C2 synthon 
 
The synthesis of the C1–C2 enolate 159 (Scheme 3.2) began from the commercially 
available bromoacetic acid (191). Reaction of the bromoacetic acid with 4-
methoxybenzyl alcohol provided the carboxylic acid 158 with a PMB ether at the C2 
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known oxazolidinone 157 gave the chiral auxiliary derived C1–C2 fragment 159 in 
48% yield.  
 
Scheme 3.2 Synthesis of C1–C2 synthon. 
 
 
 
 
 
 
 
Conditions: (a) NaH, THF, 0 °C, then 4-methoxybenzyl alcohol, RT for 15 min, then 
0 °C, then 191, RT, 5 h; (b) 158, MeCN, TEA, HBTU, RT, 30 min, then 157, nBuLi, 
THF, -78 °C, 15 min, then RT, 2 h. 
 
The oxazolidinone 157 was synthesised by well established methodology in two steps 
from the commercially available amino acid L-phenylalanine.
103
 Thus sodium 
borohydride reduction of L-phenylalanine provided phenylalaninol.
103
 Reaction of the 
phenylalaninol with potassium carbonate and diethyl carbonate at 78 °C afforded the 
oxazolidinone 157 in 50% yield over two steps.     
 
3.1.2 Synthesis of the C3–C11 synthon 
 
The synthesis of C3–C11 synthon 168 (Scheme 3.3) commenced from 2,2-dimethyl-
1,3-propanediol. Monosilylation of the diol with tert-butyldimethylsilyl chloride 
yielded 60% of the desired monoprotected alcohol 160. The other 40% was isolated as 
the disilylated product.  
 
The subsequent Swern oxidation provided the aldehyde 161 in 86% optimised yield. 
The initial oxidation attempts with one equivalent of oxalyl chloride gave lower yields 
(48%). The improvement in the yield was achieved through changes to the use of 1.6 
equivalents of oxalyl chloride. An allowance was also made for formation of the 
dimethylchlorosulfonium intermediate over a longer period. These factors improved 
the conversion of the alcohol 160 to the aldehyde 161. 
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Brown allylation
104
 of the aldehyde 161 with (-)-Ipc2Ballyl afforded the homoallylic 
alcohol 163 with 70% yield and good stereoselectivity (95% ee). The enantiomeric 
excess of the alcohol 163 was determined through formation of the corresponding 
Mosher‟s esters and NMR analysis using the method developed by Dale and 
Mosher.
105
 Acylation of the alcohol 163 with acryloyl chloride under mild basic 
conditions gave the diene 164 in 82% yield.  
 
Scheme 3.3 Synthesis of C3–C11 synthon. 
 
Conditions: (a) DMF, 0 °C, then TBSCl, RT; (b) (COCl)2, DMSO, TEA, DCM, -78 
°C; (c) (-)-Ipc2Ballyl, -100 °C, 2 h; (d) acryloyl chloride, DIPEA, DCM, 0 °C to RT; 
(e) 5 mol% Grubbs‟ 2nd geneneration catalyst, DCM, RT; (f) DIBAL-H, DCM, -23 
°C, 45 min; (g) TEA, Ac2O, DMAP, DCM, RT; (h) H2C=CHOTMS, BF3.Et2O, 
MeCN, RT, 3.5 h.  
 
The subsequent RCM reaction using Grubbs‟ 2nd generation catalyst initially gave 
poor yields. The 
1
H NMR and TLC (thin layer chromatography) of the crude reaction 
mixture showed only a single product and a considerable amount of retained starting 
diene, the isolated amount of the clean α,β-unsaturated lactone 165 was 
disappointingly low (19%). Changes in reaction time and concentration did not give 
an improved result.  
 
An apparent improvement in the observed crude reaction mixture was detected with 
the use of a new batch of Grubbs‟ 2nd generation catalyst. Although the ratio of diene 
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to lactone observed through the 
1
H NMR data had increased considerably, the isolated 
yield of lactone 165 barely increased (33%). Changing the isolation protocol by 
removing the charcoal adsorption step with a slow elution through a silica column 
remarkably provided the clean lactone 165 in 90% yield.  
 
Subsequent three-step reaction sequence converted the lactone 165 to the aldehyde 
168 in 59% yield. DIBAL-H reduction
106
 of the lactone 165 gave the corresponding 
lactol as a mixture of diastereomers. Acetylation of both diastereomers of the lactol 
gave the corresponding acetate as a mixture of diastereomers, finally, alkylation at C5 
of the dihydropyran with vinyloxy-trimethylsilane gave the aldehyde 168 as a single 
product. The resolution of the diastereomeric mixture in the formation of 168 was 
attributed to the fact that an SN1 reaction mechanism dominates, in which an oxonium 
ion was formed following the loss of the acetal group. Subsequent addition by the 
enol ether with concomitant loss of the silyl group selectively occurs from the top face 
to give the (S,S)-aldehyde 168.  
 
The stereoselectivity of 168 was determined in the previous study by Turner through 
the nOe correlation between protons of C4 and C9, and the lack of correlation between 
the protons of C5 and C9.
100
 The yield was dependent on the quality of the vinyloxy-
trimethylsilane. Freshly distilled reagent provided reasonable (59%) yield over three 
steps. Undistilled, it was found that the vinyloxy-trimethylsilane had polymerised. 
The quality of the vinyloxy-trimethylsilane reagent was determined using 
1
H NMR 
spectrum. 
 
3.1.3 Aldol coupling of the C1–C2 and C3–C11 fragments 
 
Upon successful synthesis of both the chiral auxiliary-bound C1–C2 synthon 159 and 
the aldehyde 168, an oxazolidinone-directed 1,2-syn aldol coupling reaction was 
attempted to acquire the complete C1–C11 synthon (Scheme 3.4). Although the TLC 
analysis of the reaction indicated the presence of compounds other than the starting 
materials, the 
1
H NMR spectrum contained only the starting materials. Purification of 
the crude reaction mixture through a silica column confirmed this when only the 
starting aldehyde 168 and ketone 159 were recovered. The tendency of the expected 
1,2-syn aldol product to undergo retro-aldolation upon prolonged exposure to an 
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acidic environment provides a possible explanation for the disappearance of the 
detected non-starting material compounds, due to the entire reaction mixture having 
been left in the deuterated chloroform overnight. Therefore, in subsequent attempts, 
the exposure period in NMR solvent was reduced to an hour at the most. Furthermore, 
the compound was chromatographed with 1% TEA (triethylamine) in the eluting 
solvent to counter the acidity of the silica column. These precautionary steps proved 
to be fruitful and the desired C1–C11 alcohol 169 was obtained in 52% yield. The 
inherent instability of the alcohol 169 meant that prolonged storage was inadvisable, 
even under argon at -18 °C. Therefore, the alcohol 169 was usually immediately 
methylated upon collection. 
 
Scheme 3.4 Completion of C1–C11 synthon. 
 
Conditions: (a) 159, toluene, -50 °C, TEA, Bu2BOTf, 1.5 h, then 168 in toluene, then 
-30 °C for 2 h; (b) Me3OBF4, Proton-sponge
®
, 0 °C; (c) HCl, MeOH, RT; (d) Dess-
Martin periodinane, pyridine, 0 °C, 5 h. 
 
The methylation of the C3 hydroxyl was achieved with Me3OBF4 and Proton-
sponge
®
, giving the methyl ester 170 in 87% yield. The initial methylation attempt 
failed to provide the desired methyl ether 170 and degradation of the starting material 
back to the aldehyde 168 and ketone 159 in the reaction mixture was noted through 
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chromatography and in the 
1
H NMR spectrum. This suggested the possibility that the 
reaction conditions were either too acidic or basic. Further investigation into the 
reagent used in the reaction indicated that the batch of Me3OBF4 had degraded.  
 
Upon changing to a newly opened bottle of Me3OBF4, the reaction was performed and 
the desired compound 170 obtained. However, the yield of the desired product was 
very poor. A closer look into the side products showed that the majority of the 
compound had lost the oxazolidinone at C1 and had been converted to the methyl ester 
173 (Table 3.1). The surprising conclusion was that boron side products and 
hydrolysis of the Me3OBF4 led to methanolysis of the oxazolidinone.  
 
Therefore, in subsequent attempts, the amounts of the Me3OBF4 and Proton-sponge
®
 
were gradually reduced from initially fifteen equivalents relative to the alcohol 169 
(Table 3.1). Optimum results were obtained with two equivalent of Me3OBF4 and 
Proton-sponge
®
, three hours reaction time and the reaction mixture maintained at 0 
°C. Using these conditions, the final attempt to methylate the C3 hydroxyl provided 
170 in excellent isolated yields of 87%. 
 
Table 3.1 Methylation of C3 hydroxyl. 
Reagents (eqv) Time (h) Temperature (°C) 170:173 (% yield) 
15 16 0 to RT 7:21 
12 3 0 to RT 21:7 
6 3 0 82:16 
2 3 0 87:11 
 
The TBS protecting group at the C11 was removed by methanolysis in the presence of 
hydrogen chloride to provide the alcohol 171 in 60% yield. Subsequent Dess-Martin 
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oxidation of the C11 hydroxyl proceeded with ease to provide the corresponding 
aldehyde 172 in 75% yield. With the methodology to produce protected C1–C11 
aldehyde 172 in hand, a reliable route to protected C12–C24 was required prior to their 
aldol coupling to form the complete C1–C24 backbone of the peloruside A analogue 
151. 
 
3.2 Synthesis of C12–C24 
 
The C12–C24 synthon was synthesised from two smaller fragments, a C12–C16 β-
hydroxy ketone 177 and a C17–C24 homoallylic alcohol 178 (Scheme 3.5). The 
synthesis employed a double-silylation reaction to give a tethered diene 179, followed 
by a RCM reaction to form a ketone with an eight-membered silicon bis-ether ring 
180. The formation of the silocene 180 also provided for formation of the required Z-
olefin in the side chain of peloruside A.  
 
Scheme 3.5 Retrosynthesis of C12–C24 synthon. 
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3.2.1 Synthesis of the C12–C16 synthon 
 
Aldol coupling between methacrolein and acetone (Scheme 3.6) proceeded without 
hindrance to provide the desired β-hydroxy ketone 177 with a yield of 89%. However, 
repeated attempts to determine the enantiomeric excess of the β-hydroxy ketone 177 
by formation of Mosher‟s esters were unsuccessful due to the tendency of the C15 
hydroxyl to eliminate. Attempts to follow the formation of Mosher‟s ester with in situ 
1
H NMR reactions
107
 showed that the elimination occurred in tandem with the 
formation of the Mosher‟s esters. However, the [α]D of 177 compared with molecules 
prepared by Paterson suggested formation of the correct enantiomer as the major 
product.
108
 
 
Scheme 3.6 Synthesis of C12–C16 synthon. 
 
 
 
 
 
3.2.2 Synthesis of the C17–C24 synthon 
 
The initial synthetic strategy to obtain ethylbutenol 178 (Scheme 3.7) involved an 
asymmetric carbomagnesation method developed by Hoveyda.
109,110
 The asymmetric 
carbomagnesation protocol employed 3 mol% of dichloro[(S,S)-ethylenebis(4,5,6,7-
tetrahydro-1-indenyl)]zirconium(IV) as the asymmetric catalyst to direct the 
formation of the desired (R)-178 from 2,5-dihydrofuran and ethylmagnesium chloride. 
However, due to the low yield (20%) of the reaction and cost consideration for the 
synthesis of a starting material, bis(cyclopentadienyl)zirconium(IV) dichloride was 
used instead. Bis(cyclopentadienyl)zirconium(IV) dichloride is not enantioselective 
but gave a better yield and provided the ethylbutenol 178 as a racemic mixture in 53% 
yield. It has been noted previously that the subsequent RCM is diastereoselective, 
leading to kinetic resolution in this reaction
101
 and thereby rendering prior resolution 
of 178 unnecessary. 
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Scheme 3.7 Synthesis of C17–C24 synthon. 
 
 
 
 
3.2.3 Double-silylation reaction to form silyl bis-ether 179 
 
Upon acquisition of both the alcohol 178 and the β-hydroxy ketone 177, their one-pot 
tethering to dichlorodiphenylsilane was attempted. Several of the initial trials failed to 
provide the desired diene 179. Instead, starting materials, mono-tethered butenol 
or/and mono-tethered β-hydroxy ketone were recovered from the reaction mixture. 
These results led to the conclusion that partial hydrolysis of the 
dichlorodiphenylsilane reagent (200) to chlorodiphenylsilanol (201) and/or 
diphenylsilanediol (202) had reduced the reactivity of the reagent towards silyl ether 
formation (Scheme 3.8). This issue was overcome by freshly distilling the reagent 
prior to the reaction, thus ensuring that only non-hydrolysed reagent was present in 
the reaction mixture. 
 
Scheme 3.8 Hydrolysis of dichlorodiphenylsilane to chlorodiphenylsilanol and 
diphenylsilanediol. 
 
 
 
 
 
However, with the previous problem solved, another issue arose. Although the 
consecutive attempts successfully produced the desired diene 179, the reaction yield 
was disappointingly low (10%). Further investigation revealed that the low yield was 
partly due to the formation of doubly-tethered alcohol 203 (Scheme 3.9). The solution 
that was adopted to reduce the problem was to shorten the time frame for coupling of 
the alcohol 178 to the diphenylsilane. This was done by closely monitoring the 
reaction progression. The β-hydroxy ketone 177 was added into the reaction mixture 
as soon as a trace of bis-homoallylic alcohol 203 was detected by chromatographic 
analysis. The β-hydroxy ketone 177 should be able to compete with 178 for 
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attachment to the silane 204. The reduction of alcohol tethering time gave the diene 
179 in a slightly improved yield of 38%.  
 
Scheme 3.9 Formation of bis-homoallylic alcohol 203. 
 
3.2.4 Ring closing metathesis reaction 
 
The diene 179 was subjected to RCM using Grubbs‟ 2nd generation catalyst. Initially, 
the diene solution was added gradually into a refluxing solution of the catalyst to 
ensure minimal cross-metathesis.
100
 However, the formation of the eight-membered 
ring was slow and the yield very poor (Scheme 3.10). Although the desired 
intramolecular metathesis accounted for the majority of the isolated material (180, in 
30%), the intermolecular cross-metathesis product 210 was isolated in 13% yield. The 
side products 212, the product of cross-metathesis with the styrene by-product, and 
215, the product of alkene isomerisation, were isolated as a 1:1 mixture in 12% 
combined yield.  
O
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Scheme 3.10 The cross-metathesis products of diene 179. 
 
The structure of 210 was determined from spectral examination of the HRMS, 
1
H and 
13
C NMR spectra, COSY, HSQC and HMBC data. The HRMS evaluation provided a 
calculated mass of m/z 811.3826 which fitted the formula of C48H60O6Si2Na. The 
spectroscopic data (Table 3.2) for the ketone portion of 210 matched the chemical 
shifts of both the β-hydroxy ketone 177 and the corresponding portion in the diene 
179. Observed changes in the spectroscopic data of the C17–C24 allylic portion 
between 210 and the starting material 179 included an upfield shift of approximately 
0.4 ppm in the 
1
H NMR of C17 and transformation of the peak from a multiplet to a 
doubles of doublet, which indicates a disubstituted alkene. Together with this, an 
absence of signals corresponding to the original olefinic methylene adjacent to C17 
further confirmed the cross-metathesis. Due to the symmetrical nature of the 
molecule, the cis/trans geometry of 210 was not resolved.  
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Table 3.2 Spectroscopic evidence for the cross-metathesised diene product 210. 
 
 
 
 
 
δ13C δ1H COSY position 
206.69 - - 13 
145.56 - - 16 
135.19 7.60 (m, 8H) 7.40, 7.32 Ph 
132.72 - - Ph 
132.72 5.21 (dd, J = 2.5, 5.2 Hz, 2H)  2.07 17 
139.34 7.40 (m, 4H) 7.60, 7.32 Ph 
127.86 7.32 (m, 8H) 7.60, 7.40 Ph 
112.28 4.88 (d, J = 8.0 Hz, 2H),  
4.74 (m, 2H) 
1.68;  
2.76, 1.68 
a, 
b 
73.41 4.74 (m, 2H) 2.78, 1.68 15 
66.67 3.59 (m, 4H) 2.07 24 
50.44 2.76 (m, 2H), 2.54 (m, 2H) 4.74 14 
47.10 2.07 (bs, 2H) 5.21, 3.59, 1.21 18 
31.00 2.04 (d, J = 12.0 Hz, 6H) - 12 
24.09 1.62 (m, 2H),  
1.21 (m, 2H) 
1.21, 0.86;  
2.07, 1.62, 0.86 
19 
17.52 1.68 (d, J = 7.8 Hz, 6H) 4.88, 4.47 23 
11.72 0.82 (m, 6H) 1.62, 1.21 20 
 
In order to improve the yield of the RCM reaction and reduce cross-metathesis, 
several modifications of the reaction conditions
100
 were tried. Better reaction 
conditions were found to involve addition of five small portions of the Grubbs‟ 2nd 
generation catalyst into a refluxing solution of diene in dichloromethane every hour. 
A total of 10 mol% of the catalyst was used for the reaction. Although the yield was 
improved slightly, cross-metathesis was still a problem. In order to discourage cross-
metathesis, the concentration of the reaction mixture was lowered. However, changes 
Ph
Si
O
PhO
O
OSi
O
Ph
Ph
O
12
23
1416
24
18
17
20
Ha
Hb
210
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in the concentration of the reaction mixture did not alter the amount of the cross-
metathesis.  
 
Aside from the expected product and the cross-metathesis product 210, an equal 
mixture of 212 (Table 3.3) and 215 (Table 3.4) were observed. The side-products 212 
and 215 were inseparable by silica column chromatography and were initially thought 
to be a single compound. The structures of the side-product 212 and 215 were 
determined from the 
1
H and 
13
C NMR, COSY, HSQC and HMBC spectral data. 
Examination of the spectroscopic data showed that some of the peaks were similar to 
those of the β-hydroxy in the diene 179. The integration of these peaks in the proton 
spectrum gave a 2:1 ratio. Furthermore, the integration of the 
1
H NMR for the phenyl 
moiety accounted for 25 protons. Evaluation of the remaining peaks through HMBC 
data showed disconnection of certain peaks, leading to a conclusion that two 
compounds were involved.  
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Table 3.3 Spectroscopic evidence for the side-product 212. 
 
 
 
 
 
δ13C δ1H COSY position 
206.73 - - 13 
145.56 - - 16 
137.86 - - d 
135.21 7.63 (m, 4H) 7.36 Ph 
132.17 - - Ph 
132.17 6.02 (dd, J = 8.7 Hz, 16.0 Hz, 1H) 6.40, 2.32 17 
131.29 6.40 (d, J = 15.8 Hz, 1H) 6.02 c 
130.36 7.36 (m, 2H) - Ph 
128.58 7.36 (m, 2H) 7.19 f 
127.86 7.36 (m, 4H) 7.63 Ph 
127.06 7.19 (t, J = 7.2 Hz, 1H) 7.36 g 
126.14 7.36 (m, 2H) - e 
112.40 4.89 (d, J = 7.9 Hz, 1H),  
4.77 (m, 1H) 
4.77;  
4.89 
a, 
b 
73.45 4.77 (m, 1H) 2.54, 2.78 15 
66.55 3.72 (d, J = 6.1 Hz, 2H) 2.32 24 
50.45 2.78 (m, 1H), 2.54 (m, 1H) 4.77 14 
47.48 2.32 (m, 1H) 3.72, 1.39 18 
30.99 2.03 (d, J = 13.2 Hz, 3H) - 12 
24.18 1.62 (dd, J = 6.6 Hz, 22.0 Hz, 1H),  
1.39 (m, 1H) 
1.39, 0.88;  
2.32, 1.62, 0.88 
19 
17.48 1.69 (d, J = 6.9 Hz, 3H) - 23 
11.83 0.88 (t, J = 7.7 Hz, 3H) 1.62, 1.39 20 
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Examination of one of the disconnected portions as individual compounds showed an 
expected correlation to the phenyl moiety, leading to a conclusion that the 5 
superfluous aromatic protons observed previously were a part of the allylic portion. 
HMBC and COSY correlations were employed in the determination of the structural 
connectivity between the phenyl moiety and the C17 alkene. The evidence of a 
shielding effect of the aromatic moiety was apparent in the downfield shift of the C17 
alkene. The side-product 212 was a product of metathesis between the diene 179 with 
styrene resulting from the initial cycle of the catalytic reaction (Scheme 3.11).  
 
Table 3.4 Spectroscopic evidence for the side-product 215. 
 
 
 
 
 
δ13C δ1H COSY position 
206.73 - - 13 
149.49 - - 18 
145.56 - - 16 
135.21 7.63 (m, 4H) 7.36 Ph 
132.17 - - Ph 
130.36 7.36 (m, 2H) - Ph 
127.86 7.36 (m, 4H) 7.63 Ph 
112.40 4.89 (d, J = 7.9 Hz, 1H), 4.77 (m, 1H) 4.77; 4.89 a,b 
107.81 5.11 (s, 1H), 4.84 (s, 1H) 4.84; 5.11 c,d 
73.45 4.77 (m, 1H) 2.54, 2.78 15 
65.90 4.19 (s, 2H) - 24 
50.45 2.78 (m, 1H), 2.54 (m, 1H) 4.77 14 
30.99 2.03 (d, J = 13.2 Hz, 3H) - 12 
25.56 2.03 (m, 2H) 1.01 19 
17.48 1.69 (d, J = 6.9 Hz, 3H) - 23 
12.27 1.01 (t, J = 7.4 Hz, 3H) 2.03 20 
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Examination of the 
13
C NMR spectrum accounted for five carbon environments not 
assigned to the side-product 212. The COSY correlation showed that the alkene 
moieties only connected to two methylene carbons. The upfield methylene carbon 
showed connectivity to a methyl group. The downfield methylene only showed 
connectivity to the alkene, leading to the conclusion that it was the oxy-methylene. 
Further investigation regarding the reaction conditions and the nature of the olefin, 
revealed its propensity to isomerise in the presence of Grubbs‟ 2nd generation 
catalyst.
111
 The observed side-product 215 is probably obtained from isomerisation 
into olefin 213 and cross-metathesis (Scheme 3.11). 
 
The formation of the side products 210, 212, and 215 were unexpected. A study by 
Courchay found that the coordination of the substrate with the metal centre of 
Grubbs‟ 2nd generation catalyst during the metallo-cyclobutane formation was the 
determinant to the product formed.
112
 Although two possible routes might provide for 
the desired dioxysilocene 180, from the outcome of the reaction and the ease of 
access, it was deduced that complexation of the metal centre to ethylbutene was 
preferred (Scheme 3.11).
112
 However, if prior to the second cyclobutene formation, 
another diene molecule was available, cross-metathesis will be more kinetically 
favoured, resulting in the side product 210. Therefore high dilution was the key to the 
formation of dioxysilocene 180. 
 
With both the C1–C11 segment 172 and the C12–C24 segment 180 necessary for the 
backbone assembly of peloruside A analogue 151 in hand, an aldol coupling was 
attempted using dibutylboryl trifluoromethanesulfonate. The detailed of the study will 
be discussed in the next section. 
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Scheme 3.11 Proposed mechanism of formation for the observed RCM products. 
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3.3 Attempts to synthesise C1–C24 by aldol reaction 
 
Dibutylboryl trifluoromethanesulfonate (Bu2BOTf) was employed as the coupling 
agent in the attempts to couple the ketone 180 and aldehyde 172 to obtain the desired 
C1–C24 precursor of the analogue 151 (Scheme 3.12). Unfortunately, the aldol 
coupling was unsuccessful and only degraded starting material was recovered. The 
failure of the reaction was attributed to lack of solubility of the aldehyde 172. The 
presence of the chiral auxiliary was suggested as the cause of the insolubility of the 
aldehyde 172. 
 
Scheme 3.12 Attempted aldol reaction of the ketone 180 and aldehyde 172. 
 
Therefore, in subsequent attempts, the oxazolidinone at C1 of the aldehyde 172 was 
replaced by a methyl ester. This was achieved by methanolysis of the oxazolidinone 
170 by reaction of sodium methoxide in the presence of dimethyl carbonate to give 
the corresponding methyl ester 173 in 69% yield. The presence of dimethyl carbonate 
in this reaction was found to be necessary to obtain the desired methyl ester.
100
 This 
was due to undesired methoxide ion attack on the endo-cyclic carbonyl, giving an 
amide plus dimethyl carbonate as the by-product. Presumably, this results from the 
high degree of steric hindrance at the normally preferred site of nucleophilic attack. 
However, by adding an excess (five equivalents) of dimethyl carbonate in the reaction 
mixture, the equilibrium of this undesired ring-opening was returned towards the 
starting material, by Le Chatelier‟s principle, thus facilitating reaction of methanol 
with the correct C1-carbonyl.
113
 The subsequent removal of the silyl protecting group 
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and TEMPO-BAIB oxidation of the resulting alcohol provided the aldehyde 175 in 
85% yield over two steps (Scheme 3.13). 
 
Scheme 3.13 Synthesis of the aldehyde 175. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions: (a) CO(OMe)2, NaOMe, DCM, 0°C, 1.5 h; (b) MeOH, concentrated HCl, 
RT, 30 min; (c) BAIB, TEMPO, DCM, RT, 5 h. 
 
The aldol coupling was attempted with the aldehyde 175 and the ketone 180 (Scheme 
3.14). Although the lack of solubility was no longer an issue, the reaction still failed, 
instead the starting materials decomposed in the reaction mixture. Initially, the failure 
was attributed to the degradation of the Bu2BOTf reagent. However, the successive 
coupling attempts with a newly opened bottle of reagent were also unsuccessful.  
Effort was also made to distil the Bu2BOTf, but the reagent degraded during the 
process. Various changes to the reaction conditions including the boron reagent, the 
base, and time-scale for the enolate formation were investigated in later attempts.  
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Scheme 3.14 Attempted aldol reaction of the ketone 180 and aldehyde 175. 
 
9-BBNOTf has been used to couple the C1–C11 fragment 72 with the C12–C24 
fragment 78 in Evans‟ synthesis of peloruside A (Scheme 3.15).54 The required 1,5-
anti-stereoselectivity was obtained with 20:1 diastereomeric ratio and 92% yield of 
the C1–C24 precursor 79.  
 
Scheme 3.15 Evans‟ aldol reaction between C1–C11 with C12–C24 using 9-BBNOTf.
54
 
 
Unfortunately, the aldol coupling attempts between the aldehyde 175 and the ketone 
180 using 9-BBNOTf also ended in failure with the starting materials decomposing in 
the reaction mixture (Scheme 3.16).  
 
 Scheme 3.16 Attempted aldol reaction of the ketone 180 and aldehyde 175. 
 
Since changing the coupling agent from Bu2BOTf to 9-BBNOTf did not provide an 
encouraging outcome, alternation of the base to DIPEA (N,N-diisopropylethylamine) 
was investigated. However, due to time constraints, a model with C5–C11 aldehyde 
182 instead of the full C1–C11 aldehyde 175 was used. In order to obtain the aldehyde 
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182, the silylated lactone 165 was treated with hydrochloric acid and methanol to 
remove the TBS group. The resulting alcohol 181 was then subjected to TEMPO-
BAIB oxidation to give the aldehyde 182 in an unoptimised 36% yield over two steps 
(Scheme 3.17).  
 
Scheme 3.17 Synthesis of the aldehyde 182. 
 
 
 
 
 
Conditions: (a) MeOH, concentrated HCl, RT, 30 min; (b) BAIB, TEMPO, DCM, 
RT, 5.5 h. 
 
The aldol coupling between the aldehyde 182 and the ketone 180 using Bu2BOTf as 
the coupling agent and DIPEA as the base was attempted (Scheme 3.18). 
Disappointingly, the reaction failed to provide the desired C5–C24 1,5-anti aldol 
product 218, however consumption of the starting materials was observed. The 
alcohol 181 was observed in the reaction mixture in 38% yield. Initially, the presence 
of the alcohol 181 in the reaction mixture was attributed to contamination of the 
starting aldehyde 182. However, closer analysis of the starting material indicated the 
absence of the precursor alcohol. An alternative conclusion was drawn that the 
aldehyde 182 was converted to the alcohol 181 in the reaction mixture.  
 
Scheme 3.18 Aldol coupling of the aldehyde 182 and the ketone 180 using DIPEA as 
base. 
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Recent developments by Mojtahedi and Abaee of the classic Cannizzaro reaction 
appear relevant to this discovery.
114, 115
 The Cannizzaro reaction is a well known 
redox conversion of a non-enolisable aldehyde to the corresponding alcohol and 
carboxylic acid in the presence of a strong aqueous base.
116
 Mojtahedi and Abaee 
reported a convenient conversion of aryl aldehydes to mixtures of the corresponding 
alcohols and carboxylic acids at room temperature using TEA as the base and lithium 
bromide or MgBr2.OEt2 as the Lewis acid catalyst.
114, 115
 According to the mechanism 
proposed by Mojtahedi and Abaee, magnesium or lithium coordinates to two aldehyde 
molecules through the carbonyl oxygens. Nucleophilic nitrogen attack by the base on 
the carbonyl carbon of one of the coordinated aldehydes enables a hydride transfer to 
the neighbouring carbonyl. Following the loss of coordination and water work-up, 
aldehyde and carboxylic acid are formed.
114, 115
 In the presence of excess Bu2BOTf 
and DIPEA, and taking into consideration the restricted accessibility of the six-
membered aldol transition state in our system, the Cannizzaro conversion was a 
possible explanation for the observed formation of the alcohol 181 from the aldehyde 
182 in the reaction mixture. A mechanism related to that of Mojtahedi and Abaee is 
proposed in Scheme 3.19. This would indicate that the acid 219 should be formed in 
equimolar amounts relative to the alcohol. However, 219 was not isolated and 
presumed lost during work-up due to its solubility in the aqueous phase. 
 
Scheme 3.19 Proposed mechanism for the formation of the alcohol 181 by Cannizzaro 
reaction. 
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A study with the aldehyde 182 using the reaction conditions for the aldol coupling in 
the absence of the ketone 180 was attempted to provide further evidence for the 
proposed hypothesis. Two equivalents of DIPEA and four equivalents of Bu2BOTf 
were added into a reaction vessel under argon in a -78 °C cold bath followed by the 
solution of the aldehyde 182 in diethyl ether. The reaction mixture was then warmed 
to -18 °C and allowed to react overnight. However, the alcohol 181 was not isolated 
as a product from the reaction. Instead, the bicyclic lactone 220 (Table 3.5) was 
isolated from the reaction mixture in 17% yield as a mixture of major and minor 
isomers in a diastereomeric ratio of 2:1. The structure of the bicyclic lactone 220 was 
determined from spectroscopic examination of the COSY, 
1
H and 
13
C NMR spectral 
data.  
 
Table 3.5 Spectroscopic evidence for the bicyclic lactone 220. 
 
 
 
 
major position minor 
δ13C δ1H δ13C δ1H 
172.00 - 1 172.00 - 
133.63 6.40 (m, 1H) 3 133.43 6.40 (m, 1H) 
128.53 6.51 (m, 1H) 4 129.02 6.68 (m, 1H) 
83.37 3.65 (s, 1H) 7 82.91 3.85 (s, 1H) 
73.95 4.63 (m, 1H) 5 72.86 4.63 (m, 1H) 
51.35 - 6 50.69 - 
39.65 3.54 (m, 1H) 2 41.97 3.72 (m, 1H) 
28.65 1.03 (s, 3H) 9 26.97 0.97 (s, 3H) 
21.13 1.20 (s, 3H) 8 21.58 1.21 (s, 3H) 
 
The 
13
C NMR spectrum of lactone 220 showed doubling of peaks and the COSY 
correlation of the protons gave two sets of distinct peaks which suggested the 
presence of diastereomers. The diastereomeric ratio was calculated from integration 
of the 
1
H NMR spectrum. The NMR data suggested that the alkene was not part of an 
O
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α,β-unsaturated aldehyde as found in 182 and the methylene of the original lactone 
was no longer detected. However, two pairs of oxymethine peaks were observed: the 
signals at ca. 4.63 ppm were obviously similar to those of the same position in the 
original lactone, but the other set at 3.5-4 ppm did not correspond to any signals from 
the aldehyde 182.  
 
A series of possible reaction mechanisms that might provide for the formation of the 
second oxymethine from the aldehyde 182 in the given conditions were evaluated. 
The mechanism that was deemed most probable led to the formation of the cyclic 
lactone 220 (Scheme 3.20). The mechanism presumed deprotonation of the methylene 
of the pyran ring in 182 and coordination of the dibutylboron reagent to the lactone 
carbonyl oxygen, leading to enolate formation. An ensuing intramolecular aldol 
reaction produced the lactone 220. The proposed structure of lactone 220 matched the 
available spectroscopic data of similar compounds.
117, 118, 119  
 
Scheme 3.20 Proposed mechanism of formation of cyclic lactone 220. 
 
 
 
 
 
The formation of the lactone 220 in this reaction but not the earlier attempted 
coupling between 180 and 182 is presumed to be due to the presence of excess boron 
reagent and base in the reaction mixture. In the original protocol, the base and boron 
reagent were consumed in the formation of the enolate from the ketone 180 prior to 
addition of the aldehyde 182. However, in the absence of ketone 180, the lactone 
serves as an enolate precursor.   
 
Another study with the aldehyde 182 was performed using two equivalents of 
triethylamine as the base and Bu2BOTf (Scheme 3.21). The compounds 221 and 222 
were isolated in 26% and 4% yield, respectively, from the reaction mixture.  
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Scheme 3.21 Study of the aldehyde 182 with two equivalents of TEA and Bu2BOTf. 
 
The structure of compound 221 was determined from examination of the HRMS, 
1
H 
and 
13
C NMR, COSY, HSQC and HMBC spectral data (Table 3.6). The HRMS 
evaluation provided a calculated mass of 249.1103 m/z which fitted the formula of 
C12H18O4Na. The COSY spectra showed two distinct coupled systems. The 
1
H spectra 
indicated 2:1 mixture of diastereomers. The presence of the mixture was most evident 
from the signal assigned to the C5 and C7 proton peaks. The spectroscopic 
characteristics of the lactone portion and the neighbouring gem-dimethyl group within 
compound 221 were similar to those of the starting aldehyde 182. The remaining 
protons and carbons were assigned as belonging to a hydroxy ketone. The connection 
of the hydroxy ketone portion to the lactone was identifiable from the HMBCs 
correlation of the oxymethine protons at 3.97 ppm and 4.28 ppm to the protons of the 
gem-dimethyl group. It seemed that an unexpected aldol reaction between 182 and 
acetone had occurred; the introduction of an acetone impurity into the reaction 
mixture possibly resulted from a contaminated needle.  
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Table 3.6 Determination of compound 221. 
 
 
 
 
Major position minor 
δ13C δ1H COSY δ13C δ1H COSY 
210.86 - - 9 210.00 - - 
164.90 - - 1 164.66 - - 
146.09 6.92 (m, 1H) 6.01, 
2.44 
3 145.90 6.92 (m, 1H) 6.01, 
2.44 
121.19 6.01 (m, 1H) 6.92, 
2.44 
2 121.33 6.01 (m, 1H) 6.92, 
2.44 
81.93 4.50  
(dd, J = 6.5 Hz, 
10.0 Hz, 1H) 
2.44 5 80.85 4.65  
(dd, J = 3.7 Hz, 
12.5 Hz, 1H) 
2.44 
71.59 3.97  
(dd, J = 2.0 Hz, 
9.9 Hz, 1H) 
2.65 7 69.85 4.28  
(dd, J = 2.0 Hz, 
10.2 Hz, 1H) 
2.65 
44.93 2.65 (m, 2H) 3.97 8 44.75 2.65 (m, 2H) 4.28 
40.20 - - 6 40.31 - - 
31.04 2.22 (m, 3H) - 10 31.09 2.22 (m, 3H) - 
24.72 2.44 (m, 2H) 6.92, 
4.50 
4 24.68 2.44 (m, 2H) 6.92, 
4.65 
20.15 0.94 (s, 3H) - 11 18.94 0.94 (s, 3H) - 
18.48 1.06 (s, 3H) - 12 17.97 0.89 (s, 3H) - 
 
A proper determination of the stereochemistry of compound 221 was unfeasible due 
to the issue of recovering a pure compound in reasonable quantity. However, since the 
oxymethine chiral centre within the pyran ring was controlled in its generation, the 
chirality of the newly formed hydroxyl group can be postulated based on the theory 
proposed by Kishi.
120
 Kishi‟s study of the 13C NMR spectra of 1,3-diols showed that 
in all the studied systems, the 
13
C chemical shift of position 3 in a syn-diol is 
O
O
OHO 1 2
3
4
5
6
7
8
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11 12
221
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downfield by approximately 2 ppm compared to the corresponding anti-diol.
120
 
Extending this to the hydroxylactone in compound 221, the major diastereomer (δ 
71.59 ppm) may be the syn-diol and the minor diastereomer (δ 69.85 ppm) the anti-
diol.  
 
Examination of the HRMS, 
1
H and 
13
C NMR spectra, COSY, HSQC and HMBC data 
of compound 222 (Table 3.7) identified it as the hydrated version of 221 that formed a 
complex with the residual boron reagent. The identification of compound 222 has 
been arduous and puzzling at times. The presence of an acetal at C9 was indicated by 
its 
13
C chemical shift (δ 91.45 ppm) and this was backed up by the magnitude of the 
geminal coupling of the C8 protons (J = 13.5 Hz). This is typical of methylene groups 
adjacent to an acetal group.
121, 122
 By comparison, the geminal coupling in the ketone 
221 was J = 18.2 Hz. The boron residue complex was identified through GC-MS. A 
peak identified as 2,4,6-tributyl boroxin was observed in the GC-MS and was 
proposed to be the result of breakdown of a 2,4-dibutyl-trioxadiborinane as part of the 
hydrate 222. Further HRMS analysis showed a peak at 417.1893 m/z that matched the 
formula of C20H36O6B2Na as required for acetal 222. 
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Table 3.7 Determination of compound 222. 
 
 
 
 
δ13C δ1H COSY position 
164.87 - - 1 
145.93 6.94 (m, 1H) 6.04, 2.43 3 
121.15 6.04 (d, J = 9.8 Hz, 1H) 6.94 2 
91.45 - - 9 
82.16 4.48 (dd, J = 3.6 Hz, 12.8 Hz, 1H) 2.53, 2.43 5 
70.00 4.33 (dd, J = 2.7 Hz, 11.8Hz, 1H) 1.86, 1.72 7 
39.95 - - 6 
37.65 1.86 (dd, J = 2.8 Hz, 13.5 Hz, 1H),  
1.72 (dd, J = 12.3 Hz, 13.4 Hz, 1H) 
4.33, 1.72; 
4.33, 1.86 
8 
26.06 1.28 (m, 8H) 0.86, 0.69 12, 13 
25.21 3.49 (bs, 3H) - 10 
24.69 2.53 (m, 1H),  
2.43 (m, 1H) 
4.48, 2.43; 
6.94, 4.48, 2.53 
4 
19.36 0.96 (s, 3H) - 11 
18.14 1.05 (s, 3H) - 12 
14.01 0.86 (t, J = 7.1 Hz, 6H) 1.28 14 
13.88 0.69 (t, J = 7.3 Hz, 4H) 1.28 11 
 
Due to constraints of time, further attempts to investigate the failure of the aldol 
coupling reactions were discontinued. The disappointing results from the coupling 
attempts were attributed to the quality of the boron reagents and the bulkiness and 
rigidity of the C1–C11 aldehyde and C12–C24 ketone synthons. Due to steric hindrance 
from the enol-boron complex, the bulky aldehyde was unable to intercept the six-
membered transition state required for the aldol reaction. This suggestion was based 
on a successful aldol coupling study by Turner using the ketone 180 and a des-
dimethyl version of the aldehyde 175.
100
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3.4 Synthesis of other analogues 
 
The syntheses of the analogues 152 to 155 (Figure 2.2, Chapter 2) through 
derivatisations of the pyran ring were attempted. For the precursor to analogue 152, 
which was to have a fully saturated pyran ring, hydrogenation of the α,β-unsaturated 
lactone 165 with Adam‟s catalyst was attempted and the saturated lactone 187 was 
acquired in 71% yield (Scheme 3.22). The subsequent reduction and acetylation 
proceeded as expected and provided the acetate 189 in quantitative amount. However, 
attempted substitution at C5 with vinyloxy-trimethylsilane to provide the 
corresponding C3–C11 aldehyde failed to provide the desired aldehyde 225.  
 
Scheme 3.22. The synthesis of precursor to analogue 152. 
 
Conditions: (a) PtO2, H2, EtOAc, RT, 4 h; (b) DIBAL-H, DCM, -23 °C, 45 min; (c) 
TEA, Ac2O, DMAP, DCM, RT; (d) H2C=CHOTMS, BF3.Et2O, MeCN, RT, 3.5 h.  
 
Further investigation of the reaction mixture by chromatography led to the isolation of 
4,4-dimethyl-2,9-dioxa-bicyclo[3.3.1]nonane (226, Scheme 3.24) in 26% from the 
lactone 187. Although the lack of material did not allow for in-depth characterisation, 
the structure of bicycle 226 was elucidated from the 
1
H NMR spectrum through the 
presence of an oxymethine at δ 5.30 and 4.05 ppm. Methylene peaks were found as 
multiplets at δ 3.53-3.32 and 2.05-1.25 ppm, and the gem-dimethyl signals at δ 0.92 
and 0.88 ppm. Although a compound with an exact structural match to bicycle 226 is 
not known for use as a spectroscopic reference, similar compounds can be found in 
the work of Aiguade and Astashko.
123, 124
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In the earlier substitution of the dihydropyran 165 by vinyloxy-trimethylsilane, we 
proposed that the presence of the alkene helps to provide stabilisation of the 
carbocation (Scheme 3.23). The subsequent top-face attack on the oxonium ion 
resonance form by a nucleophile such as the vinyloxy-trimethylsilane provides the 
correct stereoselectivity and the desired aldehyde 168.  
 
Scheme 3.23 Substitution of α,β-unsaturated pyran ring. 
 
 
 
 
 
In the case of our saturated pyran ring system, the oxonium ion formed lacks the π-
bond stabilisation. The oxonium ion is therefore more readily attacked by the electron 
rich silylated oxygen and undergoes intramolecular cyclisation (Scheme 3.24).
125
 Also 
important was the chair conformation of the pyran system that provided a favourable 
orientation to enable the interception by the nucleophile. The silyl protecting group 
will would have been cleaved before or during work up, and the bicycle 226 was 
isolated by chromatography. The changes in the conformation of the pyran ring from 
a half-chair in the dihydropyran 165, due to the limitation imposed by the olefin 
moiety, to the full-chair conformation in 189 may also assist the formation of the 
bicyclic structure of 226. 
 
 
Scheme 3.24 Proposed mechanism for the formation of 4,4-dimethyl-2,9-dioxa-
bicyclo[3.3.1]nonane 226. 
 
 
 
 
 
Precedence consistent with the formation of the bicyclic compound 226 was found in 
the work of a PhD from the same group working on cyclopropanated carbohydrates. 
A part of the study was focussed on the influence of various protecting groups on the 
ring expansion reaction of a cyclopropanated glycal to form the corresponding 
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oxepine.
126
 The study found that, in the presence of a Lewis acid, the silyl protecting 
group was cleaved from the primary alcohol during the reaction.
126
 This 
intramolecular nucleophile competed with the intermolecular nucleophile to give the 
bicyclic oxepine as the major product in cases where the external nucleophile was 
particularly unreactive (Scheme 3.25).
126
 
 
Scheme 3.25 Interception of an oxonium intermediate by an internal silyloxy 
nucleophile by Batchelor.
126
 
 
 
  
 
Attempts at the dihydroxylation of the C6=C7 alkene to provide the precursor to the 
analogue 153 resulted in complete degradation of the starting material. Combined 
with the above-discussed problem of substituting the unsaturated pyran, further 
attempts at functionalisation of the pyran ring by removal of the alkene bond were 
abandoned. It was decided that functionalisation will be best achieved immediately 
prior to the 1,5-anti coupling or, preferably, at the very end of the synthesis.  
 
Attention then turned to acquiring a precursor to the alkenyl methyl analogues 154 
and 155. The attempt to obtain a precursor to the analogue 154 was through 
esterification of the allyl alcohol 163 with methacryloyl chloride. However, due to the 
degraded quality of the methacryloyl chloride used, the alcohol 163 was desilylated in 
the reaction mixture and a double esterification with the degraded substrate occurred 
instead of the desired monoesterification to give 227 (Scheme 3.26). Therefore, it was 
decided to temporarily abandon the attempt to obtain a precursor to the analogue 154. 
 
Scheme 3.26 The attempted synthesis of precursor to analogue 154. 
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A precursor to the analogue 155 was attempted by installation of a methyl group at 
C7. After various attempts, the aldehyde 161 was successfully methallylated to give 
the alcohol 183 (Scheme 3.27). However, this zinc-mediated methallyllation was poor 
yielding (25%) and not stereoselective. An initial attempt with methallylmagnesium 
bromide returned the starting aldehyde 161. An attempt to obtain methallyl alcohol 
183 asymmetrically using methallyldiisopinocamphenylborane failed to provide the 
desired result. 
 
Scheme 3.27 The synthesis of a precursor to analogue 155. 
 
 
 
 
 
 
 
 
 
 
 
Conditions: (a) 3-bromo-2-methylpropane, zinc powder, THF, 65 °C, 20 min; (b) 
acryloyl chloride, DIPEA, DCM, 0 °C to RT; (c) 5 mol% Grubbs‟ 2nd generation 
catalyst., DCM, RT. 
 
The methallyl alcohol 183 was subjected to an esterification with acryloyl choride and 
provided the desired diene 184 in moderate yield (60%). RCM of the diene 184 gave 
the 7-methyl lactone 185 in 78% yield. The presence of the additional methyl group at 
C7 was anticipated to provide steric hindrance and lower the reaction efficiency 
significantly compared to the diene 164. A decrease of 12% in yield was observed 
between the formation of lactone 165 and the C7-methyl lactone 185. Although the 
synthesis of the precursor was achieved, following the discovery that the subsequent 
aldol coupling reaction was unproductive, further analogue development was halted.   
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3.5 Evaluation of the synthetic strategy 
 
Utilising the synthetic strategy proposed in chapter 2, the necessary carbon skeleton 
for the peloruside A analogue 151 was obtained as two main fragments: the main C1–
C11 backbone and the sidechain C12–C24. The C1–C11 backbone was synthesised with 
a total yield of 4% in 13 steps from 2,2-dimethyl-1,3-propanediol. The sidechain C12–
C24 was synthesised with a total yield of 11% in 3 steps from acetone. However, to 
our disappointment, the coupling reaction to assemble the two fractions has been 
unsuccessful.  
 
As discussed in section 1.7, De Brabander‟s synthesis of (-)-peloruside A took 29 
steps with an overall yield of 3%.
51
 Jin and Taylor synthesised (+)-peloruside A with 
an overall yield of 0.4% in 29 steps.
52
 Ghosh achieved the synthesis of (+)-peloruside 
A in 30 steps with an overall yield of 1%.
53
 Evans‟ synthesis of (+)-peloruside A was 
a marked improvement with a total yield of 12% and overall 18 steps.
54
 Smith‟s 
unexpected synthesis of (-)-2-epi-peloruside A was completed in 21 steps with a 2% 
total yield.
57
 Ghosh‟s synthesis of peloruside B took an overall 29 steps and gave an 
overall yield of 0.3%.
44
 
 
(+)-Peloruside A is generally acknowledged to be a challenging synthetic target due 
to its numerous stereocentres and large ring size. The effectiveness of our synthetic 
strategy for the analogue 151 was evaluated by comparing with the previous syntheses 
of peloruside A. The analogue 151 was intended to provide an alternative to 
peloruside A that would be easier to synthesise and better yielding. However, given 
the optimised yields of the aldehyde 175 and ketone 180, and setting aside the 
troublesome aldol coupling, the end-game manipulations that will include C13 
reduction and methylation, protecting group manipulations, macrolactonisation and 
global deprotection are each going to further reduce the overall yield significantly.  If 
each of these steps were to proceed with approximately 60% yield, the total overall 
yield would be approximately 0.3% in 20 steps. This analysis leads us to the key 
conclusion that our proposed route to 151 is too inefficient compared to the literature 
syntheses of peloruside A, and indicates that further work on the 1,5-anti aldol 
coupling of 175 and 180 is not warranted.   
 105 
Furthermore, an alteration of the synthetic approach to the major fragments to 151 is 
necessary. Although the C1-C11 fragment can be synthesised reliably, the optimised 
4% yield for this fragment alone is unsatisfactory when compared to the total yields 
for peloruside A achieved by others, particularly Evans. This is especially true when 
bearing in mind that this fragment contains a simplification of the peloruside structure 
designed to improve synthetic yields. The synthetic strategy also failed to be efficient 
in the generation of the sidechain C12–C24 fragment. Although the fragment was 
readily available within three synthetic steps from acetone, the yield of each reaction 
step was poor. Furthermore, the dichloro[(S,S)-ethylenebis(4,5,6,7-tetrahydro-1-
indenyl)]zirconium(IV) and Grubbs‟ 2nd generation catalyst needed for the generation 
of the C12–C24 fragment are uneconomical for large scale synthesis. Therefore, an 
alternative synthetic strategy to build the sidechain fragment should be contemplated. 
 
3.6 Conclusion 
 
The attempt to synthesise the desired analogue 151 thus far has been unsuccessful. 
The main C1–C11 backbone was successfully synthesised from 2,2-dimethyl-1,3-
propanediol, allylmagnesium bromide, acryloyl chloride, vinyloxy-trimethylsilane, 
bromoacetic acid and (S)-4-benzyloxazolidin-2-one. The key steps in the synthesis of 
the main C1–C11 backbone were Brown allylation, RCM to provide the α,β-
unsaturated pyran ring of laulimalide, formation of the aldehyde 168 by alkylation 
reaction with vinyloxy-trimethylsilane, 1,2-syn aldol coupling to assemble the main 
C1–C11 backbone and the subsequent methylation of the resulting alcohol to provide 
the methyl ester moiety at C3. 
 
The synthesis of the sidechain C12–C24 was achieved from acetone, methacrolein, 2,5-
dihydrofuran and ethylmagnesium chloride. The key reaction steps in the synthesis of 
the sidechain C12–C24 involved an aldol coupling reaction to provide the β-hydroxy 
ketone 177, an asymmetric carbomagnesation reaction to obtain the ethylbutenol 178, 
A double silylation reaction to get the diene 179, and a RCM reaction to acquire the 
ketone 180. The RCM reaction gave the desired dioxasilocene 180 in poor yield due 
to intermolecular cross metathesis, formation of methylidene complex and 
ethylbutene isomerisation.  
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The subsequent attempts to induce 1,5-anti aldol coupling between C11 aldehyde of 
the main C1–C11 backbone and the C12 ketone of the C12–C24 sidechain were 
unsuccessful. The failure of the aldol coupling reactions was attributed to the steric 
hindrance posed by the bulkiness of the C1–C11 structure as well as the C12–C24 
sidechain. The model study using the C11–C5 pyran 127 illustrated the problems posed 
by the bulkiness of the ketone sidechain. Due to the steric hindrance from the ketone-
boron complex, the aldehyde was unable to intercept the six-membered transition 
state required for the 1,5-anti aldol reaction.  
 
Instead, the aldehyde complexed with the excess boron reagent in a Cannizzaro type 
reaction. Attempts to understanding the aldol coupling reaction and the Cannizzaro 
type reaction led to the discovery of several interesting side products. The conclusion 
obtained at the end of the attempt to synthesise the desired analogue 151 was that 1,5-
anti aldol coupling between the C11 aldehyde and the C12 ketone is not an efficient 
route to assembly the C1–C11 mainchain to the C12–C24 sidechain.  
 
Attempts at the synthesis of the analogues 152, 153, 154, and 155 were also 
unsuccessful. The presence of an α,β-unsaturated alkene provides a crucial 
conformational constraint and oxonium carbocation stabilisation that enable 
substitution of vinyloxy-trimethylsilane at C5 and prevent intramolecular cyclisation. 
Therefore, functionalisation of the pyran ring that results in the removal of the α,β-
unsaturation should be avoided at this stage. The syntheses of the precursors to the 
analogues 152, 153, 154, and 155 have thus far been temporarily discontinued until 
the assembly C1–C24 of the proposed peloruside A analogue becomes feasible. 
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Chapter 4 - Future work 
 
Future studies will include analysis of an alternative route to the analogue 151. A 
more linear synthetic strategy that builds the analogue in a stepwise fashion using 
aldol chemistry is a possible alternative approach to obtain the desired analogue 151. 
For instance, construction of the C11–C12 bond as an earlier step using an aldol 
reaction of simpler, less bulky substrates is anticipated to be more fruitful. Subsequent 
elongation to the full analogue backbone could set up a similar end-game to that 
originally proposed. One possible scenario is presented in scheme 4.1. Thus, 151 
could be generated from the linear precursor 228, akin to compound 216 in section 
3.3, by deprotection and Yamaguchi macrolactonisation. 
 
Scheme 4.1 Alternative retrosynthesis for analogue 151. 
 
Precursor 228 can be constructed from truncated skeleton 229 by elongation with 
vinyloxy-trimethylsilane followed by an Evans aldol reaction with 230. The C5–C24 
portion 229 could in turn be derived from the C9–C16 segment 232 via the C9–C24 
fragment 231. This sequence would enable the key C11–C12 connection to be made by 
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1,5-anti aldol reaction of partners 233 and 234, having much lower bulk than those 
previously employed in our route to 151. 
 
Furthermore, there are numerous alternative routes to install the C18-C24 fragments 
into the precursor 232 in scheme 4.1, other than using the current silocene 
methodology.  Such approach in the end game has the advantages of providing an 
opportunity for orthogonal protection of the C15 and C24 hydroxyl groups and 
facilitating the selective revelation of the C15 hydroxyl prior to macrolactonisation.   
 
Future studies should also look into other possible disconnections applicable to a 
convergent route, particularly those that avoid the problematic coupling adjacent to 
the quaternary carbon centre at C11. Further research should be focussed on 
understanding of the role of the gem-dimethyl moiety at C10 in the aldol coupling 
between ketone 180 and the aldehyde 175. An alternative protocol to install the gem-
dimethyl group using a similar approach to that of Jin and Taylor (Scheme 4.2) would 
involve aldol coupling to construct the C10–C11 bond.
60
 Thus, Mukaiyama aldol 
reaction of the C11–C24 hemisphere with silyl enol ether 40 could be tested for 
efficacy with the expectation that this less complex nucleophilic partner would have 
better reactivity than the enolate of ketone 180 with the aldehyde 175. 
 
Scheme 4.2 Alternative route for installation of the C10 gem-dimethyl group. 
 
Future studies should contemplate an alternative route to generate the sidechain C12–
C24 fragment as the current synthetic strategy is not sufficiently high yielding. 
Although the fragment was readily available within three synthetic steps from 
acetone, the yield of each reaction step was poor and the catalysts employed were 
uneconomical for large scale synthesis.  
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Chapter 5 - Experimental methods 
 
Unless otherwise stated, all of the following conditions apply to all presented 
reactions. All reactions were performed under zero grade argon at atmospheric 
pressure in vacuum- and flame-dried vessels. Standard syringe techniques were 
applied whenever necessary. Acetonitrile, dichloromethane, and triethylamine were 
freshly distilled from calcium hydride. Tetrahydrofuran was freshly distilled from the 
sodium benzophenone ketyl radical ion. Methanol and toluene were distilled from 
sodium. Acetone was distilled from calcium sulfate. Anhydrous diethyl ether and 
hexane were dried with sodium. Sodium hydride was obtained as 60% (w/w) 
dispersion in mineral oil and washed with anhydrous hexane prior to use. Anhydrous 
sodium methoxide was prepared fresh for each reaction in dried vessel. Sodium pieces 
were cleaned with anhydrous hexane, vacuum dried, and then dissolved in anhydrous 
methanol. Excess methanol was removed by vacuum and sodium methoxide was 
obtained as white powder. 0.5 M sodium phosphate buffer at pH 7.0 was prepared 
from 0.5 M solutions of sodium dihydrogen phosphate and disodium hydrogen 
phosphate. All other reagents were of commercial quality and distilled prior to use 
whenever necessary. The measurements of reagents and products were accurate to 
two decimal places, unless otherwise stated. The progress of each reaction was 
monitored using aluminium-backed TLC on plates pre-coated with UV254 silica. UV 
radiation at 254 nm, iodine dip, and anisaldehyde dip were employed as means of 
visualisation. Product purification was achieved by column chromatography, 
performed with P60 silica gel and solvent system as indicated. 
1
H and 
13
C NMR 
spectra were recorded on a Varian Unity Inova 500 spectrometer. CDCl3 solvent peak 
(7.26 ppm for 
1
H and 77.16 ppm for 
13
C) was used as references for all observed 
chemical shifts. Optical rotation was measured on a Perkin-Elmer Polarimeter 
(sodium lamp) at the concentration of mg/10 mL. High-resolution mass spectrometry 
was performed on a Waters Q-TOF PremierTM Tandem Mass Spectrometer. 
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(S)-2-Amino-3-phenylpropan-1-ol (156) 
 
Sodium borohydride (9.55 g, 252.45 mmol) was dried under vacuum and 
suspended in tetrahydrofuran (200.00 mL), then cooled to 0 °C. L-phenylalanine 
(16.53 g, 100.07 mmol) was added into the reaction flask. A solution of iodine (31.82 
g, 125.37 mmol) in tetrahydrofuran (140.00 mL) was added dropwise into the stirring 
reaction mixture. The resulting reaction mixture was stirred at 0 °C for 30 minutes 
and then refluxed at 80 °C for 36 hours. The reaction mixture was returned to room 
temperature and slowly quenched with methanol (150 mL) over 2 hours. The reaction 
mixture was concentrated under vacuum. The white solid obtained was dissolved in 
20% (w/w) potassium hydroxide solution (300 mL) and stirred at room temperature 
for 36 hours. The aqueous mixture was extracted with dichloromethane (3 x 150 mL). 
The organic extracts were combined and washed with saturated aqueous brine (2 x 
100 mL) and then dried with anhydrous magnesium sulfate. The solvent was removed 
under vacuum and white solid obtained. Recrystallisation from hot ethyl acetate 
provided 156 as white fine crystals (9.78 g, 64.68 mmol, 65%). 
1
H NMR (500 MHz, 
CDCl3) δ 7.33-7.19 (m, 5H), 3.64 (dd, J = 3.9 Hz, 10.5 Hz, 1H), 3.38 (dd, J = 7.3 Hz, 
10.5 Hz, 1H), 3.12 (m, 1H), 2.80 (dd, J = 5.4 Hz, 13.4 Hz, 1H), 2.53 (dd, J = 8.6 Hz, 
13.4 Hz, 1H).
100, 103
 
 
(S)-4-Benzyloxazolidin-2-one (157) 
 
Potassium carbonate (0.41 g, 2.97 mmol) was flame dried in a distillation 
apparatus. 156 (3.00 g, 19.84 mmol) was added, followed by diethyl 
carbonate (5.20 mL, 5.07 g, 42.92 mmol). The reaction mixture was stirred and heated 
to 78 °C. Ethanol was distilled from the reaction mixture and the residual liquid 
returned to room temperature. The reaction was quenched with distilled water (15 
mL). The aqueous slurry was extracted with dichloromethane (3 x 40 mL). The 
organic extracts were combined and washed with saturated aqueous brine (50 mL) 
and then dried with anhydrous magnesium sulfate. The solvent was removed under 
vacuum and white crystals obtained. Recrystallisation from hot ethyl acetate and 
hexane provided 157 as white long crystals (2.70 g, 15.24 mmol, 77%). 
1
H NMR (500 
MHz, CDCl3) δ 7.37-7.18 (m, 5H), 4.94 (bs, 1H), 4.49 (t, J = 8.3 Hz, 1H), 4.17 (dd, J 
= 5.5 Hz, 8.7 Hz, 1H), 4.09 (m, 1H), 2.87 (m, 2H).
100, 103
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2-(4-Methoxybenzyloxy)acetic acid (158) 
  
Sodium hydride (4.22 g, 175.63 mmol, 60% in mineral oil) was 
divided into two portions and washed with anhydrous hexane (3 x 20 mL). The first 
portion of sodium hydride was suspended in tetrahydrofuran (36.00 mL) and cooled 
to 0 °C. 4-Methoxybenzyl alcohol (6.50 mL, 7.23 g, 52.36 mmol) was added 
dropwise and the reaction mixture stirred for 15 minutes. The reaction was then 
returned to room temperature and stirred for 15 minutes, then recooled to 0 °C. The 
second portion of sodium hydride was suspended in tetrahydrofuran (18.00 mL) at 0 
°C. A solution of bromoacetic acid (6.95 g, 50.02 mmol) in tetrahydrofuran (18.00 
mL) was added dropwise and the reaction mixture stirred for 5 minutes. The activated 
alcohol mixture was cannulated dropwise into the carboxylate mixture. The reaction 
mixture was returned to room temperature and stirred for 3 hours. The reaction was 
quenched with distilled water (20 mL) and stirred until the slurry fully dissolved. The 
organic solvent was removed under vacuum and the aqueous layer washed with 
diethyl ether (2 x 50 mL). The aqueous layer was acidified with concentrated 
sulphuric acid (1 mL) to pH 4 and extracted with diethyl ether (3 x 50 mL). The 
organic extracts were combined and washed with distilled water (2 x 30 mL) and then 
dried with anhydrous magnesium sulfate. Removal of solvent under vacuum provided 
158 as white long crystals (5.20 g, 26.50 mmol, 53%). 
1
H NMR (500 MHz, CDCl3) δ 
7.27 (d, 8.8 Hz, 2H), 6.91 (d, J = 8.2 Hz, 2H), 4.59 (s, 2H), 4.08 (s, 2H), 3.89 (s, 
3H).
100
 
 
(S)-4-Benzyl-3-(2-[4-methoxybenzyloxy]acetyl)oxazolidin-2-
one (159) 
 
To a solution of 158 (3.87 g, 19.72 mmol) in acetonitrile (159.00 
mL) at room temperature, was added triethylamine (3.50 mL, 2.54 g, 25.11 mmol) 
and HBTU (8.24 g, 21.73 mmol). The reaction mixture was stirred for 30 minutes and 
gradually turned orange coloured. To a solution of 157 (3.50 g, 19.75 mmol) in 
tetrahydrofuran (25.00 mL) at -78 °C, was added butyllithium (2.0 M in cyclohexane, 
11.00 mL, 22.00 mmol). The reaction mixture was stirred for 15 minutes. The 
activated carboxylic acid mixture was cannulated dropwise into the deprotonated 
oxazolidinone mixture. The reaction mixture was returned to room temperature and 
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stirred for 2 hours. The reaction was quenched with saturated aqueous brine (50 mL). 
The aqueous and organic layers were separated. The aqueous layer was extracted with 
dichloromethane (3 x 50 mL). The organic extracts were combined and washed with 
10% HCl (100 mL), followed with saturated aqueous NaHCO3 (100 mL), and finally 
with distilled water (100 mL). The organic extract was dried with anhydrous 
magnesium sulfate and concentrated. Gradient flash chromatography (5:1 to 1:1 
hexane/ethyl acetate) provided 159 as a white solid (3.34 g, 9.40 mmol, 48%). Rf 0.21 
(2:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 7.36-7.27 (m, 5H), 7.21 (d, 
J = 7.0 Hz, 2H), 6.90 (d, J = 7.9 Hz, 2H), 4.70 (m, 1H), 4.68 (s, 2H), 4.63 (s, 2H), 
4.25 (m, 2H), 3.81 (s, 3H), 3.33 (dd, J = 3.3 Hz, 13.5 Hz, 1H), 2.81 (dd, J = 9.3 Hz, 
13.5 Hz, 1H).
100
 
 
3-(tert-Butyldimethylsilyloxy)-2,2-dimethylpropan-1-ol (160) 
 
To a solution of 2,2-dimethyl-1,3-propanediol (5.23 g, 50.22 mol) in 
N,N-dimethylformamide (16.00 mL) at 0 °C, was added imidazole (6.81 g, 100.03 
mmol) and tert-butyldimethylsilyl chloride (7.54 g, 50.03 mmol). The reaction 
mixture was returned to room temperature and stirred overnight. The reaction was 
diluted with diethyl ether (100 mL) and extracted with saturated aqueous NaHCO3 (3 
x 30 mL), followed by distilled water (2 x 30 mL). The organic extract was dried with 
anhydrous magnesium sulfate and concentrated. Flash chromatography (20:1 
hexane/ethyl acetate) provided 160 as a colourless oil (6.57 g, 30.08 mmol, 60%). Rf 
0.28 (10:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 3.47 (s, 4H), 2.88 (t, J 
= 5.8 Hz, 1H), 0.90 (s, 9H), 0.88 (s, 6H), 0.06 (s, 6H).
100
 
 
3-(tert-Butyldimethylsilyloxy)-2,2-dimethylpropanal (161) 
 
To a solution of oxalyl chloride (4.00 mL, 6.00 g, 47.27 mol) in 
dichloromethane (46.00 mL) at -78 °C, was added dropwise dimethyl sulfoxide (4.30 
mL, 4.73 g, 60.54 mmol). The reaction mixture was stirred for 30 minutes and a 
solution of 160 (6.57 g, 30.08 mmol) in dichloromethane (60. 00 mL) was added 
dropwise. The reaction mixture was stirred for 30 minutes and triethylamine (17.00 
mL, 12.34 g, 121.97 mmol) was added dropwise. The reaction mixture was stirred for 
a further 2 hours. The reaction was quenched with saturated aqueous NaHCO3 (50 
TBSO OH
TBSO O
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mL) and returned to room temperature. The aqueous and organic layers were 
separated. The aqueous layer was extracted with dichloromethane (3 x 50 mL). The 
organic extracts were combined and washed with saturated aqueous NaHSO3 (2 x 50 
mL) and then with saturated aqueous brine (75 mL). The organic extract was dried 
with anhydrous magnesium sulfate and concentrated. Flash chromatography (20:1 
hexane/ethyl acetate) provided 161 as a colourless oil (5.60 g, 25.88 mmol, 86%). Rf 
0.73 (10:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 9.57 (s, 1H), 3.59 (s, 
2H), 1.04 (s, 6H), 0.87 (s, 9H), 0.03 (s, 6H).
100 
 
(-)-B-Allyldiisopinocamphenylborane (162) 
 
To a solution of (+)-α-pinene (19.00 mL, 16.30 g, 119.67 mmol) 
in tetrahydrofuran (12.00 mL) at room temperature was added dropwise borane 
dimethyl sulfide complex (4.00 mL, 3.20 g, 42.17 mmol). The reaction mixture was 
cooled to -18 °C and a white solid settled out overnight. The solvent was removed and 
the white solid was rinsed with anhydrous diethyl ether (3 x 15.00 mL), then dried 
under vacuum. The white solid was suspended in anhydrous diethyl ether (20.00 mL) 
and cooled to 0 °C. Methanol (3.80 mL, 3.01 g, 93.81 mmol) was added dropwise and 
the resulting reaction mixture was stirred until no white solid remained. The reaction 
mixture was concentrated under vacuum, then returned to atmospheric pressure and 
diluted in anhydrous diethyl ether (20. 00 mL) at 0 °C. Allylmagnesium bromide 
solution (1.0 M in diethyl ether, 25.00 mL, 25.00 mmol) was added dropwise. The 
reaction mixture was returned to room temperature and stirred for 4 hours. A white 
slurry formed was used immediately for formation of 163.
100, 104
 
 
 (S)-1-(tert-Butyldimethylsilyloxy)-2,2-dimethylhex-5-en-3-ol 
(163) 
 
To the white slurry containing 162 (25.00 mol) at -100 °C, was added dropwise a 
solution of 161 (5.60 g, 25.88 mmol). The reaction mixture was stirred for 2 hours 
and quenched with sequential addition of methanol (5 mL), 0.5 M sodium phosfate 
buffer (pH 7.0, 5 mL), and 30% hydrogen peroxide (5 mL). The solution was stirred 
at room temperature overnight. The aqueous and organic layers were separated. The 
aqueous layer was extracted with ethyl acetate (3 x 50 mL). The organic extracts were 
TBSO OH
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combined and washed with saturated aqueous NH4Cl (3 x 40 mL) and then dried with 
anhydrous magnesium sulfate and concentrated. Gradient flash chromatography (50:1 
to 10:1 hexane/ethyl acetate) provided 163 as a colourless oil (4.71 g, 18.22 mmol, 
70%, 95% ee). Rf 0.39 (10:1 hexane/ethyl acetate).
 
IR (KBr, cm
-1
) νmax 3495.0, 
2951.0, 1219.0, 1073.0, 837.0, 771.0. [α]
23
D -73 (C 0.1, CHCl3).
 1
H NMR (500 MHz, 
CDCl3) δ 5.94 (m, 1H), 5.10 (m, 2H), 3.55 (d, J = 10.0 Hz, 1H), 3.48 (s, 2H), 2.27 (m, 
1H), 2.09 (m, 1H), 0.91 (s, 3H), 0.90 (s, 9H), 0.84 (s, 3H), 0.07 (s, 6H).
100, 104
 
 
 (S)-1-(tert-Butyldimethylsilyloxy)-2,2-dimethylhex-5-en-3-yl 
acrylate (164) 
 
To a solution of 163 (4.52 g, 17.49 mmol) in dichloromethane 
(96.00 mL) at 0 °C, was added N,N-diisopropylethylamine (7.60 mL, 5.64 g, 43.63 
mmol), followed by acryloyl chloride (2.80 mL, 3.12 g, 34.46 mmol). The reaction 
mixture was returned to room temperature and stirred overnight. The reaction was 
quenched with saturated aqueous NH4Cl (50 mL). The aqueous and organic layers 
were separated. The aqueous layer was extracted with dichloromethane (3 x 50 mL). 
The organic extracts were combined and washed with saturated aqueous brine (100 
mL). The organic extract was dried with anhydrous magnesium sulfate and 
concentrated. Flash chromatography (20:1 hexane/ethyl acetate) provided 164 as a 
colourless oil (4.50 g, 14.40 mmol, 82%). Rf 0.64 (10:1 hexane/ethyl acetate).
 1
H 
NMR (500 MHz, CDCl3) δ 6.37 (dd, J = 1.5 Hz, 17.3 Hz, 1H), 6.10 (dd, J = 10.5 Hz, 
17.3 Hz, 1H), 5.79 (dd, J = 1.6 Hz, 10.4 Hz, 1H), 5.73 (m, 1H), 5.09 (dd, J = 2.9 Hz, 
10.3 Hz, 1H), 5.02 (d, J = 18.6 Hz, 1H), 4.97 (d, J = 10.3 Hz, 1H), 3.33 (d, J = 5.6 Hz, 
2H), 2.44 (m, 1H), 2.25 (m, 1H), 0.91 (s, 3H), 0.89 (s, 9H), 0.87 (s, 3H), 0.01 (s, 
6H).
100
 
 
 (S)-6-(1-[tert-Butyldimethylsilyloxy]-2-methylpropan-2-yl)-5,6-
dihydropyran-2-one (165) 
 
To a solution of 164 (4.50 g, 14.40 mmol) in dichloromethane 
(1440.00 mL) at room temperature, was added Grubbs‟ 2nd generation catalyst (0.63 
g, 0.74 mmol). The reaction mixture was stirred overnight. The reaction mixture was 
TBSO O
O
TBSO O
O
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concentrated to a brown oil. Flash chromatography (10:1 hexane/ethyl acetate) 
provided 165 as a yellow oil (3.68 g, 12.94 mmol, 90%). Rf 0.18 (10:1 hexane/ethyl 
acetate).
 1
H NMR (500 MHz, CDCl3) δ 6.92 (m, 1H), 6.01 (d, J = 9.6 Hz, 1H), 4.36 
(d, J = 13.8 Hz, 1H), 3.53 (dd, J = 4.4 Hz, 14.2 Hz, 1H), 3.37 (dd, J = 4.4 Hz, 14.2 
Hz, 1H), 2.44 (m, 1H), 2.27 (m, 1H), 0.97 (s, 3H), 0.91 (s, 3H), 0.87 (s, 9H), 0.03 (s, 
6H).
100
 
 
 (6S)-6-(1-[tert-Butyldimethylsilyloxy]-2-methylpropan-2-yl)-
5,6-dihydro-2H-pyran-2-ol (166) 
 
To a solution of 165 (3.68 g, 12.94 mmol) in dichloromethane 
(182.00 mL) at -23 °C, was added diisobutylaluminium hydride (1.0 M in toluene, 
20.00 mL, 20.00 mmol) and the reaction mixture was stirred for 45 minutes. The 
reaction was quenched with methanol (10 mL) and returned to room temperature. A 
saturated aqueous solution of Rochelle‟s salt (100 mL) was added to the reaction 
mixture. The aqueous and organic layers were separated. The aqueous layer was 
extracted with dichloromethane (3 x 50 mL). The organic extracts were combined and 
dried with anhydrous magnesium sulfate. Removal of solvent provided 166 as a 
brown oil and was used without further purification. Rf 0.22 (10:1 hexane/ethyl 
acetate).
 1
H NMR (500 MHz, CDCl3) δ 6.05 (m, 1H), 5.79 (d, J = 10.0 Hz, 1H), 5.37 
(m, 1H), 3.87 (dd, J = 3.0 Hz, 11.5 Hz, 1H), 3.45 (d, J = 9.5 Hz, 1H), 3.34 (d, J = 9.5 
Hz, 1H), 2.13 (m, 1H), 1.90 (m, 1H), 0.89 (s, 9H), 0.85 (s, 6H), 0.03 (s, 6H).
100, 106 
 
 (6S)-6-(1-[tert-Butyldimethylsilyloxy]-2-methylpropan-2-yl)-
5,6-dihydro-2H-pyran-2-yl acetate (167) 
 
To a solution of 166 (assumed to be 12.94 mmol) in 
dichloromethane (104.00 mL) at room temperature, was added triethylamine (4.50 
mL, 3.27 g, 32.29 mmol). Acetic anhydride (2.00 mL, 2.16 g, 31.16 mmol) was added 
to the reaction mixture, followed by N,N-dimethyl-4-aminopyridine (0.02 g, 0.16 
mmol). The reaction mixture was stirred overnight at room temperature. The reaction 
mixture was extracted with saturated aqueous KHSO4 (25 mL), followed with 
saturated aqueous NaHCO3 (25 mL) and saturated aqueous brine (25 mL). The 
organic layer was dried with anhydrous magnesium sulfate. Removal of solvent 
TBSO O
OH
TBSO O
OAc
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provided 167 as a brown oil and was used without further purification. Rf 0.19 (10:1 
hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 6.28 (m, 1H), 6.16 (m, 1H), 6.10 
(m, 1H), 5.73 (d, J = 10.0 Hz, 1H), 5.63 (d, 10.0 Hz, 1H), 3.82 (dd, J = 3.3 Hz, 11.6 
Hz, 1H), 3.74 (dd, J = 3.3 Hz, 11.6 Hz, 1H), 3.45 (dd, J = 9.5 Hz, 27.9 Hz, 1H), 3.28 
(dd, J = 9.5 Hz, 23.0 Hz, 1H), 2.23 (s, 3H), 2.10 (m, 2H), 0.89 (s, 9H), 0.87 (s, 3H), 
0.83 (s, 3H), 0.02 (s, 6H).
100
 
 
2-([2S,6S]-6-[1-{tert-Butyldimethylsilyloxy}-2-methylpropan-2-
yl]-5,6-dihydro-2H-pyran-2-yl)acetaldehyde (168) 
 
To a solution of 167 (assumed to be 12.94 mmol) in acetonitrile 
(130.00 mL) at room temperature was added freshly distilled 
vinyloxy-trimethylsilane (2.90 mL, 2.26 g, 19.44 mmol), followed with freshly 
distilled boron trifluoride diethyl etherate (0.16 mL, 0.18 g, 1.30 mmol). The reaction 
mixture was stirred for 3.5 hours at room temperature. The reaction was quenched 
with saturated aqueous NaHCO3 (100 mL). The aqueous and organic layers were 
separated. The aqueous layer was extracted with dichloromethane (3 x 100 mL). The 
organic extracts were combined and dried with anhydrous magnesium sulfate, then 
concentrated. Flash chromatography (20:1 hexane/ethyl acetate) provided 168 as a 
colourless oil (2.39 g, 7.65 mmol, 59%). Rf 0.35 (10:1 hexane/ethyl acetate).
 1
H NMR 
(500 MHz, CDCl3) δ 9.82 (s, 1H), 5.92 (m, 1H), 5.68 (d, J = 10.3 Hz, 1H), 4.78 (m, 
1H), 3.57 (dd, J = 2.8 Hz, 10.9 Hz, 1H), 3.43 (d, J = 10.2 Hz, 1H), 3.24 (d, J = 10.2 
Hz, 1H), 2.82 (m, 1H), 2.46 (d, J = 11.9 Hz, 1H), 2.13 (m, 1H), 1. 87 (d, J = 17.2 Hz, 
1H), 0.89 (s, 9H), 0.84 (s, 3H), 0.82 (s, 3H), 0.02 (s, 6H).
100
 
 
(S)-4-Benzyl-3-([2S,3R]-4-[{2S,6S}-6-{1-(tert-
butyldimethylsilyloxy)-2-methylpropan-2-yl}-5,6-dihydro-
2H-pyran-2-yl]-3-hydroxy-2-[4-
methoxybenzyloxy]butanoyl)oxazolidin-2-one (169) 
 
To a solution of 159 (3.34 g, 9.40 mmol) in toluene (50.00 mL) at -50 °C, was added 
triethylamine (1.50 mL, 1.09 g, 10.76 mmol), followed by dibutylboryl 
trifluoromethanesulfonate (1.0 M in dichloromethane, 10.00 mL, 10.00 mmol). The 
reaction mixture was stirred for 1.5 hours and a solution of 168 (2.39 g, 7.65 mmol) in 
TBSO O
O
O
N
Ph
O
PMBO
O
O
OH
TBSO
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toluene (23.00 mL) was added. The reaction mixture was warmed gradually to -30 °C 
and stirred for 2 hours. The reaction was quenched with sequential addition of 0.5 M 
sodium phosfate buffer (pH 7.0, 5 mL), methanol (5 mL), tetrahydrofuran (5 mL), and 
30% hydrogen peroxide (5 mL). The reaction mixture was warmed to 0 °C and stirred 
for 60 minutes. The reaction mixture was returned to room temperature and the 
solvent removed under vacuum. The white solid was dissolved in saturated aqueous 
NaHCO3 (50 mL) and ethyl acetate (50 mL). The aqueous and organic layers were 
separated. The aqueous layer was extracted with ethyl acetate (3 x 50 mL). The 
organic extracts were combined and dried with anhydrous magnesium sulfate, then 
concentrated. Flash chromatography (1% triethylamine in 2:1 hexane/ethyl acetate) 
provided 169 as a colourless oil (2.66 g, 3.98 mmol, 52%). Rf 0.31 (2:1 hexane/ethyl 
acetate).
 1
H NMR (500 MHz, CDCl3) δ 7.34-7.28 (m, 5H), 7.21 (d, J = 7.1 Hz, 2H), 
6.89 (dd, J = 2.1 Hz, 6.5 Hz, 2H), 5.81 (m, 1H), 5.67 (d, J = 9.4 Hz, 1H), 5.19 (d, J = 
3.0 Hz, 1H), 4.65 (m, 1H), 4.63 (s, 2H), 4.53 (m, 1H), 4.15 (m, 2H), 3.79 (m, 1H), 
3.78 (s, 3H), 3.46 (m, 1H), 3.43 (d, J = 9.6 Hz, 1H), 3.30 (d, J = 9.7 Hz, 1H), 3.27 
(dd, J = 3.2 Hz, 13.8 Hz, 1H), 2.67 (dd, J = 9.8 Hz, 13.2 Hz, 1H), 2.11 (m, 1H), 1.87 
(m, 2H), 1.70 (m, 1H), 0.91 (s, 3H), 0.87 (s, 9H), 0.82 (s, 3H), 0.01 (s, 6H).
100
 
 
 (S)-4-Benzyl-3-([2S,3R]-4-[{2S,6S}-6-{1-(tert-
butyldimethylsilyloxy)-2-methylpropan-2-yl}-5,6-dihydro-
2H-pyran-2-yl]-3-methoxy-2-[4-
methoxybenzyloxy]butanoyl)oxazolidin-2-one (170) 
 
To a solution of 169 (2.66 g, 3.98 mmol) in dichloromethane (100.00 mL) at 0 °C, 
was added 1:1 (mol/mol) mixture of trimethyloxonium tetrafluoroborate (1.18 g, 7.96 
mmol) and Proton-sponge
®
 (1.71 g, 7.96 mmol). The reaction mixture was stirred for 
3 hours at 0 °C. The reaction was quenched with saturated aqueous NaHCO3 (50 mL). 
The aqueous and organic layers were separated. The aqueous layer was extracted with 
dichloromethane (3 x 50 mL). The organic extracts were combined and washed with 
saturated aqueous brine (75 mL). The organic extract was dried with anhydrous 
magnesium sulfate and concentrated. Gradient flash chromatography (5:1 to 2:1 
hexane/ethyl acetate) provided 170 as a colourless oil (2.37 g, 3.48 mmol, 87%). Rf 
0.52 (10:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 7.33-7.28 (m, 5H), 
7.20 (d, J = 7.0 Hz, 2H), 6.86 (dd, J = 2.1 Hz, 6.8 Hz, 2H), 5.81 (m, 1H), 5.64 (d, J = 
O
N
Ph
O
PMBO
O
O
OMe
TBSO
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10.3 Hz, 1H), 5.50 (d, J = 4.7 Hz, 1H), 4.58 (m, 1H), 4.57 (s, 2H), 4.36 (d, J = 10.3 
Hz, 1H), 4.13 (m, 2H), 3.83 (m, 1H), 3.76 (s, 3H), 3.50 (d, J = 9.4 Hz, 1H), 3.45 (s, 
3H), 3.41 (dd, J = 2.7 Hz, 10.5 Hz, 1H), 3.30 (d, J = 9.4 Hz, 1H), 3.18 (dd, J = 3.2 Hz, 
13.8 Hz, 1H), 2.58 (dd, J = 10.0 Hz, 13.2 Hz, 1H), 2.12 (m, 1H), 1.97 (m, 1H), 1. 86 
(d, J = 17.0 Hz, 1H), 1.47 (m, 1H), 0.95 (s, 3H), 0.88 (s, 9H), 0.84 (s, 3H), 0.02 (s, 
6H).
100
 
 
(S)-4-Benzyl-3-([2S,3R]-4-[{2S,6S}-6-{1-hydroxy-2-
methylpropan-2-yl}-5,6-dihydro-2H-pyran-2-yl]-3-
methoxy-2-[4-methoxybenzyloxy]butanoyl)oxazolidin-2-one 
(171) 
 
To a solution of 170 (0.10 g, 0.15 mmol) in methanol (2.00 mL) at room temperature, 
was added hydrogen chloride solution (2.0 M in diethyl ether, 0.10 mL, 0.20 mmol). 
The reaction mixture was stirred for 15 minutes. The reaction was quenched with 
saturated aqueous NaHCO3 (2 mL). The reaction mixture was extracted with 
dichloromethane (3 x 6 mL). The organic extracts were combined and dried with 
anhydrous magnesium sulfate, then concentrated. Gradient flash chromatography (2:1 
to 1:1 hexane/ethyl acetate) provided 171 as a colourless oil (0.05 g, 0.09 mmol, 
60%). Rf 0.26 (2:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 7.36-7.29 (m, 
5H), 7.20 (d, J = 7.0 Hz, 2H), 6.87 (dd, J = 2.1 Hz, 6.8 Hz, 2H), 5.84 (m, 1H), 5.62 (d, 
J = 10.3 Hz, 1H), 5.45 (d, J = 4.1 Hz, 1H), 4.59 (dd, J = 11.6 Hz, 26.8 Hz, 2H), 4.57 
(m, 1H), 4.36 (d, J = 10.8 Hz), 4.16 (m, 2H), 3.80 (m, 1H), 3.77 (s, 3H), 3.68 (dd, J = 
5.1 Hz, 10.7 Hz, 1H), 3.60 (dd, J = 3.0 Hz, 10.9 Hz, 1H), 3.43 (s, 3H), 3.25 (d, J = 5.7 
Hz, 10.7 Hz, 1H), 3.17 (m, 1H), 2.61 (dd, J = 9.8 Hz, 13.4 Hz, 1H), 2.14 (m, 1H), 
1.96 (m, 1H), 1. 86 (m, 1H), 1.46 (m, 1H), 0.96 (s, 3H), 0.83 (s, 3H).
100
 
 
2-([2S,6S]-6-[{2R,3S}-4-{(S)-4-Benzyl-2-oxooxazolidin-3-
yl}-2-methoxy-3-{4-methoxybenzyloxy}-4-oxobutyl]-3,6-
dihydro-2H-pyran-2-yl)-2-methylpropanal (172) 
 
Dess-Martin periodinane (0.13 g, 0.31 mmol) was suspended in 
dichloromethane (3.80 mL) at 0 °C. Pyridine (0.07 mL, 0.07 g, 0.87 mmol) was added 
to the suspension and a solution of 171 (0.09 g, 0.16 mmol) in dichloromethane (2.40 
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mL) was then added dropwise into the reaction mixture. The reaction mixture was 
stirred for 5 hours at 0 °C. The reaction was quenched with saturated aqueous NaS2O3 
(2 mL) and saturated aqueous NaHCO3 (2 mL). The aqueous and organic layers were 
separated. The aqueous layer was extracted with dichloromethane (3 x 5 mL). The 
organic extracts were combined and dried with anhydrous magnesium sulfate, then 
concentrated. Flash chromatography (2:1 hexane/ethyl acetate) provided 172 as a 
white solid (0.07 g, 0.12 mmol, 75%). Rf 0.19 (2:1 hexane/ethyl acetate).
 1
H NMR 
(500 MHz, CDCl3) δ 9.53 (s, 1H), 7.36-7.29 (m, 5H), 7.21 (d, J = 7.0 Hz, 2H), 6.87 
(d, J = 8.8 Hz, 2H), 5.82 (m, 1H), 5.65 (d, J = 10.3 Hz, 1H), 5.41 (d, J = 4.1 Hz, 1H), 
4.59 (m, 1H), 4.63 (d, J = 11.4 Hz, 1H), 4.52 (d, 11.4 Hz, 1H), 4.34 (m, 1H), 4.19 (m, 
2H), 3.77 (s, 3H), 3.73 (m, 1H), 3.68 (m, 1H), 3.37 (s, 3H), 3.22 (dd, J = 3.2 Hz, 13.2 
Hz, 1H), 2.66 (dd, J = 9.9 Hz, 13.4 Hz, 1H), 2.11 (m, 1H), 1.91 (m, 2H), 1.52 (m, 
1H), 1.04 (s, 3H), 1.02 (s, 3H).
100
 
 
(2S,3R)-Methyl 4-([2S,6S]-6-[1-{tert-butyldimethylsilyloxy}-2-
methylpropan-2-yl]-5,6-dihydro-2H-pyran-2-yl)-3-methoxy-
2-(4-methoxybenzyloxy)butanoate (173) 
 
To a solution of 170 (1.09 g, 1.60 mmol) in dichloromethane 
(17.00 mL) at 0 °C, was added dimethyl carbonate (0.69 mL, 0.74 g, 8.19 mmol), 
followed by fresh anhydrous sodium methoxide (0.44 g, 8.15 mmol). The yellow-
coloured reaction mixture was stirred at 0 °C for 1.5 hours. The reaction was 
quenched with distilled water (20 mL). The aqueous and organic layers were 
separated. The aqueous layer was extracted with dichloromethane (3 x 20 mL). The 
organic extracts were combined and washed with 10% hydrochloric acid (20 mL). 
The organic extract was dried with anhydrous magnesium sulfate and concentrated. 
Gradient flash chromatography (5:1 hexane/ethyl acetate to neat ethyl acetate) 
provided 173 as a colourless oil (0.59 g, 1.10 mmol, 69%). Rf 0.53 (2:1 hexane/ethyl 
acetate).
 1
H NMR (500 MHz, CDCl3) δ 7.25 (d, J = 8.8 Hz, 2H), 6.86 (dd, J = 2.1 Hz, 
8.8 Hz, 2H), 5.82 (m, 1H), 5.63 (d, J = 10.3 Hz, 1H), 4.70 (d, J = 11.9 Hz, 1H), 4.38 
(m, 1H), 4.38 (d, J = 11.5 Hz, 2H), 3.90 (d, J = 4.2 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 
3.46 (s, 3H), 3.43 (d, J = 9.5 Hz, 1H), 3.37 (dd, J = 2.9 Hz, 10.7 Hz, 1H), 3.33 (d, J = 
9.5 Hz, 1H), 2.10 (m, 1H), 1.83 (d, J = 17.1 Hz, 1H), 1.65 (m, 2H), 0.92 (s, 3H), 0.87 
(s, 9H), 0.83 (s, 3H), 0.02 (s, 6H). 
13
C NMR (500 MHz, CDCl3) δ 171.63, 159.50, 
MeO
PMBO
O
O
OMe
TBSO
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129.90, 129.90, 129.83, 129.47, 125.03, 113.95, 113.87, 79.68, 78.29, 72.55, 71.24, 
69.75, 69.46, 59.86, 55.39, 51.96, 38.94, 34.85, 26.05, 25.40, 20.83, 20.62, 18.39, -
5.35, -5.45.
100, 113
 
 
(2S,3R)-Methyl 4-([2S,6S]-6-[1-hydroxy-2-methylpropan-2-yl]-
5,6-dihydro-2H-pyran-2-yl)-3-methoxy-2-(4-
methoxybenzyloxy)butanoate (174) 
 
To a solution of 173 (0.18 g, 0.34 mmol) in methanol (1.40 mL) at 
room temperature was added, dropwise, 36% aqueous hydrochloric acid solution 
(0.01 mL). The reaction mixture was stirred for 30 minutes. The reaction was 
quenched with saturated aqueous NaHCO3 (1 mL). The reaction mixture was 
extracted with dichloromethane (3 x 3 mL). The organic extracts were combined and 
dried with anhydrous magnesium sulfate, then concentrated. Flash chromatography 
(5:1 hexane/ethyl acetate) provided 174 as a colourless oil (0.13 g, 0.31 mmol, 91%). 
Rf 0.16 (2:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 8.5 Hz, 
2H), 6.87 (d, J = 2.1 Hz, 8.5 Hz, 2H), 5.83 (m, 1H), 5.61 (d, J = 10.0 Hz, 1H), 4.70 (d, 
J = 11.7 Hz, 1H), 4.40 (d, J = 11.7 Hz, 2H), 4.39 (m, 1H), 4.02 (d, J = 4.4 Hz, 1H), 
3.80 (s, 3H), 3.76 (s, 3H), 3.68 (d, 11.0 Hz, 1H), 3.51 (dd, J = 3.0 Hz, 11.0 Hz, 1H), 
3.44 (s, 3H), 3.26 (dd, J = 4.6 Hz, 10.7 Hz, 1H), 3.03 (bs, 1H), 2.14 (m, 1H), 1.85 (m, 
2H), 1.45 (m, 1H), 0.96 (s, 3H), 0.83 (s, 3H).
13
C NMR (500 MHz, CDCl3) δ 171.62, 
159.62, 130.06,129.39, 129.09, 124.73, 113.95, 78.35, 78.15, 73.03, 72.48, 70.26, 
70.08, 59.46, 55.42, 52.12, 38.00, 34.64, 25.30, 22.74, 19.64.
100
 
 
(2S,3R)-Methyl 3-methoxy-2-(4-methoxybenzyloxy)-4-([2S,6S]-
6-[2-methyl-1-oxopropan-2-yl]-5,6-dihydro-2H-pyran-2-
yl)butanoate (175) 
 
To a solution of 174 (0.12 g, 0.28 mmol) in dichloromethane (4.20 
mL) at room temperature was added (bisacetoxyiodo)benzene (0.20 g, 0.62 mmol) 
and TEMPO (5.00 mg, 0.03 mmol). The reaction mixture was stirred for 5 hours at 
room temperature. The reaction was quenched with saturated aqueous Na2S2O3 (10 
mL) and stirred at room temperature for 15 minutes. The aqueous and organic layers 
were separated. The aqueous layer was extracted with dichloromethane (3 x 10 mL). 
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The organic extracts were combined and washed with saturated aqueous NaHCO3 (10 
mL). The organic extract was dried with anhydrous magnesium sulfate and 
concentrated. Flash chromatography (2:1 hexane/ethyl acetate) provided 175 as a 
colourless oil (0.11 g, 0.26 mmol, 93%). Rf 0.23 (2:1 hexane/ethyl acetate).
 1
H NMR 
(500 MHz, CDCl3) δ 9.55 (s, 1H), 7.28 (d, J = 8.5 Hz, 2H), 6.87 (d, J = 2.1 Hz, 8.5 
Hz, 2H), 5.81 (m, 1H), 5.64 (d, J = 9.3 Hz, 1H), 4.69 (d, J = 11.4 Hz, 1H), 4.39 (d, J = 
11.5 Hz, 2H), 4.36 (d, J = 11.2 Hz, 1H), 4.01 (d, J =  4.7 Hz, 1H), 3.80 (s, 3H), 3.77 
(s, 3H), 3.69 (m, 1H), 3.42 (s, 3H), 2.11 (m, 1H), 1.84 (m, 2H), 1.48 (m, 1H), 1.06 (s, 
3H), 1.02 (s, 3H).
13
C NMR (500 MHz, CDCl3) δ 206.22, 171.57, 159.58, 129.98, 
129.90, 129.37, 123.87, 113.92, 78.48, 78.04, 77.03, 72.50, 70.86, 70.03, 59.47, 
55.42, 52.07, 49.22, 34.59, 25.08, 19.41, 16.63.
100 
 
(+)-B-Diisopinocamphenyl trifluoromethanesulfonate (176) 
 
To a solution of (-)-α-pinene (15.00 mL, 12.83 g, 94.14 mmol) in 
tetrahydrofuran (12.00 mL) at room temperature was added dropwise borane dimethyl 
sulfide complex (3.80 mL, 3.04 g, 40.07 mmol). The reaction mixture was cooled to -
18 °C and a white solid settled out overnight. The solvent was removed and the white 
solid was rinsed with anhydrous diethyl ether (3 x 15 mL), then dried under vacuum. 
The white solid was suspended in anhydrous hexane (13.00 mL) and cooled to 0 °C. 
Freshly distilled trifluoromethanesulfonic acid (3.30 mL, 5.60 g, 37.29 mmol) was 
added dropwise and reaction mixture returned to room temperature. The reaction 
mixture was stirred until no white solid remained. Stirring was stopped and reaction 
mixture separated into two layers. The upper yellow coloured layer was used for 
formation of 177. Assumed 176 was formed in 60% yield, as a 1.9 M solution in 
hexane.
100, 108
 
 
(S)-4-Hydroxy-5-methylhex-5-en-2-one (177) 
 
To a solution of 176 (1.9 M in hexane, 20.00 mL, 38.00 mmol) in 
dichloromethane (11.00 mL) at -78 °C, was added N,N-diisopropylethylamine (7.50 
mL, 5.57 g, 43.06 mmol). The reaction mixture turned colourless and freshly distilled 
acetone (1.30 mL, 1.03 g, 17.70 mmol) was added dropwise. The reaction mixture 
was stirred at -78 °C for 2 hours. Freshly distilled methacrolein (2.80 mL, 2.38 g, 
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33.96 mmol) was added dropwise and the reaction mixture cooled to -18 °C 
overnight. The reaction was quenched with 0.5 M sodium phosfate buffer (pH 7.0, 30 
mL) and returned to room temperature. The aqueous and organic layers were 
separated. The aqueous layer was extracted with dichloromethane (3 x 30 mL). The 
organic extracts were combined and concentrated. The yellow slurry was dissolved in 
methanol (25 mL), 0.5 M sodium phosfate buffer (pH 7.0, 25 mL), and 30% hydrogen 
peroxide (20 mL). The solution was stirred at room temperature for 2 hours. The 
solution was added into distilled water (30 mL) and extracted with dichloromethane 
(3 x 30 mL).  The organic extracts were combined and washed with saturated aqueous 
brine (30 mL). The organic extract was dried with anhydrous magnesium sulfate and 
concentrated. Gradient flash chromatography (10:1 to 5:1 hexane/ethyl acetate) 
provided 177 as a colourless oil (2.01 g, 15.68 mmol, 89%). Rf 0.20 (2:1 hexane/ethyl 
acetate). [α]
23
D -37 (C 0.9 CHCl3).
 1
H NMR (500 MHz, CDCl3) δ 5.02 (s, 1H), 4.87 
(s, 1H), 4.51 (m, 1H), 2.91 (d, J = 3.2 Hz, 2H), 2.68 (d, J = 6.1 Hz, 3H) 1.75 (s, 
3H).
100, 108
 
 
(±)-2-Ethylbut-3-en-1-ol (178) 
 
To a solution of 2,5-dihydrofuran (3.70 mL, 3.43 g, 48.94 mmol) in tetrahydrofuran 
(15.00 mL) at 0 °C, was added dropwise ethylmagnesium chloride (2.0 M in 
tetrahydrofuran, 26.00 mL, 52.00 mmol). The reaction mixture was returned to room 
temperature and bis(cyclopentadienyl)zirconium(IV) dichloride (0.40 g, 1.37 mmol) 
was added. The reaction mixture was stirred at room temperature overnight. The 
reaction was quenched with distilled water (50 mL). The aqueous and organic layers 
were separated. The aqueous layer was extracted with dichloromethane (3 x 50 mL). 
The organic extracts were combined and washed with saturated aqueous brine (2 x 20 
mL). The organic extract was dried with anhydrous magnesium sulfate and 
concentrated. Vacuum distillation (5 mmHg, 60 °C) provided 178 as a colourless oil 
(2.60 g, 25.96 mmol, 53%). Rf 0.62 (2:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, 
CDCl3) δ 5.58 (m, 1H), 5.21 (m, 2H), 3.74 (m, 1H), 3.41 (m, 1H), 2.14 (m, 1H), 1.46 
(m, 1H), 1.39 (m, 1H), 1.28 (m, 1H), 0.90 (t, J = 7.6 Hz, 3H).
100
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(S)-4-([{R}-2-Ethylbut-3-enyloxy]diphenylsilyloxy)-5-
methylhex-5-en-2-one (179) 
 
To a solution of freshly distilled dichlorodiphenylsilane (2.50 
mL, 3.01 g, 11.89 mmol) in dichloromethane (62.00 mL) at 0 °C, was added 
triethylamine (1.60 mL, 1.16 g, 11.48 mmol). A solution of 178 (1.07 g, 10.68 mmol) 
in dichloromethane (16.00 mL) was added to the reaction mixture. The reaction 
mixture was warmed to 50 °C and refluxed for 20 hours. The reaction mixture was 
returned to room temperature and then cooled to 0 °C. Triethylamine (5.00 mL, 3.63 
g, 35.87 mmol) was added to the reaction mixture followed with a solution of 177 
(2.00 g, 15.60 mmol) in dichloromethane (9.50 mL). The reaction mixture was 
returned to room temperature and stirred for 2 days. The reaction was quenched with 
saturated aqueous NaHCO3 (50 mL). The aqueous and organic layers were separated. 
The aqueous layer was extracted with dichloromethane (3 x 50 mL). The organic 
extracts were combined and washed with saturated aqueous brine (2 x 50 mL). The 
organic extract was dried with anhydrous magnesium sulfate and concentrated. Flash 
chromatography (20:1 hexane/ethyl acetate) provided 179 as a colourless oil (1.64 g, 
4.01 mmol, 38%). Rf 0.31 (10:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 
7.62 (d, J = 7.8 Hz, 4H), 7.44-7.33 (m, 6H), 5.63 (m, 1H), 5.06 (m, 2H), 5.06 (s, 1H), 
4.77 (s, 1H), 4.76 (m, 1H), 3.64 (d, J = 6.3 Hz, 2H), 2.78 (dd, J = 7.6 Hz, 14.9 Hz, 
1H), 2.55 (dd, J = 5.1 Hz, 14.9 Hz, 1H), 2.13 (m, 1H), 2.07 (s, 3H), 1.70 (s, 3H), 1.57 
(m, 1H), 1.26 (m, 1H), 0.85 (t, J = 7.5 Hz, 3H). 
13
C NMR (500 MHz, CDCl3) δ 
206.74, 145.58, 140.10, 140.06, 135.21, 135.20, 134.92, 132.88, 132.80, 130.42, 
130.37, 127.88, 127.81, 115.90, 112.42, 112.40, 73.41, 66.37, 66.36, 50.47, 48.03, 
48.02, 31.04, 30.22, 23.67, 17.53, 17.52, 11.62.
100
 
 
Side product: 
Bis(2-ethylbut-3-enyloxy)diphenylsilane (203) 
 
Flash chromatography (20:1 hexane/ethyl acetate) provided 203 
as a colourless oil (0.01 g, 0.03 mmol, 3%). Rf 0.88 (20:1 
hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.8 Hz, 4H), 7.44-
7.35 (m, 6H), 5.65 (m, 2H), 5.07 (s, 2H), 5.05 (d, J = 3.9 Hz, 2H), 3.69 (d, J = 6.4 Hz, 
4H), 2.17 (m, 2H), 1.60 (m, 2H), 1.28 (m, 2H), 0.86 (t, J = 7.5 Hz, 3H). 
 
O
SiO Ph
Ph
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([4S,7R,Z]-7-Ethyl-5-methyl-2,2-diphenyl-7,8-dihydro-4H-
1,3,2-dioxasilocin-4-yl)propan-2-one (180) 
 
Method 1:  
A solution of Grubbs‟ 2nd generation catalyst (0.02 g, 0.02 mmol) in dichloromethane 
(4.00 mL) was refluxed at 50 °C. A solution of 179 (0.11 g, 0.27 mmol) in 
dichloromethane (42.00 mL) was then added at a constant rate of 1.5 mL/hour over 24 
hours. The reaction mixture was stirred for another 24 hours after addition of the 
diene solution was completed. The reaction mixture was returned to room temperature 
and concentrated. Flash chromatography (20:1 hexane/ethyl acetate) provided 180 as 
a white solid (0.03 g, 0.08 mmol, 30%).  
 
Method 2:  
A solution of 179 (0.30 g, 0.73 mmol) in dichloromethane (124.00 mL) was refluxed 
at 50 °C. A solution of Grubbs‟ 2nd generation catalyst (0.07 g, 0.08 mmol) in 
dichloromethane (13.00 mL) was then added as follows; 1 mL was added initially, 
then 2 mL every hour over 6 hours. The reaction mixture was stirred and refluxed 
overnight after addition of the catalyst solution was completed. The reaction mixture 
was returned to room temperature and concentrated. Flash chromatography (20:1 
hexane/ethyl acetate) provided 180 as a white solid (0.09 g, 0.24 mmol, 33%). 
 
Rf 0.38 (5:1 hexane/ethyl acetate).
 
[α]
23
D +24 (C 3.8, CHCl3). HRMS: m/z 
C23H28O3SiNa
+
 [M+Na]
+
 calcd 403.1705, found 403.1712. 
1
H NMR (500 MHz, 
CDCl3) δ 7.58 (m, 4H), 7.36 (m, 6H), 5.39 (dd, J = 4.7 Hz, 9.1 Hz, 1H), 5.05 (dd, J = 
1.4 Hz, 8.9 Hz, 1H), 4.08 (dd, J = 3.2 Hz, 10.6 Hz, 1H), 3.59 (t, J = 10.6 Hz, 1H), 
3.05 (dd, J = 9.1 Hz, 15.2 Hz, 1H), 2.73 (m, 1H), 2.60 (dd, J = 4.6 Hz, 15.5 Hz, 1H), 
2.22 (s, 3H), 1.70 (s, 3H), 1.33 (m, 1H), 1.17 (m, 1H), 0.88 (t, J = 7.5 Hz, 3H). 
13
C 
NMR (500 MHz, CDCl3) δ 207.56, 207.13, 138.61, 134.60, 134.43, 134.07, 130.12, 
130.07, 127.93, 127.83, 70.05, 67.64, 48.36, 42.60, 31.20, 31.08, 24.79, 19.25, 
12.07.
100
 
 
 
 
O
SiO Ph
Ph
O
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Side product: 
(4S,17S)-9,12-Diethyl-6,6,15,15-
tetraphenyl-4,17-di(prop-1-en-2-yl)-
5,7,14,16-tetraoxa-6,15-disilaicos-10-ene-
2,19-dione (210) 
 
Flash chromatography (20:1 hexane/ethyl acetate) provided 210 as a colourless oil 
(0.03 g, 0.04 mmol, 13%). Rf 0.28 (5:1 hexane/ethyl acetate). HRMS: m/z 
C48H60O6Si2Na
+
 [M+Na]
+
 calcd 811.3826, found 811.3833. 
1
H NMR (500 MHz, 
CDCl3) δ 7.60 (m, 8H), 7.40 (m, 4H), 7.32 (m, 8H), 5.21 (dd, J = 2.5, 5.2 Hz, 2H), 
4.88 (d, J = 8.0 Hz, 2H), 4.74 (m, 4H), 3.59 (m, 4H), 2.76 (m, 2H), 2.54 (m, 2H), 2.07 
(bs, 2H), 2.04 (d, J = 12.0 Hz, 6H), 1.68 (d, J = 7.8 Hz, 6H), 1.62 (m, 2H), 1.21 (m, 
2H), 0.82 (m, 6H). 
13
C NMR (500 MHz, CDCl3) δ 206.69, 145.56, 139.34, 135.19, 
132.72, 127.86, 112.28, 73.41, 66.67, 50.44, 47.10, 31.00, 24.09, 17.52, 11.72. 
 
(S,E)-4-([2-Ethyl-4-phenylbut-3-
enyloxy]diphenylsilyloxy)-5-methylhex-5-en-2-one 
(212) 
 
Flash chromatography (20:1 hexane/ethyl acetate) 
provided 212 as a colourless oil (3.45 mg, 0.01 mmol, 6%). Rf 0.49 (5:1 hexane/ethyl 
acetate).
 1
H NMR (500 MHz, CDCl3) δ 7.63 (m, 4H), 7.36 (m, 10H), 7.19 (t, J = 7.2 
Hz, 1H), 6.40 (d, J = 15.8 Hz, 1H), 6.02 (dd, J = 8.7 Hz, 16.0 Hz, 1H), 4.89 (d, J = 7.9 
Hz, 1H), 4.77 (m, 2H), 3.72 (d, J = 6.1 Hz, 2H), 2.78 (m, 1H), 2.54 (m, 1H), 2.32 (m, 
1H), 2.03 (d, J = 13.2 Hz, 3H), 1.69 (d, J = 6.9 Hz, 3H), 1.62 (dd, J = 6.6 Hz, 22.0 Hz, 
1H), 1.39 (m, 1H), 0.88 (t, J = 7.7 Hz, 3H). 
13
C NMR (500 MHz, CDCl3) δ 206.73, 
145.56, 137.86, 135.21, 132.17, 131.29, 130.36, 128.58, 127.86, 127.06, 126.14, 
112.40, 73.45, 66.55, 50.45, 47.48, 30.99, 24.18, 17.48, 11.83. 
 
(S)-5-Methyl-4-([2-methylenebutoxy]diphenylsilyloxy)hex-5-
en-2-one (215) 
 
Flash chromatography (20:1 hexane/ethyl acetate) provided 215 
Ph
Si
O
PhO
O
OSi
O
Ph
Ph
O
Ph
Si
O
PhO
O
Ph
Si
O
PhO
O
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as a colourless oil (3.45 mg, 0.01 mmol, 6%). Rf 0.49 (5:1 hexane/ethyl acetate).
 1
H 
NMR (500 MHz, CDCl3) δ 7.63 (m, 4H), 7.36 (m, 6H), 5.11 (s, 1H), 4.89 (d, J = 7.9 
Hz, 1H), 4.84 (s, 1H), 4.77 (m, 2H), 4.19 (s, 2H), 2.78 (m, 1H), 2.54 (m, 1H), 2.03 (d, 
J = 13.2 Hz, 3H), 2.03 (m, 2H), 1.69 (d, J = 6.9 Hz, 3H), 1.01 (t, J = 7.4 Hz, 3H). 
13
C 
NMR (500 MHz, CDCl3) δ 206.73, 149.49, 145.56, 135.21, 132.17, 130.36, 127.86, 
112.40, 107.81, 73.45, 65.90, 50.45, 30.99, 25.56, 17.48, 12.27. 
 
(S)-6-(1-Hydroxy-2-methylpropan-2-yl)-5,6-dihydropyran-2-one 
(181) 
 
To a solution of 165 (0.19 g, 0.67 mmol) in methanol (7.00 mL) at room 
temperature was added, dropwise, 36% aqueous hydrochloric acid solution (0.10 mL). 
The reaction mixture was stirred for 30 minutes. The reaction was quenched with 
saturated aqueous NaHCO3 (10 mL). The reaction mixture was extracted with 
dichloromethane (3 x 15 mL). The organic extracts were combined and dried with 
anhydrous magnesium sulfate, then concentrated. Gradient flash chromatography (3:1 
to 1:1 hexane/ethyl acetate) provided 181 as a colourless oil (0.06 g, 0.35 mmol, 
52%). Rf 0.03 (3:1 hexane/ethyl acetate).
 
IR (KBr, cm
-1
) νmax 3476.0, 2921.0, 1701.0, 
1388.0, 1265.0, 1038.0, 914.0, 818.9, 748.7. [α]
23
D -81 (C 0.6, CHCl3). HRMS: m/z 
C9H14O3Na
+
 [M+Na]
+
 calcd 193.0841, found 193.0836.
 1
H NMR (500 MHz, CDCl3) 
δ 6.94 (m, 1H), 6.02 (d, J = 9.5 Hz, 1H), 4.42 (dd, J = 3.6 Hz, 13.8 Hz, 1H), 3.66 (d, J 
= 10.7 Hz, 1H), 3.45 (d, J = 10.9 Hz, 1H), 2.46 (m, 1H), 2.31 (m, 1H), 1.00 (s, 3H), 
0.97 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 145.57, 121.27, 81.99, 69.09, 38.57, 
24.60, 21.04, 19.59. 
 
(S)-2-Methyl-2-(6-oxo-3,6-dihydro-2H-pyran-2-yl)propanal (182) 
 
To a solution of 181 (0.06 g, 0.35 mmol) in dichloromethane (5.20 mL) 
at room temperature, was added (bisacetoxyiodo)benzene (0.23 g, 0.71 
mmol) and TEMPO (7.00 mg, 0.04 mmol). The reaction mixture was stirred for 5.5 
hours at room temperature. The reaction was quenched with saturated aqueous 
Na2S2O3 (10 mL) and stirred at room temperature for 15 minutes. The aqueous and 
organic layers were separated. The aqueous layer was extracted with dichloromethane 
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(3 x 10 mL). The organic extracts were combined and washed with saturated aqueous 
NaHCO3 (10 mL). The organic extract was dried with anhydrous magnesium sulfate 
and concentrated. Flash chromatography (2:1 hexane/ethyl acetate) provided 182 as a 
colourless oil (0.04 g, 0.24 mmol, 69%). Rf 0.35 (1:1 hexane/ethyl acetate).
 1
H NMR 
(500 MHz, CDCl3) δ 9.63 (s, 1H), 6.93 (m, 1H), 6.05 (ddd, J = 1.0 Hz, 3.0 Hz, 10.0 
Hz, 1H), 4.58 (dd, J = 4.7 Hz, 11.9 Hz, 1H), 2.38 (m, 2H), 1.23 (s, 3H), 1.19 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 203.77, 145.16, 121.46, 80.87, 48.924, 24.76, 18.58, 
18.13. 
 
1-(tert-Butyldimethylsilyloxy)-2,2,5-trimethylhex-5-en-3-ol 
(183) 
 
To a solution of 161 (0.13 g, 0.60 mmol) in tetrahydrofuran (6.00 mL) at room 
temperature, was added 3-bromo-2-methylpropene (0.07 mL, 0.09 g, 0.89 mmol) 
followed with zinc powder (0.09 g, 1.38 mmol). The reaction mixture was stirred and 
heated at 65 °C for 20 minutes. Tetrahydrofuran was then distilled off the reaction 
mixture. The residue was returned to room temperature and dissolved in diethyl ether 
(20 mL). The reaction mixture was quenched with saturated aqueous NH4Cl (3 mL) 
and the precipitate was filtered off. The aqueous and organic layers were separated. 
The organic layer was washed with saturated aqueous NH4Cl (3 x 10 mL). The 
organic extract was dried with anhydrous magnesium sulfate and concentrated. Flash 
chromatography (20:1 hexane/ethyl acetate) provided 183 as a colourless oil (0.04 g, 
0.15 mmol, 25%). Rf 0.53 (5:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 
4.85 (s, 1H), 4.81 (s, 1H), 3.65 (d, J = 10.7 Hz, 1H), 3.48 (d, J = 3.9 Hz, 2H), 2.19 (d, 
J = 14.6 Hz, 1H), 2.07 (dd, J = 10.5 Hz, 13.7 Hz, 1H), 1.79 (s, 3H), 0.91 (s, 3H), 0.90 
(s, 9H), 0.85 (s, 3H), 0.06 (s, 6H). 
13
C NMR (500 MHz, CDCl3) δ 143.99, 112.69, 
75.55, 72.75, 40.60, 38.61, 25.99, 22.45, 22.14, 19.28, 18.32, -5.49, -5.52.
 
 
1-(tert-Butyldimethylsilyloxy)-2,2,5-trimethylhex-5-en-3-yl 
acrylate (184) 
 
To a solution of 183 (0.04 g, 0.15 mmol) in dichloromethane 
(0.80 mL) at 0 °C, was added N,N-diisopropylethylamine (0.07 mL, 0.05 g, 0.40 
mmol), followed with acryloyl chloride (0.03 mL, 0.03 g, 0.37 mmol). The reaction 
TBSO OH
TBSO O
O
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mixture was returned to room temperature and stirred overnight. The reaction was 
quenched with saturated aqueous NH4Cl (5 mL). The aqueous and organic layers 
were separated. The aqueous layer was extracted with dichloromethane (3 x 10 mL). 
The organic extracts were combined and washed with saturated aqueous brine (10 
mL). The organic extract was dried with anhydrous magnesium sulfate and 
concentrated. Flash chromatography (20:1 hexane/ethyl acetate) provided 184 as a 
colourless oil (0.03 g, 0.09 mmol, 60%). Rf 0.57 (10:1 hexane/ethyl acetate).
 1
H NMR 
(500 MHz, CDCl3) δ 6.35 (dd, J = 1.5 Hz, 17.3 Hz, 1H), 6.08 (dd, J = 10.5 Hz, 17.3 
Hz, 1H), 5.77 (dd, J = 1.5 Hz, 10.5 Hz, 1H), 5.21 (dd, J = 3.2 Hz, 10.0 Hz, 1H), 4.70 
(s, 1H), 4.66 (s, 1H, H2C–C(CH3)=CH2), 3.34 (dd, J = 9.6 Hz, 33.2 Hz, 2H), 2.25 (m, 
2H), 1.76 (s, 3H), 0.92 (s, 3H), 0.90 (s, 9H), 0.88 (s, 3H), 0.02 (s, 6H). 
13
C NMR (500 
MHz, CDCl3) δ 165.75, 142.67, 130.11, 129.04, 113.33, 75.43, 69.47, 39.70, 38.75, 
25.99, 22.25, 21.48, 20.46, 18.37, 18.36, -5.48, -5.49. 
 
6-(1-[tert-Butyldimethylsilyloxy]-2-methylpropan-2-yl)-4-
methyl-5,6-dihydropyran-2-one (185) 
 
To a solution of 184 (0.03 g, 0.09 mmol) in dichloromethane 
(9.00 mL) at room temperature, was added Grubbs‟ 2nd generation catalyst (4.00 mg, 
4.71 µmol). The reaction mixture was refluxed at 50 °C for 6 hours. The reaction 
mixture was then returned to room temperature and concentrated. Flash 
chromatography (20:1 hexane/ethyl acetate) provided 185 as a colourless oil (0.02 g, 
0.07 mmol, 78%). Rf 0.14 (10:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 
5.79 (bs, 1H), 4.30 (dd, J = 3.5 Hz, 13.2 Hz, 1H), 3.53 (d, J = 9.7 Hz, 1H), 3.36 (d, J 
= 9.7 Hz, 1H), 2.45 (m, 1H), 2.09 (dd, J = 3.5 Hz, 17.9 Hz, 1H), 1.98 (s, 3H), 0.97 (s, 
3H), 0.91 (s, 3H), 0.87 (s, 9H), 0.03 (s, 6H). 
13
C NMR (500 MHz, CDCl3) δ 165.85, 
157.95, 116.47, 80.81, 68.68, 38.72, 29.97, 25.98, 23.30, 20.66, 20.13, 18.35, -5.40, -
5.46. 
 
6-(1-Hydroxy-2-methylpropan-2-yl)-4-methyl-5,6-dihydropyran-
2-one (186) 
 
To a solution of 185 (0.02 g, 0.07 mmol) in methanol (0.60 mL) at 
room temperature was added, dropwise, 36% aqueous hydrochloric acid solution 
TBSO O
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(0.01 mL). The reaction mixture was stirred for 30 minutes. The reaction was 
quenched with saturated aqueous NaHCO3 (1 mL). The reaction mixture was 
extracted with dichloromethane (3 x 5 mL). The organic extracts were combined and 
dried with anhydrous magnesium sulfate, then concentrated. Flash chromatography 
(2:1 hexane/ethyl acetate) provided 186 as a colourless oil (6.90 mg, 0.04 mmol, 
57%). Rf 0.14 (1:1 hexane/ethyl acetate).  IR (KBr, cm
-1
) νmax 3480.0, 2962.0, 1695.0, 
1389.0, 1263.0, 1047.0, 757.3. [α]
23
D -73 (C 0.1, CHCl3). HRMS: m/z C10H16O3Na
+
 
[M+Na]
+
 calcd 207.0997, found 207.0992. 
 1
H NMR (500 MHz, CDCl3) δ 5.80 (bs, 
1H), 4.36 (dd, J = 3.4 Hz, 13.2 Hz, 1H), 3.66 (d, J = 10.8 Hz, 1H), 3.44 (d, J = 11.0 
Hz, 1H), 2.46 (m, 1H), 2.13 (dd, J = 3.6 Hz, 17.7 Hz, 1H), 2.00 (s, 3H), 0.99 (s, 3H), 
0.96 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 165.57, 158.12, 116.37, 81.33, 69.20, 
38.47, 29.86, 23.33, 21.07, 19.58. 
 
 (S)-6-(1-(tert-Butyldimethylsilyloxy)-2-methylpropan-2-yl)-
tetrahydropyran-2-one (187) 
 
To platinum(IV) oxide (1.80 mg, 7.93 µmol) was added a solution 
of 165 (0.02 g, 0.07 mmol) in ethyl acetate (2.20 mL) at room temperature. The 
reaction vessel was purged with hydrogen gas and the reaction mixture was stirred for 
4 hours at room temperature. The reaction mixture was filtered through a pad of celite 
and washed with ethyl acetate. The collected filtrate was concentrated to provide 187 
as a colourless oil (17.00 mg, 0.05 mmol, 71%) and was used without further 
purification. Rf 0.27 (10:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 4.25 
(dd, J = 2.9 Hz, 12.0 Hz, 1H), 3.51 (d, J = 9.8 Hz, 1H), 3.32 (d, J = 9.7 Hz, 1H), 2.35 
(m, 1H), 1.97 (m, 1H), 1.97 (m, 3H), 1.57 (m, 1H), 0.93 (s, 3H), 0.88 (s, 9H), 0.87 (s, 
3H), 0.03 (s, 6H).
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 (S)-6-(1-[tert-Butyldimethylsilyloxy]-2-methylpropan-2-yl)-
tetrahydro-2H-pyran-2-ol (188) 
 
To a solution of 187 (17.00 mg, 0.05 mmol) in dichloromethane 
(0.84 mL) at -23 °C, was added diisobutylaluminium hydride (1.0 M in toluene, 0.07 
mL, 0.07 mmol) and the reaction mixture was stirred for 45 minutes. The reaction was 
TBSO O
O
TBSO O
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quenched with methanol (0.5 mL) and returned to room temperature. A saturated 
aqueous solution of Rochelle‟s salt (5 mL) was added to the reaction mixture. The 
aqueous and organic layers were separated. The aqueous layer was extracted with 
dichloromethane (3 x 5 mL). The organic extracts were combined and dried with 
anhydrous magnesium sulfate. Removal of solvent provided 188 as a yellow slurry 
and was used without further purification. Rf 0.42 (10:1 hexane/ethyl acetate).
 1
H 
NMR (500 MHz, CDCl3) δ 4.67 (m, 1H), 3.85 (dd, J = 2.0 Hz, 11.7 Hz, 1H), 3.47 (d, 
J = 9.3 Hz, 1H), 3.26 (d, J = 9.3 Hz, 1H), 2.64 (bs, 1H), 1.90-1.18 (m, 6H), 0.89 (s, 
9H), 0.87 (s, 3H), 0.83 (s, 3H), 0.02 (s, 6H).
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 (S)-6-(1-[tert-Butyldimethylsilyloxy]-2-methylpropan-2-yl)-
tetrahydro-2H-pyran-2-yl acetate (189) 
 
To a solution of 188 (assumed to be 0.05 mmol) in 
dichloromethane (0.50 mL) at room temperature, was added triethylamine (0.02 mL, 
14.52 mg, 0.14 mmol). Acetic anhydride (0.01 mL, 0.01 g, 0.11 mmol) was added to 
the reaction mixture, followed with N,N-dimethyl-4-aminopyridine (3.00 mg, 24.55 
µmol). The reaction mixture was stirred overnight at room temperature. The reaction 
mixture was diluted with dichloromethane (10 mL) and extracted with saturated 
aqueous KHSO4 (5 mL), followed with saturated aqueous NaHCO3 (5 mL) and 
saturated aqueous brine (5 mL). The organic layer was dried with anhydrous 
magnesium sulfate. Removal of solvent provided 189 as a yellow oil and was used 
without further purification. Rf 0.76 (10:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, 
CDCl3) δ 5.58 (dd, J = 2.1 Hz, 9.7 Hz, 1H), 3.40 (m, 1H), 3.31 (m, 1H), 2.09 (s, 3H), 
1.91 (m, 1H), 1.77 (m, 1H), 1.67 (m, 1H), 1.55 (m, 1H), 1.39 (m, 1H), 1.27 (m, 1H), 
0.89 (s, 6H), 0.88 (s, 9H), 0.01 (s, 6H). 
 
4,4-Dimethyl-2,9-dioxa-bicyclo[3.3.1]nonane (226) 
 
To a solution of 189 (assumed to be 0.05 mmol) in acetonitrile (0.40 mL) 
at room temperature was added freshly distilled vinyloxy-trimethylsilane (0.01 mL, 
7.79 mg, 0.70 mmol), followed with freshly distilled boron trifluoride diethyl etherate 
(0.50 µL, 0.58 mg, 4.09 µmol). The reaction mixture was stirred for 3.5 hours at room 
temperature. The reaction was quenched with saturated aqueous NaHCO3 (5 mL). The 
TBSO O
OAc
O
O
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aqueous and organic layers were separated. The aqueous layer was extracted with 
dichloromethane (3 x 10 mL). The organic extracts were combined and dried with 
anhydrous magnesium sulfate, then concentrated to provided 226 as a crude product 
(9.00 mg, 0.06 mmol, 26%). Rf 0.24 (10:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, 
CDCl3) δ 5.30 (s, 1H), 4.05 (m, 1H), 3.53-3.32 (m, 2H), 2.05-1.25 (m, 6H), 0.92 (s, 
3H), 0.88 (s, 3H). 
 
(S)-4-(Dimethyl[phenyl]silyloxy)-5-methylhex-5-en-2-one (190) 
 
To a solution of 177 (0.11 g, 0.86 mol) in N,N-dimethylformamide 
(0.30 mL) at 0 °C, was added imidazole (0.12 g, 1.76 mmol) and 
chloro(dimethyl)phenylsilane (0.16 mL, 0.16 g, 0.95 mmol). The reaction mixture 
was returned to room temperature and stirred overnight. The reaction was diluted with 
diethyl ether (5 mL) and extracted with saturated aqueous NaHCO3 (3 x 3 mL), 
followed with distilled water (2 x 3 mL). The organic extract was dried with 
anhydrous magnesium sulfate and concentrated. Flash chromatography (5:1 
hexane/ethyl acetate) provided 190 as a colourless oil (0.16 g, 0.61 mmol, 71%). Rf 
0.33 (5:1 hexane/ethyl acetate).  IR (KBr, cm
-1
) νmax 3418.0, 2960.0, 1717.0, 1429.0, 
897.3, 833.4. [α]
23
D -26 (C 0.2, CHCl3). HRMS: m/z C15H22O2SiNa
+
 [M+Na]
+
 calcd 
285.1287, found 285.1291. 
1
H NMR (500 MHz, CDCl3) δ 7.55 (dd, J = 1.6Hz, 7.5 
Hz, 2H), 7.37 (m, 3H), 4.91 (s, 1H), 4.77 (s, 1H), 4.57 (dd, J = 4.1 Hz, 8.65 Hz, 1H), 
2.74 (dd, J = 8.8 Hz, 14.9 Hz, 1H), 2.42 (dd, J = 3.8 Hz, 15.0 Hz, 1H), 2.10 (s, 3H) 
1.67 (s, 3H), 0.36 (s, 3H), 0.35 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 207.45, 
146.49, 137.84, 133.67, 129.73, 127.86, 111.79, 73.60, 50.38, 31.55, 17.53, -1.18, -
1.48. 
 
Representative procedure for 1,5-anti aldol reaction: 
 
To a solution of ketone 180 (1.5 equivalent) in anhydrous diethyl ether (10 mL/mmol) 
at -78 °C, was added triethylamine (4.0 equivalent), followed by dibutylboryl 
trifluoromethanesulfonate (1.0 M in dichloromethane, 2.0 equivalent). The reaction 
mixture was stirred for 45 minutes and a solution of aldehyde (1.0 equivalent) in 
anhydrous diethyl ether (5 mL/mmol) was added. The reaction mixture was warmed 
OMe2PhSiO
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to -18 °C and reacted overnight. Silica gel was added, the reaction mixture was 
warmed to 0 °C and stirred for 45 minutes. The reaction mixture was filtered and 
rinsed with diethyl ether. The solvent was removed under reduced pressure and the 
residue was purified by gradient flash chromatography. 
 
8-Hydroxy-7,7-dimethyl-2-oxa-bicyclo[2.2.2]oct-5-en-3-one (220) 
 
 
To N,N-diisopropylethylamine (0.04 mL, 0.03 g, 0.23 mmol) at -78 °C, 
was added dibutylboryl trifluoromethanesulfonate (1.0 M in dichloromethane, 0.48 
mL, 0.48 mmol). The reaction mixture was stirred for 45 minutes and a solution of 
182 (0.02 g, 0.12 mmol) in anhydrous diethyl ether (1.20 mL) was added. The 
reaction mixture was warmed to -18 °C and reacted overnight. Silica gel was added, 
the reaction mixture was warmed to 0 °C and stirred for 45 minutes. The reaction 
mixture was filtered and rinsed with diethyl ether (3 x 5 mL) and the solvent removed 
under reduced pressure. Gradient flash chromatography (2:1 hexane/ethyl acetate to 
neat ethyl acetate) provided 220 as a colourless oil (3.00 mg, 0.02 mmol, 17%). Rf 
0.19 (1:1 hexane/ethyl acetate).
 1
H NMR (500 MHz, CDCl3) δ 6.68 (m, 1H), 6.51 (m, 
1H), 6.40 (m, 2H), 4.63 (m, 2H), 3.85 (s, 1H), 3.72 (m, 1H), 3.65 (s, 1H), 3.54 (m, 
1H), 1.21 (s, 3H), 1.20 (s, 3H), 1.03 (s, 3H), 0.97 (s, 3H). 
13
C NMR (500 MHz, 
CDCl3) δ 172.00, 172.00, 133.63, 133.43, 128.53, 129.02, 83.37, 82.91, 73.95, 72.86, 
51.35, 50.69, 39.65, 41.97, 28.65, 26.97, 21.13, 21.58. 
 
(S)-6-(3-Hydroxy-2-methyl-5-oxohexan-2-yl)-5,6-
dihydropyran-2-one (221) 
 
To N,N-diisopropylethylamine (0.04 mL, 0.03 g, 0.23 mmol) at -
78 °C, was added dibutylboryl trifluoromethanesulfonate (1.0 M in dichloromethane, 
0.24 mL, 0.24 mmol). The reaction mixture was stirred for 45 minutes and a solution 
of 182 (0.02 g, 0.12 mmol) in anhydrous diethyl ether (1.20 mL) was added. The 
reaction mixture was warmed to -18 °C and reacted overnight. Silica gel was added, 
the reaction mixture was warmed to 0 °C and stirred for 45 minutes. The reaction 
mixture was filtered and rinsed with diethyl ether (3 x 5 mL) and the solvent removed 
under reduced pressure. Gradient flash chromatography (2:1 hexane/ethyl acetate to 
O
OH
O
O
O
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neat ethyl acetate) provided 221 as a colourless oil (0.01 g, 0.03 mmol, 26%). Rf 0.09 
(1:1 hexane/ethyl acetate). HRMS: m/z C12H18O4Na
+
 [M
+
Na]
+
 calcd 249.1103, found 
249.1106. 
1
H NMR (500 MHz, CDCl3) δ 6.92 (m, 2H), 6.01 (m, 2H), 4.65 (dd, J = 
3.7 Hz, 12.5 Hz, 1H), 4.50 (dd, J = 6.5 Hz, 10.0 Hz, 1H), 4.28 (dd, J = 2.0 Hz, 10.2 
Hz, 1H), 3.97 (dd, J = 2.0 Hz, 9.9 Hz, 1H), 2.65 (m, 4H), 2.44 (m, 4H), 2.22 (m, 6H), 
1.06 (s, 3H), 0.94 (s, 6H), 0.89 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 210.86, 
210.00, 164.90, 164.66, 146.09, 145.90, 121.33, 121.19, 81.93, 80.85, 71.59, 69.85, 
44.93, 44.75, 40.31, 40.20, 31.09, 31.04, 24.72, 24.68, 20.15, 18.94, 18.48, 17.97. 
 
(S)-6-(4-[2,4-Dibutyl-6-methyl-1,3,5,2,4-
trioxadiborinan-6-yl]-3-hydroxy-2-methylbutan-2-
yl)-5,6-dihydropyran-2-one (222) 
 
To N,N-diisopropylethylamine (0.04 mL, 0.03 g, 0.23 mmol) at -78 °C, was added 
dibutylboryl trifluoromethanesulfonate (1.0 M in dichloromethane, 0.24 mL, 0.24 
mmol). The reaction mixture was stirred for 45 minutes and a solution of 182 (0.02 g, 
0.12 mmol) in anhydrous diethyl ether (1.20 mL) was added. The reaction mixture 
was warmed to -18 °C and reacted overnight. Silica gel was added, the reaction 
mixture was warmed to 0 °C and stirred for 45 minutes. The reaction mixture was 
filtered and rinsed with diethyl ether (3 x 5 mL) and the solvent removed under 
reduced pressure. Gradient flash chromatography (2:1 hexane/ethyl acetate to neat 
ethyl acetate) provided 222 as a colourless oil (2.00 mg, 5.07 µmol, 4%). Rf 0.33 (1:1 
hexane/ethyl acetate).
 
HRMS: m/z C20H36O6B2Na
+
 [M
+
Na]
+
 calcd 418.1889, found 
417.1893. 
1
H NMR (500 MHz, CDCl3) δ 6.94 (m, 1H), 6.04 (d, J = 9.8 Hz, 1H), 4.48 
(dd, J = 3.6 Hz, 12.8 Hz, 1H), 4.33 (dd, J = 2.7 Hz, 11.8Hz, 1H), 1.86 (dd, J = 2.8 Hz, 
13.5 Hz, 1H), 1.72 (dd, J = 12.3 Hz, 13.4 Hz, 1H), 1.28 (m, 8H), 3.49 (bs, 3H), 2.53 
(m, 1H), 2.43 (m, 1H), 1.05 (s, 3H), 0.96 (s, 3H), 0.86 (t, J = 7.1 Hz, 6H), 0.69 (t, J = 
7.3 Hz, 4H). 
13
C NMR (500 MHz, CDCl3) δ 164.87, 145.93, 121.15, 91.45, 82.16, 
70.00, 39.95, 37.65, 26.06, 25.21, 24.69, 19.36, 18.14, 14.01, 13.88. 
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